


# Vitamin B<sub>12</sub>

From Wikipedia, the free encyclopedia


[Jump to navigation](#)[Jump to search](#)

*This article is about the family of vitamers. For individual forms, see [hydroxocobalamin](#), [cyanocobalamin](#), [methylcobalamin](#), and [adenosylcobalamin](#).*

## Vitamin B<sub>12</sub> (data for cyanocobalamin)



R = 5'-deoxyadenosyl, Me, OH, CN



## Clinical data

**Synonyms** vitamin B12, vitamin B-12

[AHFS/Drugs.com](#) [Monograph](#)

<b><u>Routes of administration</u></b>	by mouth, sublingual, <a href="#">IV</a> , <a href="#">IM</a> , intranasal
<b><u>ATC code</u></b>	<a href="#">B03BA01</a> ( <a href="#">WHO</a> )
<b>Legal status</b>	
<b><u>Legal status</u></b>	UK: <a href="#">POM</a> (Prescription only) US: <a href="#">OTC</a>
<b>Pharmacokinetic data</b>	
<b><u>Bioavailability</u></b>	Readily absorbed in distal half of the ileum
<b><u>Protein binding</u></b>	Very high to specific <a href="#">transcobalamins</a> plasma proteins Binding of <a href="#">hydroxocobalamin</a> is slightly higher than cyanocobalamin.
<b><u>Metabolism</u></b>	<a href="#">liver</a>
<b><u>Elimination half-life</u></b>	Approximately 6 days (400 days in the liver)
<b><u>Excretion</u></b>	<a href="#">kidney</a>
<b>Identifiers</b>	
<b><u>IUPAC name</u></b> <a href="#">[show]</a>	
<b><u>CAS Number</u></b>	<a href="#">68-19-9</a> ✓
<b><u>PubChem CID</u></b>	<a href="#">184933</a>
<b><u>DrugBank</u></b>	<a href="#">DB00115</a> ✗
<b><u>ChemSpider</u></b>	<a href="#">10469504</a> ✓
<b><u>KEGG</u></b>	<a href="#">D00166</a> ✓
<b><u>ChEMBL</u></b>	<a href="#">ChEMBL2110563</a> ✗
<b>Chemical and physical data</b>	
<b><u>Formula</u></b>	$C_{63}H_{88}CoN_{14}O_{14}P$
<b><u>Molar mass</u></b>	1355.388 g·mol <sup>-1</sup>
<b><u>3D model</u></b> ( <a href="#">JSmol</a> )	<a href="#">Interactive image</a>

[SMILES](#)<sup>[show]</sup>

[InChI](#)<sup>[show]</sup>

 [\(what is this?\)](#) [\(verify\)](#)

**Vitamin B<sub>12</sub>**, also known as **cobalamin**, is a water-soluble [vitamin](#) that is involved in the [metabolism](#) of every [cell](#) of the human body: it is a [cofactor](#) in [DNA synthesis](#), and in both [fatty acid](#) and [amino acid metabolism](#).<sup>[1]</sup> It is particularly important in the normal functioning of the [nervous system](#) via its role in the [synthesis of myelin](#),<sup>[2][3]</sup> and in the maturation of developing red blood cells in the [bone marrow](#).<sup>[4]</sup>

Vitamin B<sub>12</sub> is one of eight [B vitamins](#); it is the largest and most structurally complex vitamin. It consists of a class of chemically related compounds ([vitamers](#)), all of which show [physiological activity](#). It contains the biochemically rare element [cobalt](#) (chemical symbol **Co**) positioned in the center of a [corrin](#) ring. The only organisms to produce vitamin B<sub>12</sub> are certain [bacteria](#), and [archaea](#). Some of these bacteria are found in the soil around the grasses that [ruminants](#) eat; they are taken into the animal, proliferate, form part of their [gut flora](#), and continue to produce vitamin B<sub>12</sub>.

Because there are few common vegetable sources of the vitamin, [vegans](#) must use a supplement or fortified foods for B<sub>12</sub> intake or risk serious health consequences.<sup>[3][5]</sup> Otherwise, most omnivorous people in [developed countries](#) obtain enough vitamin B<sub>12</sub> from consuming animal products including meat, milk, eggs, and fish.<sup>[6]</sup> [Staple foods](#), especially those that form part of a [vegan](#) diet, are often [fortified](#) by having the vitamin added to them. Vitamin B<sub>12</sub> [supplements](#) are available in single agent or multivitamin tablets; and [pharmaceutical](#) preparations may be given by [intramuscular injection](#).<sup>[3][7]</sup>

The most common cause of vitamin B<sub>12</sub> deficiency in developed countries is [impaired absorption](#) due to a loss of [gastric intrinsic factor](#), which must be bound to food-source B<sub>12</sub> in order for absorption to occur.<sup>[3]</sup> Another group affected are those on long term antacid therapy,<sup>[8]</sup> using [proton pump inhibitors](#), [H2 blockers](#) or other antacids. This condition may be characterised by limb [neuropathy](#) or a blood disorder called [pernicious anemia](#), a type of [megaloblastic anemia](#). [Folate](#) levels in the individual may affect the course of pathological changes and symptomatology. Deficiency is more likely after age 60, and increases in incidence with advancing age.<sup>[3]</sup> Dietary deficiency is very rare in developed countries due to access to dietary meat and fortified foods, but children in some regions of [developing countries](#) are at particular risk due to increased requirements during growth coupled with lack of access to dietary B<sub>12</sub>; adults in these regions are also at risk. Other causes of vitamin B<sub>12</sub> deficiency are much less frequent.<sup>[9]</sup>



## Contents

- [1](#)Deficiency
- [2](#)Medical uses
  - [2.1](#)Repletion of deficiency
  - [2.2](#)Cyanide poisoning
- [3](#)Dietary recommendations
- [4](#)Sources
  - [4.1](#)Bacteria and archaea
  - [4.2](#)Animals
  - [4.3](#)Plants and algae
  - [4.4](#)Fortified foods

- 4.5Supplements
- 4.6Parenteral administration
- 4.7Pseudovitamin-B<sub>12</sub>
- 5Drug interactions
  - 5.1H<sub>2</sub>-receptor antagonists and proton-pump inhibitors
  - 5.2Metformin
- 6Chemistry
  - 6.1Vitimers
- 7Biochemistry
  - 7.1Coenzyme function
  - 7.2Enzyme function
- 8Physiology
  - 8.1Absorption
  - 8.2Storage and excretion
- 9Production
  - 9.1Industrial
  - 9.2Laboratory
- 10History
- 11References
- 12External links



Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
 Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
 Lipoic Acid 1.5 mg Tablets

## Deficiency [[edit](#)]

*Main article:* [Vitamin B<sub>12</sub> deficiency](#)

Vitamin B<sub>12</sub> deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system.<sup>[3][10]</sup> At levels only slightly lower than normal, a range of symptoms such as [fatigue](#), [lethargy](#), difficulty walking (staggering balance problems)<sup>[11]</sup> [depression](#), poor [memory](#), breathlessness, headaches, and pale skin, among others, may be experienced, especially in elderly people (over age 60)<sup>[3][12]</sup> who produce less stomach acid as they age, thereby increasing their probability of B<sub>12</sub> deficiencies.<sup>[9]</sup> Vitamin B<sub>12</sub> deficiency can also cause symptoms of [mania](#) and [psychosis](#).<sup>[13]</sup>

Vitamin B<sub>12</sub> deficiency is most commonly caused by low intakes, but can also result from malabsorption, certain intestinal disorders, low presence of binding proteins, and use of certain medications.<sup>[3]</sup> Vitamin B<sub>12</sub> is rare from plant sources, so vegetarians are more likely to suffer from vitamin B<sub>12</sub> deficiency. Infants are at a higher risk of vitamin B<sub>12</sub> deficiency if they were born to vegetarian mothers. The elderly who have diets with limited meat or animal products are vulnerable populations as well. Vitamin B<sub>12</sub> deficiency may occur in between 40% to 80% of the vegetarian population who are not also consuming a vitamin B<sub>12</sub> supplement.<sup>[14]</sup> In Hong Kong and India, vitamin B<sub>12</sub> deficiency has been found in roughly 80% of the vegan population as well. Vegans can avoid this by eating B12 fortified foods like cereals, plant-based milks, and nutritional yeast as a regular part of their diet.<sup>[15]</sup> In addition to worries concerning those following a vegetarian or vegan diet, research has found that approximately 39 percent of the general population may have possible B12 deficiencies or difficulty with the absorption of this nutrient. Taking a B12 supplement could be beneficial to most people.<sup>[16]</sup>

B<sub>12</sub> is a co-substrate of various cell reactions involved in methylation synthesis of nucleic acid and neurotransmitters. Synthesis of the trimonoamine neurotransmitters can enhance the effects of a traditional antidepressant.<sup>[17]</sup> The intracellular concentrations of vitamin B<sub>12</sub> can be inferred through the total plasma concentration of homocysteine, which can be converted to methionine through an enzymatic reaction that uses 5-methyltetrahydrofolate as the methyl donor group. Consequently, the plasma concentration of homocysteine falls as the intracellular concentration of vitamin B<sub>12</sub> rises. The

active metabolite of vitamin B<sub>12</sub> is required for the methylation of homocysteine in the production of methionine, which is involved in a number of biochemical processes including the monoamine neurotransmitters metabolism. Thus, a deficiency in vitamin B<sub>12</sub> may impact the production and function of those neurotransmitters.<sup>[18]</sup>

## Medical uses<sup>[edit]</sup>



A vitamin B<sub>12</sub> solution (hydroxocobalamin) in a multi-dose bottle, with a single dose drawn up into a syringe for injection. Preparations are usually bright red.

## Repletion of deficiency<sup>[edit]</sup>

Severe vitamin B<sub>12</sub> deficiency is corrected with frequent intramuscular injections of large doses of the vitamin, followed by maintenance doses at longer intervals. Tablets are sometimes used for repletion in mild deficiency; and for maintenance regardless of severity. Vitamin B12 supplementation sometimes leads to [acneiform eruptions](#) (acne-like rashes).<sup>[19]</sup>

## Cyanide poisoning<sup>[edit]</sup>

For [cyanide](#) poisoning, a large amount of hydroxocobalamin may be given [intravenously](#) and sometimes in combination with [sodium thiosulfate](#).<sup>[20]</sup> The mechanism of action is straightforward: the hydroxocobalamin hydroxide [ligand](#) is displaced by the toxic cyanide ion, and the resulting harmless B<sub>12</sub> complex is excreted in [urine](#). In the United States, the [Food and Drug Administration](#) approved the use of hydroxocobalamin for acute treatment of cyanide poisoning.<sup>[21]</sup>

## Dietary recommendations<sup>[edit]</sup>

The U.S. Institute of Medicine (renamed [National Academy of Medicine](#) in 2015) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for vitamin B<sub>12</sub> in 1998.<sup>[3]</sup> The EAR for vitamin B<sub>12</sub> for women and men ages 14 and up is 2.0 µg/day; the RDA is 2.4 µg/day. RDAs are higher than EARs so as to identify amounts that will cover people with higher than average requirements. RDA for pregnancy equals 2.6 µg/day. RDA for lactation equals 2.8 µg/day. For infants up to 12 months the Adequate Intake (AI) is 0.4–0.5 µg/day. (AIs are established when there is insufficient information to determine EARs and RDAs.) For children ages 1–13 years the RDA increases with age from 0.9 to 1.8 µg/day. Because 10 to 30 percent of older people may be unable to effectively absorb vitamin B<sub>12</sub> naturally occurring in foods, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with vitamin B<sub>12</sub> or a

supplement containing vitamin B<sub>12</sub>. As for safety, [Tolerable Upper Intake Levels](#) (known as ULs) are set for vitamins and minerals when evidence is sufficient. In the case of vitamin B<sub>12</sub> there is no UL, as there is no human data for adverse effects from high doses. Collectively the EARs, RDAs, AIs and ULs are referred to as [Dietary Reference Intakes](#) (DRIs).<sup>[22]</sup>

The [European Food Safety Authority](#) (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. For women and men over age 18 the Adequate Intake (AI) is set at 4.0 µg/day. AI for pregnancy is 4.5 µg/day, for lactation 5.0 µg/day. For children aged 1–17 years the AIs increase with age from 1.5 to 3.5 µg/day. These AIs are higher than the U.S. RDAs.<sup>[23]</sup> The EFSA also reviewed the safety question and reached the same conclusion as in United States - that there was not sufficient evidence to set a UL for vitamin B<sub>12</sub>.<sup>[24]</sup>

For U.S. food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For vitamin B<sub>12</sub> labeling purposes 100% of the Daily Value was 6.0 µg, but as of May 27, 2016, was revised downward to 2.4 µg.<sup>[25]</sup> A table of the old and new adult Daily Values is provided at [Reference Daily Intake](#). The original deadline to be in compliance was July 28, 2018, but on September 29, 2017, the [Food and Drug Administration](#) (FDA) released a proposed rule that extended the deadline to January 1, 2020, for large companies and January 1, 2021, for small companies.<sup>[26]</sup> Manufacturers of single-ingredient sugars such as honey and maple syrup and certain cranberry products have until July 1, 2021, to make the changes.<sup>[26]</sup>

## Sources<sup>[edit]</sup>

Most omnivorous people in developed countries obtain enough vitamin B<sub>12</sub> from consuming animal products including, meat, fish, eggs, and milk.<sup>[31][6]</sup> Vegan sources in the common food supply are rare.<sup>[27]</sup>

## Bacteria and archaea<sup>[edit]</sup>

B<sub>12</sub> is only produced in nature by certain [bacteria](#), and [archaea](#).<sup>[31][28][29][30]</sup> It is synthesized by some bacteria in the [gut flora](#) in humans and other animals, but humans cannot absorb this as it is made in the [colon](#), downstream from the [small intestine](#), where the absorption of most nutrients occurs.<sup>[31]</sup> Ruminants, such as cows and sheep, absorb B<sub>12</sub> produced by bacteria in their guts.<sup>[31]</sup> For gut bacteria of ruminants to produce B<sub>12</sub> the animal must consume sufficient amounts of [cobalt](#).<sup>[32]</sup> These grazing animals acquire the bacteria that produce vitamin B<sub>12</sub>, and the vitamin itself.

[Feces](#) are a rich source of vitamin B<sub>12</sub>, and are eaten by many animals, including dogs and cats.<sup>[33][34]</sup> [Lagomorpha](#) species, including [rabbits](#) and [hares](#), form fecal pellets in their [cecum](#) called [cecotropes](#), which consist of chewed plant material that has been metabolized by cecal bacteria; cecotropes contain digestible carbohydrates and B vitamins synthesized by the resident bacteria.<sup>[citation needed]</sup> These animals ingest cecotropes which have been expelled in their feces.<sup>[citation needed]</sup>

## Animals<sup>[edit]</sup>

Animals store vitamin B<sub>12</sub> in the [liver](#) and [muscles](#) and some pass the vitamin into their [eggs](#) and [milk](#); meat, liver, eggs and milk are therefore sources of the vitamin for other animals as well as humans.<sup>[7][9][33]</sup> For humans, the bioavailability from eggs is less than 9%, compared to 40% to 60% from fish, fowl and meat.<sup>[35]</sup> Insects are a source of B<sub>12</sub> for animals (including other insects and humans).<sup>[33][36]</sup>

Food sources with a high concentration of vitamin B<sub>12</sub>—50 to 99 µg B<sub>12</sub> per 100 grams of food<sup>[37]</sup>—include [clams](#); [liver](#) and other [organ meats](#) from [lamb](#), [veal](#), [beef](#), and [turkey](#); [mackerel](#); and [crab meat](#).<sup>[31][7]</sup>

## Plants and algae[[edit](#)]

Natural sources of B<sub>12</sub> include [fermented](#) plant foods, such as [tempeh](#),<sup>[38][39][40]</sup> [nori](#)<sup>[27]</sup> and [laver](#), a seaweed.<sup>[27][41][42]</sup> Many other types of [algae](#) are rich in vitamin B<sub>12</sub>, with some species, such as *Porphyra yezoensis*,<sup>[27]</sup> containing as much cobalamin as liver.<sup>[43]</sup> [Methylcobalamin](#) has been identified in *Chlorella vulgaris*.<sup>[44]</sup> In all cases of plant foods which contain B<sub>12</sub>, the vitamin is produced by bacterial fermentation or by bacterial symbiosis with various species of algae.

## Fortified foods[[edit](#)]

The UK [Vegan Society](#), the Vegetarian Resource Group, and the [Physicians Committee for Responsible Medicine](#), among others, recommend that every vegan who is not consuming adequate B<sub>12</sub> from fortified foods take supplements.<sup>[35][45][46][47]</sup>

Foods for which B<sub>12</sub>-fortified versions are widely available include [breakfast cereals](#), [soy](#) products, [energy bars](#), and [nutritional yeast](#).<sup>[37]</sup>

## Supplements[[edit](#)]



A blister pack of 500 µg methylcobalamin tablets

Vitamin B<sub>12</sub> is included in multivitamin pills; and in some countries grain-based foods such as bread and pasta are fortified with B<sub>12</sub>. In the U.S. non-prescription products can be purchased providing up to 5,000 µg per serving, and it is a common ingredient in [energy drinks](#) and [energy shots](#), usually at many times the recommended dietary allowance of B<sub>12</sub>. The vitamin can also be a prescription product via injection or other means. Tablets have sufficiently large quantities of the vitamin such that 1% to 5% of the free crystalline B<sub>12</sub> is absorbed along the entire intestine by passive diffusion.<sup>[citation needed]</sup>

Sublingual [methylcobalamin](#), which contains no [cyanide](#), is available in 5-mg tablets. The metabolic fate and biological distribution of methylcobalamin are expected to be similar to that of other sources of vitamin B<sub>12</sub> in the diet,<sup>[48]</sup> but the amount of cyanide in cyanocobalamin even in the largest available dose—20 µg of cyanide in a 1,000-µg cyanocobalamin tablet—is less than the daily consumption of cyanide from food, and so cyanocobalamin is not considered a health risk.<sup>[48]</sup>

## Parenteral administration[[edit](#)]

Injection and patches are sometimes used if digestive absorption is impaired, but this course of action may not be necessary with high-potency oral supplements (such as 0.5–1 mg or more).<sup>[49][50]</sup> A person with cobalamin C disease combined with [methylmalonic aciduria](#) and [homocystinuria](#) may require treatment with intravenous, intramuscular [hydroxocobalamin](#) or transdermal B<sub>12</sub>.<sup>[51]</sup>

### **Pseudovitamin-B<sub>12</sub>**[\[edit\]](#)

Pseudovitamin-B<sub>12</sub> refers to B<sub>12</sub>-like analogues that are biologically inactive in humans and yet found to be present alongside B<sub>12</sub> in humans,<sup>[52]</sup> many food sources (including animals<sup>[53][54]</sup>), and possibly supplements and fortified foods.<sup>[55]</sup> Most cyanobacteria, including [Spirulina](#), and some algae, such as dried Asakusa-nori ([Porphyra tenera](#)), have been found to contain mostly pseudovitamin-B<sub>12</sub> instead of biologically active B<sub>12</sub>.<sup>[56][57]</sup> In one common form of pseudo-B<sub>12</sub> available to [Salmonella enterica serovar Typhimurium](#), the  $\alpha$ -axial ligand is changed from [dimethylbenzimidazole](#) to [adenine](#).<sup>[58]</sup>

### **Drug interactions**[\[edit\]](#)

#### **H<sub>2</sub>-receptor antagonists and proton-pump inhibitors**[\[edit\]](#)

Gastric acid is needed to release vitamin B<sub>12</sub> from protein for absorption. Reduced secretion of [gastric acid](#) and [pepsin](#) produced by [H<sub>2</sub> blocker](#) or proton-pump inhibitor (PPI) drugs can reduce absorption of protein-bound (dietary) vitamin B<sub>12</sub>, although not of supplemental vitamin B<sub>12</sub>. H<sub>2</sub>-receptor antagonist examples include [cimetidine](#), [famotidine](#), [nizatidine](#), and [ranitidine](#). PPIs examples include [omeprazole](#), [lansoprazole](#), [rabeprazole](#), [pantoprazole](#), and [esomeprazole](#). Clinically significant vitamin B<sub>12</sub> deficiency and megaloblastic anemia are unlikely, unless these drug therapies are prolonged for two or more years, or if in addition the person's diet is below recommended intakes. Symptomatic vitamin deficiency is more likely if the person is rendered [achlorhydric](#) (complete absence of gastric acid secretion), which occurs more frequently with proton pump inhibitors than H<sub>2</sub> blockers.<sup>[59]</sup>

#### **Metformin**[\[edit\]](#)

Reduced serum levels of vitamin B<sub>12</sub> occur in up to 30% of people taking long-term [anti-diabetic metformin](#).<sup>[60][61][62]</sup> Deficiency does not develop if dietary intake of vitamin B<sub>12</sub> is adequate or prophylactic B<sub>12</sub> supplementation is given. If the deficiency is detected, metformin can be continued while the deficiency is corrected with B<sub>12</sub> supplements.<sup>[63]</sup>

### **Chemistry**[\[edit\]](#)






Methylcobalamin (shown) is a form of vitamin B<sub>12</sub>. Physically it resembles the other forms of vitamin B<sub>12</sub>, occurring as dark red crystals that freely form cherry-colored transparent solutions in water.

B<sub>12</sub> is the most chemically complex of all the vitamins.<sup>[3]</sup> The structure of B<sub>12</sub> is based on a [corrin](#) ring, which is similar to the [porphyrin](#) ring found in [heme](#). The central metal ion is [cobalt](#). Four of the six coordination sites are provided by the corrin ring, and a fifth by a [dimethylbenzimidazole](#) group. The sixth coordination site, the [reactive center](#), is variable, being a [cyano group](#) (–CN), a [hydroxyl](#) group (–OH), a [methyl](#) group (–CH<sub>3</sub>) or a 5'-deoxyadenosyl group (here the C5' atom of the deoxyribose forms the [covalent bond with cobalt](#) respectively, to yield the four [vitamers](#) (forms) of B<sub>12</sub>. Historically, the covalent C-Co bond is one of the first examples of carbon-metal bonds to be discovered in biology. The [hydrogenases](#) and, by necessity, enzymes associated with cobalt utilization, involve metal-carbon bonds.<sup>[64]</sup>

Vitamin B<sub>12</sub> is a generic descriptor name referring to a collection of [cobalt](#) and [corrin ring](#) molecules which are defined by their particular vitamin function in the body. All of the substrate cobalt-corrin molecules from which B<sub>12</sub> is made must be synthesized by bacteria. After this synthesis is complete, the human body has the ability (except in rare cases) to convert any form of B<sub>12</sub> to an active form, by means of enzymatically removing certain prosthetic chemical groups from the cobalt atom and replacing them with others.



The structures of the four most common vitamers of cobalamin, together with some synonyms. The structure of the 5'-deoxyadenosyl group, which forms the R group of adenosylcobalamin is also shown.

## Vitamers<sup>[edit]</sup>

The four vitamers of B<sub>12</sub> are all deeply red-colored crystals and water solutions, due to the color of the cobalt-corrin complex.


- [Cyanocobalamin](#) is one form of B<sub>12</sub> because it can be metabolized in the body to an active [coenzyme](#) form.<sup>[3]</sup> The cyanocobalamin form of B<sub>12</sub> does not occur in nature normally, but is a byproduct of the fact that other forms of B<sub>12</sub> are avid binders of cyanide (–CN) which they pick up in the process of [activated charcoal](#) purification of the vitamin after it is made by bacteria in the commercial process. Since the cyanocobalamin form of B<sub>12</sub> is easy to crystallize and is not sensitive to air-oxidation, it is typically used as a form of B<sub>12</sub> for food additives and in many common multivitamins. Pure cyanocobalamin possesses the deep pink color associated with most octahedral cobalt(II) complexes and the crystals are well formed and easily grown up to millimeter size.
- [Hydroxocobalamin](#) is another vitamer of B<sub>12</sub> commonly encountered in pharmacology, but is not normally present in the human body. Hydroxocobalamin is sometimes denoted B<sub>12a</sub>. This is the form of B<sub>12</sub> produced by bacteria, and which is converted to cyanocobalamin in the commercial charcoal filtration step of production. Hydroxocobalamin has an avid affinity for [cyanide](#) ions and has been used as an antidote to cyanide poisoning. It is supplied typically in water solution for injection. Hydroxocobalamin is thought to be converted to the active enzymic forms of B<sub>12</sub> more easily than cyanocobalamin, and since it is little more expensive than

cyanocobalamin, and has longer retention times in the body, has been used for vitamin replacement in situations where added reassurance of activity is desired. Intramuscular administration of hydroxocobalamin is also the preferred treatment for [pediatric](#) patients with intrinsic cobalamin [metabolic diseases](#), for vitamin B<sub>12</sub> deficient patients with [tobacco amblyopia](#) (which is thought to perhaps have a component of cyanide poisoning from cyanide in cigarette smoke); and for treatment of patients with pernicious anemia who have optic neuropathy.

- [Adenosylcobalamin](#) (adoB<sub>12</sub> or AdoCbl) and [methylcobalamin](#) (MeB<sub>12</sub> or MeCbl) are the two enzymatically active cofactor forms of B<sub>12</sub> that naturally occur in the body. Most of the body's reserves are stored as adoB<sub>12</sub> in the liver. These are converted to the other methylcobalamin form as needed.

A review of what is reported in the literature about cobalamin chemistry, transport, and processing suggests that despite the increased cost, there is unlikely to be any advantage to the use of adenosylcobalamin or methylcobalamin for treatment of vitamin B<sub>12</sub> deficiency over the other two forms except possibly in very rare circumstances in which an inborn metabolic disorder reduces the efficiency of the conversion of cyanocobalamin to MeCbl or AdoCbl. The use of parenteral hydroxocobalamin has been suggested in these cases. However, due to its excellent shelf-life and stability, cyanocobalamin is still considered the best choice for oral administration.<sup>[65]</sup> (For the treatment of cyanide poisoning, hydroxocobalamin is the required form.)

## Biochemistry<sup>[edit]</sup>



[Metabolism](#) of vitamin B<sub>12</sub> is seen at bottom left.

## Coenzyme function<sup>[edit]</sup>

Vitamin B<sub>12</sub> functions as a [coenzyme](#), meaning that its presence is required for enzyme-catalyzed reactions.<sup>[3][66][67]</sup> Three types of enzymes:

### 1. [Isomerases](#)

Rearrangements in which a hydrogen atom is directly transferred between two adjacent atoms with concomitant exchange of the second substituent, X, which may be a carbon atom with substituents, an oxygen atom of an alcohol, or an amine. These use the adoB<sub>12</sub> (adenosylcobalamin) form of the vitamin.

### 2. [Methyltransferases](#)

Methyl (–CH<sub>3</sub>) group transfers between two molecules. These use MeB<sub>12</sub> (methylcobalamin) form of the vitamin.

### 3. [Dehalogenases](#)

Reactions in which a halogen atom is removed from an organic molecule. Enzymes in this class have not been identified in humans.

In humans, two major coenzyme B<sub>12</sub>-dependent enzyme families corresponding to the first two reaction types, are known. These are typified by the following two enzymes:

1. **MUT** is an isomerase which uses the AdoB<sub>12</sub> form and reaction type 1 to catalyze a carbon skeleton rearrangement (the X group is -COSC<sub>o</sub>A). MUT's reaction converts **MMI-CoA** to **Su-CoA**, an important step in the extraction of energy from proteins and fats. This functionality is lost in **vitamin B<sub>12</sub> deficiency**, and can be measured clinically as an increased **methylmalonic acid** (MMA) level. Unfortunately, an elevated MMA is a **sensitive but not specific test**, and not all who have it actually have B<sub>12</sub> deficiency. For example, MMA is elevated in 90–98% of patients with B<sub>12</sub> deficiency; 20–25% of patients over the age of 70 have elevated levels of MMA, yet 25–33% of them do not have B<sub>12</sub> deficiency. For this reason, assessment of MMA levels is not routinely recommended in the elderly. There is no "gold standard" test for B<sub>12</sub> deficiency because as a B<sub>12</sub> deficiency occurs, serum values may be maintained while tissue B<sub>12</sub> stores become depleted. Therefore, serum B<sub>12</sub> values above the cut-off point of deficiency do not necessarily indicate adequate B<sub>12</sub> status. The MUT function is necessary for proper **myelin** synthesis and is not affected by folate supplementation.
2. **MTR**, also known as methionine synthase, is a methyltransferase enzyme, which uses the MeB<sub>12</sub> and reaction type 2 to transfer a methyl group from **5-methyltetrahydrofolate** to **homocysteine**, thereby generating **tetrahydrofolate** (THF) and **methionine**.<sup>[69]</sup> This functionality is lost in **vitamin B<sub>12</sub> deficiency**, resulting in an increased **homocysteine** level and the trapping of **folate** as 5-methyl-tetrahydrofolate, from which THF (the active form of folate) cannot be recovered. THF plays an important role in DNA synthesis so reduced availability of THF results in ineffective production of cells with rapid turnover, in particular red blood cells, and also intestinal wall cells which are responsible for absorption. **THF** may be regenerated via MTR or may be obtained from fresh folate in the diet. Thus all of the DNA synthetic effects of B<sub>12</sub> deficiency, including the **megaloblastic anemia** of **pernicious anemia**, resolve if sufficient dietary folate is present. Thus the best-known "function" of B<sub>12</sub> (that which is involved with DNA synthesis, cell-division, and anemia) is actually a facultative function which is mediated by B<sub>12</sub>-conservation of an active form of folate which is needed for efficient DNA production.<sup>[69]</sup> Other cobalamin-requiring methyltransferase enzymes are also known in bacteria, such as Me-H<sub>4</sub>-MPT, coenzyme M methyltransferase.

## Enzyme function<sup>[edit]</sup>

If folate is present in quantity, then of the two absolutely vitamin B<sub>12</sub>-dependent enzyme-family reactions in humans, the **MUT**-family reactions show the most direct and characteristic secondary effects, focusing on the nervous system (see below). This is because the MTR (methyltransferase-type) reactions are involved in regenerating folate, and thus are less evident when folate is in good supply.

Since the late 1990s, folic acid has begun to be added to fortify flour in many countries, so folate deficiency is now more rare. At the same time, since DNA synthetic-sensitive tests for **anemia** and **erythrocyte** size are routinely done in even simple medical test clinics (so that these folate-mediated biochemical effects are more often directly detected), the **MTR**-dependent effects of B<sub>12</sub> deficiency are becoming apparent not as anemia due to DNA-synthetic problems (as they were classically), but now mainly as a simple and less obvious elevation of homocysteine in the blood and urine (**homocysteinuria**). This condition may result in long-term damage to arteries and in clotting (stroke and heart attack), but this effect is difficult to separate from other common processes associated with atherosclerosis and aging.

The specific myelin damage resulting from B<sub>12</sub> deficiency, even in the presence of adequate folate and methionine, is more specifically and clearly a vitamin deficiency problem.<sup>[3]</sup> It has been connected to B<sub>12</sub> most directly by reactions related to MUT, which is absolutely required to convert

methylmalonyl coenzyme A into succinyl coenzyme A. Failure of this second reaction to occur results in elevated levels of MMA, a myelin destabilizer. Excessive MMA will prevent normal [fatty acid synthesis](#), or it will be incorporated into [fatty acids](#) itself rather than normal [malonic acid](#). If this abnormal fatty acid subsequently is incorporated into myelin, the resulting myelin will be too fragile, and demyelination will occur. Although the precise mechanism or mechanisms are not known with certainty, the result is [subacute combined degeneration of spinal cord](#).<sup>[70]</sup> Whatever the cause, it is known that B<sub>12</sub> deficiency causes [neuropathies](#), even if folic acid is present in good supply, and therefore anemia is not present.

Vitamin B<sub>12</sub>-dependent [MTR](#) reactions may also have neurological effects, through an indirect mechanism. Adequate [methionine](#) (which, like folate, must otherwise be obtained in the diet, if it is not regenerated from [homocysteine](#) by a B<sub>12</sub> dependent reaction) is needed to make [S-adenosyl methionine](#) (S-AdoMet), which is in turn necessary for methylation of [myelin](#) sheath [phospholipids](#). Although production of S-AdoMet is not B<sub>12</sub> dependent, help in recycling for provision of one adequate substrate for it (the [essential amino acid](#) methionine) is assisted by B<sub>12</sub>. In addition, S-AdoMet is involved in the manufacture of certain [neurotransmitters](#), [catecholamines](#) and in brain metabolism. These neurotransmitters are important for maintaining mood, possibly explaining why depression is associated with B<sub>12</sub> deficiency. Methylation of the myelin sheath [phospholipids](#) may also depend on adequate folate, which in turn is dependent on MTR recycling, unless ingested in relatively high amounts.

## Physiology<sup>[edit]</sup>

### Absorption<sup>[edit]</sup>

Methyl-B<sub>12</sub> is absorbed by two processes. The first is an intestinal mechanism using [intrinsic factor](#) through which 1–2 micrograms can be absorbed every few hours. The second is a diffusion process by which approximately 1% of the remainder is absorbed.<sup>[71]</sup> The human physiology of vitamin B<sub>12</sub> is complex, and therefore is prone to mishaps leading to [vitamin B<sub>12</sub> deficiency](#). Protein-bound vitamin B<sub>12</sub> must be released from the proteins by the action of digestive proteases in both the stomach and small intestine.<sup>[72]</sup> [Gastric acid](#) releases the vitamin from food particles; therefore [antacid](#) and acid-blocking medications (especially [proton-pump inhibitors](#)) may inhibit absorption of B<sub>12</sub>.

B<sub>12</sub> taken in a low-solubility, non-chewable supplement pill form may bypass the mouth and stomach and not mix with gastric acids, but acids are not necessary for the absorption of free B<sub>12</sub> not bound to protein; acid is necessary only to recover naturally-occurring vitamin B<sub>12</sub> from foods.

[R-protein](#) (also known as haptocorrin and cobalophilin) is a B<sub>12</sub> binding protein that is produced in the salivary glands. It must wait to bind food-B<sub>12</sub> until B<sub>12</sub> has been freed from proteins in food by [pepsin](#) in the stomach. B<sub>12</sub> then binds to the R-protein to avoid degradation of it in the acidic environment of the stomach.<sup>[73]</sup>

This pattern of B<sub>12</sub> transfer to a special binding protein secreted in a previous digestive step, is repeated once more before absorption. The next binding protein for B<sub>12</sub> is intrinsic factor (IF), a protein synthesized by gastric [parietal cells](#) that is secreted in response to [histamine](#), [gastrin](#) and [pentagastrin](#), as well as the presence of food. In the [duodenum](#), [proteases](#) digest R-proteins and release their bound B<sub>12</sub>, which then binds to IF, to form a complex (IF/B<sub>12</sub>). B<sub>12</sub> must be attached to IF for it to be efficiently absorbed, as receptors on the enterocytes in the terminal [ileum](#) of the [small bowel](#) only recognize the B<sub>12</sub>-IF complex; in addition, intrinsic factor protects the vitamin from [catabolism](#) by intestinal bacteria.

Absorption of food vitamin B<sub>12</sub> thus requires an intact and functioning [stomach](#), [exocrine pancreas](#), intrinsic factor, and small bowel.<sup>[31]</sup> Problems with any one of these organs makes a [vitamin B<sub>12</sub> deficiency](#) possible. Individuals who lack intrinsic factor have a decreased ability to absorb B<sub>12</sub>. In [pernicious anemia](#), there is a lack of IF due to autoimmune [atrophic gastritis](#), in which antibodies

form against parietal cells. Antibodies may alternately form against and bind to IF, inhibiting it from carrying out its B<sub>12</sub> protective function. Due to the complexity of B<sub>12</sub> absorption, geriatric patients, many of whom are hypoacidic due to reduced parietal cell function, have an increased risk of B<sub>12</sub> deficiency.<sup>[74]</sup> This results in 80–100% excretion of oral doses in the feces versus 30–60% excretion in feces as seen in individuals with adequate IF.<sup>[74]</sup>

Once the IF/B<sub>12</sub> complex is recognized by specialized [ileal receptors](#), it is transported into the [portal circulation](#). The vitamin is then transferred to [transcobalamin II](#) (TC-II/B<sub>12</sub>), which serves as the plasma transporter. Hereditary defects in production of the transcobalamins and their receptors may produce functional deficiencies in B<sub>12</sub> and infantile [megaloblastic anemia](#), and abnormal B<sub>12</sub> related biochemistry, even in some cases with normal blood B<sub>12</sub> levels. For the vitamin to serve inside cells, the TC-II/B<sub>12</sub> complex must bind to a cell receptor, and be [endocytosed](#). The transcobalamin-II is degraded within a [lysosome](#), and free B<sub>12</sub> is finally released into the cytoplasm, where it may be transformed into the proper coenzyme, by certain cellular enzymes (see above).

Investigations into the intestinal absorption of B<sub>12</sub> point out that the upper limit of absorption per single oral dose, under normal conditions, is about 1.5 µg: "Studies in normal persons indicated that about 1.5 µg is assimilated when a single dose varying from 5 to 50 µg is administered by mouth. In a similar study Swendseid *et al.* stated that the average maximum absorption was 1.6 µg [...]"<sup>[75]</sup> The bulk diffusion process of B<sub>12</sub> absorption noted in the first paragraph above, may overwhelm the complex R-factor and IGF-factor dependent absorption, when oral doses of B<sub>12</sub> are very large (a thousand or more µg per dose) as commonly happens in dedicated-pill oral B<sub>12</sub> supplementation. It is this last fact which allows pernicious anemia and certain other defects in B<sub>12</sub> absorption to be treated with oral megadoses of B<sub>12</sub>, even without any correction of the underlying absorption defects.<sup>[76]</sup> See the section on supplements above.

## Storage and excretion<sup>[edit]</sup>

The total amount of vitamin B<sub>12</sub> stored in body is about 2–5 mg in adults. Around 50% of this is stored in the liver. Approximately 0.1% of this is lost per day by secretions into the gut, as not all these secretions are reabsorbed. Bile is the main form of B<sub>12</sub> excretion; most of the B<sub>12</sub> secreted in the bile is recycled via enterohepatic circulation. Excess B<sub>12</sub> beyond the blood's binding capacity is typically excreted in urine. Owing to the extremely efficient enterohepatic circulation of B<sub>12</sub>, the liver can store 3 to 5 years' worth of vitamin B<sub>12</sub>,<sup>[77]</sup> therefore, nutritional deficiency of this vitamin is rare. How fast B<sub>12</sub> levels change depends on the balance between how much B<sub>12</sub> is obtained from the diet, how much is secreted and how much is absorbed. B<sub>12</sub> deficiency may arise in a year if initial stores are low and genetic factors unfavourable, or may not appear for decades. In infants, B<sub>12</sub> deficiency can appear much more quickly.<sup>[78]</sup>

## Production<sup>[edit]</sup>

---

### Industrial<sup>[edit]</sup>

Industrial production of B<sub>12</sub> is achieved through [fermentation](#) of selected microorganisms.<sup>[79]</sup> [Streptomyces griseus](#), a bacterium once thought to be a [fungus](#), was the commercial source of vitamin B<sub>12</sub> for many years.<sup>[80][81]</sup> The species [Pseudomonas denitrificans](#) and [Propionibacterium freudenreichii subsp. shermanii](#) are more commonly used today.<sup>[82]</sup> These are frequently grown under special conditions to enhance yield, and at least one company uses genetically engineered versions of one or both of these species.<sup>[citation needed]</sup> Since a number of species of [Propionibacterium](#) produce no [exotoxins](#) or [endotoxins](#) and are generally recognized as safe (have been granted [GRAS](#) status) by the [Food and Drug Administration](#) of the United States, they are presently the FDA-preferred bacterial fermentation organisms for vitamin B<sub>12</sub> production.<sup>[83]</sup>

The total world production of vitamin B<sub>12</sub>, by four companies (the French Sanofi-Aventis and three Chinese companies) in 2008 was 35 tonnes.<sup>[84]</sup>

## Laboratory[[edit](#)]

No [eukaryotic](#) organisms (including plants, animals, and fungi) are independently capable of constructing vitamin B<sub>12</sub>.<sup>[85]</sup> Only [bacteria](#) and [archaea](#)<sup>[86]</sup> have the enzymes required for its biosynthesis. Like all tetrapyrroles, it is derived from [uroporphyrinogen III](#). This [porphyrinogen](#) is methylated at two pyrrole rings to give [dihydrosirohydrochlorin](#), which is oxidized to [sirohydrochlorin](#), which undergoes further reactions, notably a ring contraction, to give the corrin ring.

The complete laboratory [synthesis of B<sub>12</sub>](#) was achieved by [Robert Burns Woodward](#)<sup>[87]</sup> and [Albert Eschenmoser](#) in 1972,<sup>[88][89]</sup> and remains one of the classic feats of organic synthesis, requiring the effort of 91 postdoctoral fellows (mostly at Harvard) and 12 PhD students (at [ETH Zurich](#)) from 19 nations. The synthesis constitutes a formal total synthesis, since the research groups only prepared the known intermediate cobalamin, whose chemical conversion to vitamin B<sub>12</sub> was previously reported. Though it constitutes an intellectual achievement of the highest caliber, the Eschenmoser–Woodward synthesis of vitamin B<sub>12</sub> is of no practical consequence due to its length, taking 72 chemical steps and giving an overall chemical yield well under 0.01%.<sup>[90]</sup> And although there have been sporadic synthetic efforts since 1972,<sup>[91]</sup> the Eschenmoser–Woodward synthesis remains the only completed (formal) total synthesis. Bacterial (or, perhaps archaeal) fermentation remains the only industrially viable source of the vitamin for food production and medicine.

Species from the following [genera](#) and species are known to synthesize B<sub>12</sub>: [Propionibacterium shermanii](#), [Pseudomonas denitrificans](#), [Streptomyces griseus](#),<sup>[92]</sup> [Acetobacterium](#), [Aerobacter](#), [Agrobacterium](#), [Alcaligenes](#), [Azotobacter](#), [Bacillus](#), [Clostridium](#), [Corynebacterium](#), [Favobacterium](#), [Lactobacillus](#), [Micromonospora](#), [Mycobacterium](#), [Nocardia](#), [Protaminobacter](#), [Proteus](#), [Rhizobium](#), [Salmonella](#), [Serratia](#), [Streptococcus](#) and [Xanthomonas](#).<sup>[93][94]</sup>

## History[[edit](#)]

---

- 1849 - [Thomas Addison](#) first described a case of [pernicious anemia](#).<sup>[4]</sup>
- 1877 - [William Osler](#) and William Gardner first described a case of neuropathy in this condition.<sup>[4]</sup>
- 1878 - Hayem first described large red cells in the peripheral blood in this condition, which he called "giant blood corpuscles", now called [macrocytes](#).<sup>[4]</sup>
- 1880 - [Paul Ehrlich](#) first identified [megaloblasts](#) in the bone marrow in this condition.<sup>[4]</sup>
- 1887 - [Ludwig Lichtheim](#) first described a case of [myelopathy](#) in this condition.<sup>[4]</sup>
- 1920 - [George Whipple](#) discovered that ingesting large amounts of [liver](#) seemed to most rapidly cure the anemia of blood loss in dogs, and hypothesized that eating liver might treat pernicious anemia.<sup>[citation needed]</sup>
- 1926 - [George Minot](#) shared the 1934 [Nobel Prize](#) with [William Murphy](#) and [George Whipple](#), for discovery of an effective treatment for pernicious anemia using liver concentrate, later found to contain a large amount of vitamin B<sub>12</sub>.<sup>[4]</sup>
- 1928 - [Edwin Cohn](#) prepared a liver extract that was 50 to 100 times more potent in treating pernicious anemia than the natural liver products. Whipple, Minot, and Murphy shared the 1934 [Nobel Prize in Physiology or Medicine](#).<sup>[95]</sup>
- 1929 - [William Castle](#) demonstrated that gastric juice contained an "intrinsic factor" which when combined with meat ingestion resulted in absorption of the vitamin in this condition.<sup>[4]</sup>
- 1947 - [Mary Shaw Shorb](#), in a collaborative project with [Karl Folkers](#), was provided with a US\$400 grant to develop the so-called "LLD assay" for B<sub>12</sub>. LLD stood for *Lactobacillus lactis* Dorner,<sup>[96]</sup> a strain of bacterium which required "LLD factor" for growth, which was eventually identified as B<sub>12</sub>.
- 1948 - Shorb and colleagues [Karl A. Folkers](#) and [Alexander R. Todd](#) used the LLD assay to rapidly extract the anti-pernicious anemia factor from liver extracts, and pure B<sub>12</sub> was isolated.<sup>[97]</sup>

- 1949 - Shorb and Folkers received the Mead Johnson Award from the American Society of Nutritional Sciences for their discovery.<sup>[97]</sup>
- 1956 - The [chemical structure](#) of the molecule was determined by [Dorothy Hodgkin](#), based on [crystallographic](#) data.<sup>[98]</sup> She was awarded the 1964 Nobel Prize in Chemistry for determining the structure of vitamin B<sub>12</sub> and other complex molecules.
- 1959 - methods of producing the vitamin in large quantities from bacteria cultures were developed.
- 1981 - Observations of stereospecificity encountered by [R. B. Woodward](#) during the synthesis of vitamin B<sub>12</sub> led to the formulation of the [principle of the conservation of orbital symmetry](#), which would result in a Nobel Prize in Chemistry by [R. Hoffmann](#) and [K. Fukui](#).

Six Nobel Prizes have been awarded for direct and indirect studies of vitamin B<sub>12</sub>.<sup>[99]</sup>

## References<sup>[edit]</sup>

1. <sup>^</sup> Yamada K (2013). "Chapter 9. Cobalt: Its Role in Health and Disease". In Sigel A, Sigel H, Sigel RK (eds.). *Interrelations between Essential Metal Ions and Human Diseases. Metal Ions in Life Sciences*. **13**. Springer. pp. 295–320. doi:10.1007/978-94-007-7500-8\_9. ISBN 978-94-007-7499-5. PMID 24470095.
2. <sup>^</sup> Miller A, Korem M, Almog R, Galboiz Y (June 2005). "Vitamin B12, demyelination, remyelination and repair in multiple sclerosis". *Journal of the Neurological Sciences*. **233**(1–2): 93–7. doi:10.1016/j.ins.2005.03.009. PMID 15896807.
3. <sup>^</sup> Jump up to:<sup>a b c d e f g h i j k l m n o p q r</sup> "Vitamin B<sub>12</sub>". Micronutrient Information Center, Linus Pauling Institute, Oregon State University, Corvallis, OR. 4 June 2015. Retrieved 5 April 2019.
4. <sup>^</sup> Jump up to:<sup>a b c d e f g h</sup> Greer JP (2014). *Wintrobe's Clinical Hematology Thirteenth Edition*. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins. ISBN 978-1-4511-7268-3. Chapter 36: Megaloblastic anemias: disorders of impaired DNA synthesis by Ralph Carmel
5. <sup>^</sup> "What Every Vegan Should Know About Vitamin B12". The Vegan Society. 2012-06-12. Retrieved 2018-10-15.
6. <sup>^</sup> Jump up to:<sup>a b</sup> "Office of Dietary Supplements - Vitamin B12".
7. <sup>^</sup> Jump up to:<sup>a b c</sup> "Foods highest in Vitamin B<sub>12</sub> (based on levels per 100-gram serving)". Nutrition Data. Condé Nast, USDA National Nutrient Database, release SR-21. 2014. Retrieved February 16, 2017.
8. <sup>^</sup> "Acid-Reflux Drugs Tied to Lower Levels of Vitamin B-12".
9. <sup>^</sup> Jump up to:<sup>a b c</sup> "Dietary Supplement Fact Sheet: Vitamin B<sub>12</sub>". Office of Dietary Supplements, National Institutes of Health. Retrieved September 28, 2011.
10. <sup>^</sup> van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ (April 2001). "Folate, homocysteine and neural tube defects: an overview". *Experimental Biology and Medicine*. **226** (4): 243–70. doi:10.1177/153537020122600402. PMID 11368417.
11. <sup>^</sup> Skerrett, Patrick J. (2013-01-10). "Vitamin B12 deficiency can be sneaky, harmful". Harvard Health Blog. Retrieved 2018-12-14.
12. <sup>^</sup> "Vitamin B<sub>12</sub> or folate deficiency anaemia - Symptoms". National Health Service, England. May 16, 2016. Retrieved February 16, 2017.
13. <sup>^</sup> Masalha R, Chudakov B, Muhamad M, Rudoy I, Volkov I, Wirguin I (September 2001). "Cobalamin-responsive psychosis as the sole manifestation of vitamin B12 deficiency". *The Israel Medical Association Journal*. **3** (9): 701–3. PMID 11574992.
14. <sup>^</sup> Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D (February 2013). "How prevalent is vitamin B(12) deficiency among vegetarians?". *Nutrition Reviews*. **71** (2): 110–7. doi:10.1111/nure.12001. PMID 23356638.
15. <sup>^</sup> Woo KS, Kwok TC, Celermajer DS (August 2014). "Vegan diet, subnormal vitamin B-12 status and cardiovascular health". *Nutrients*. **6** (8): 3259–73. doi:10.3390/nu6083259. PMC 4145307. PMID 25195560.
16. <sup>^</sup> Tucker KL, Rich S, Rosenberg I, Jacques P, Dallal G, Wilson PW, Selhub J (February 2000). "Plasma vitamin B-12 concentrations relate to intake source in the Framingham Offspring study". *The American Journal of Clinical Nutrition*. **71** (2): 514–22. doi:10.1093/ajcn/71.2.514. PMID 10648266.

17. <sup>^</sup> [Biemans E, Hart HE, Rutten GE, Cuellar Renteria VG, Kooijman-Buiting AM, Beulens JW \(April 2015\). "Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin". \*Acta Diabetologica\*. \*\*52\*\* \(2\): 383–93. \[doi:10.1007/s00592-014-0661-4\]\(#\). \[PMID 25315630\]\(#\).](#)
18. <sup>^</sup> [Bottiglieri T, Laundry M, Crellin R, Toone BK, Carney MW, Reynolds EH \(August 2000\). "Homocysteine, folate, methylation, and monoamine metabolism in depression". \*Journal of Neurology, Neurosurgery, and Psychiatry\*. \*\*69\*\* \(2\): 228–32. \[doi:10.1136/jnnp.69.2.228\]\(#\). \[PMC 1737050\]\(#\). \[PMID 10896698\]\(#\).](#)
19. <sup>^</sup> [Kang D, Shi B, Erfe MC, Craft N, Li H \(June 2015\). "Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis". \*Science Translational Medicine\*. \*\*7\*\* \(293\): 293ra103. \[doi:10.1126/scitranslmed.aab2009\]\(#\). \[PMC 6049814\]\(#\). \[PMID 26109103\]\(#\).](#)
20. <sup>^</sup> [Hall AH, Rumack BH \(1987\). "Hydroxycobalamin/sodium thiosulfate as a cyanide antidote". \*The Journal of Emergency Medicine\*. \*\*5\*\* \(2\): 115–121. \[doi:10.1016/0736-4679\\(87\\)90074-6\]\(#\). \[PMID 3295013\]\(#\).](#)
21. <sup>^</sup> [Dart RC \(2006\). "Hydroxocobalamin for acute cyanide poisoning: new data from preclinical and clinical studies; new results from the prehospital emergency setting". \*Clinical Toxicology\*. \*\*44\*\* Suppl 1 \(Suppl. 1\): 1–3. \[doi:10.1080/15563650600811607\]\(#\). \[PMID 16990188\]\(#\).](#)
22. <sup>^</sup> [Institute of Medicine \(1998\). "Vitamin B<sub>12</sub>". \*Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Pantothenic Acid, Biotin, and Choline\*. Washington, DC: The National Academies Press. pp. 306–356. \[ISBN 978-0-309-06554-2\]\(#\). Retrieved February 7, 2012.](#)
23. <sup>^</sup> ["Overview on Dietary Reference Values for the EU population as derived by the EFSA Panel on Dietetic Products, Nutrition and Allergies" \(PDF\). 2017.](#)
24. <sup>^</sup> ["Tolerable Upper Intake Levels For Vitamins And Minerals" \(PDF\). European Food Safety Authority. 2006.](#)
25. <sup>^</sup> ["Food Labeling: Revision of the Nutrition and Supplement Facts Labels" \(PDF\). Federal Register. May 27, 2016. p. 33982.](#)
26. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> "Changes to the Nutrition Facts Label". \*Food and Drug Administration\* \(FDA\). June 18, 2019. Retrieved July 16, 2019. <sup>Ⓒ</sup> This article incorporates text from this source, which is in the \[public domain\]\(#\).](#)
27. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> Watanabe F, Yabuta Y, Bito T, Teng F \(May 2014\). "Vitamin B<sub>12</sub>-containing plant food sources for vegetarians". \*Nutrients\*. \*\*6\*\* \(5\): 1861–73. \[doi:10.3390/nu6051861\]\(#\). \[PMC 4042564\]\(#\). \[PMID 24803097\]\(#\).](#)
28. <sup>^</sup> [Fang H, Kang J, Zhang D \(January 2017\). "12: a review and future perspectives". \*Microbial Cell Factories\*. \*\*16\*\* \(1\): 15. \[doi:10.1186/s12934-017-0631-y\]\(#\). \[PMC 5282855\]\(#\). \[PMID 28137297\]\(#\).](#)
29. <sup>^</sup> [Moore SJ, Warren MJ \(June 2012\). "The anaerobic biosynthesis of vitamin B12". \*Biochemical Society Transactions\*. \*\*40\*\* \(3\): 581–6. \[doi:10.1042/BST20120066\]\(#\). \[PMID 22616870\]\(#\).](#)
30. <sup>^</sup> [Graham RM, Deery E, Warren MJ \(2009\). "18: Vitamin B<sub>12</sub>: Biosynthesis of the Corrin Ring". In Warren MJ, \[Smith AG\]\(#\) \(eds.\). \*Tetrapyrroles Birth, Life and Death\*. New York, NY: Springer-Verlag. p. 286. \[doi:10.1007/978-0-387-78518-9\\\_18\]\(#\). \[ISBN 978-0-387-78518-9\]\(#\).](#)
31. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> Gille D, Schmid A \(February 2015\). "Vitamin B12 in meat and dairy products". \*Nutrition Reviews\*. \*\*73\*\* \(2\): 106–15. \[doi:10.1093/nutrit/nuu011\]\(#\). \[PMID 26024497\]\(#\).](#)
32. <sup>^</sup> [McDowell LR \(2008\). \*Vitamins in Animal and Human Nutrition\* \(2nd ed.\). Hoboken: John Wiley & Sons. pp. 525, 539. \[ISBN 9780470376683\]\(#\).](#)
33. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> Rooke J \(October 30, 2013\). "Do carnivores need Vitamin B<sub>12</sub> supplements?". \*Baltimore Post Examiner\*.](#)
34. <sup>^</sup> ["Vitamin B<sub>12</sub>". DSM. Retrieved January 17, 2017.](#)
35. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> Watanabe F \(November 2007\). "Vitamin B12 sources and bioavailability". \*Experimental Biology and Medicine\*. \*\*232\*\* \(10\): 1266–74. \[doi:10.3181/0703-MR-67\]\(#\). \[PMID 17959839\]\(#\).](#)
36. <sup>^</sup> [Dossey AT \(February 1, 2013\). "Why Insects Should Be in Your Diet". \*The Scientist\*.](#)
37. <sup>^</sup> [Jump up to:<sup>a</sup> <sup>b</sup> "Vitamin B<sub>12</sub> content, all foods ordered by content in µg per 100 g". United States Department of Agriculture, Agricultural Research Service, National Nutrient Database for Standard Reference, Release 28. May 2016. Retrieved April 6, 2017.](#)
38. <sup>^</sup> [Liem IT, Steinkraus KH, Cronk TC \(December 1977\). "Production of vitamin B-12 in tempeh, a fermented soybean food". \*Applied and Environmental Microbiology\*. \*\*34\*\* \(6\): 773–6. \[PMC 242746\]\(#\). \[PMID 563702\]\(#\).](#)



39. [^ Keuth, S; Bisping, B \(May 1994\). "Vitamin B12 production by \*Citrobacter freundii\* and \*Klebsiella pneumoniae\* during tempeh fermentation" \(PDF\). \*Applied and Environmental Microbiology\*. \*\*60\*\* \(5\): 1495–9. \[PMC 201508\]\(#\). \[PMID 8017933\]\(#\).](#)
40. [^ Mo H, Kariluoto S, Piironen V, Zhu Y, Sanders MG, Vincken JP, et al. \(December 2013\). "Effect of soybean processing on content and bioaccessibility of folate, vitamin B12 and isoflavones in tofu and tempe". \*Food Chemistry\*. \*\*141\*\* \(3\): 2418–25. \[doi:10.1016/j.foodchem.2013.05.017\]\(#\). \[PMID 23870976\]\(#\).](#)
41. [^ Kwak CS, Lee MS, Lee HJ, Whang JY, Park SC \(June 2010\). "Dietary source of vitamin B\(12\) intake and vitamin B\(12\) status in female elderly Koreans aged 85 and older living in rural area". \*Nutrition Research and Practice\*. \*\*4\*\* \(3\): 229–34. \[doi:10.4162/nrp.2010.4.3.229\]\(#\). \[PMC 2895704\]\(#\). \[PMID 20607069\]\(#\).](#)
42. [^ Kwak CS, Lee MS, Oh SI, Park SC \(2010\). "Discovery of novel sources of vitamin b\(12\) in traditional Korean foods from nutritional surveys of centenarians". \*Current Gerontology and Geriatrics Research\*. \*\*2010\*\*: 374897. \[doi:10.1155/2010/374897\]\(#\). \[PMC 3062981\]\(#\). \[PMID 21436999\]\(#\).](#)
43. [^ Croft MT, Lawrence AD, Raux-Deery E, Warren MJ, \[Smith AG\]\(#\) \(November 2005\). "Algae acquire vitamin B12 through a symbiotic relationship with bacteria". \*Nature\*. \*\*438\*\* \(7064\): 90–3. \[doi:10.1038/nature04056\]\(#\). \[PMID 16267554\]\(#\).](#)
44. [^ Kumudha A, Selvakumar S, Dilshad P, Vaidyanathan G, Thakur MS, Sarada R \(March 2015\). "Methylcobalamin--a form of vitamin B12 identified and characterised in \*Chlorella vulgaris\*". \*Food Chemistry\*. \*\*170\*\*: 316–20. \[doi:10.1016/j.foodchem.2014.08.035\]\(#\). \[PMID 25306351\]\(#\).](#)
45. [^ Walsh S. "Vegan Society B<sub>12</sub> factsheet". \*Vegan Society\*. Archived from the original on May 26, 2008. Retrieved January 17, 2008.](#)
46. [^ \[Mangels R\]\(#\). "Vitamin B<sub>12</sub> in the Vegan Diet". \*Vegetarian Resource Group\*. Retrieved January 17, 2008.](#)
47. [^ "Don't Vegetarians Have Trouble Getting Enough Vitamin B<sub>12</sub>?". \[Physicians Committee for Responsible Medicine\]\(#\). Retrieved January 17, 2008.](#)
48. [^ \[Jump up to:<sup>a</sup> <sup>b</sup> \\[European Food Safety Authority\\]\\(#\\) \\(September 25, 2008\\). "5'-deoxyadenosylcobalamin and methylcobalamin as sources for Vitamin B<sub>12</sub> added as a nutritional substance in food supplements: Scientific opinion of the Scientific Panel on Food Additives and Nutrient Sources added to food". \\*EFSA Journal\\*. \\*\\*815\\*\\* \\(10\\): 1–21. \\[doi:10.2903/j.efsa.2008.815\\]\\(#\\). "the metabolic fate and biological distribution of methylcobalamin and 5'-deoxyadenosylcobalamin are expected to be similar to that of other sources of vitamin B<sub>12</sub> in the diet."\]\(#\)](#)
49. [^ \[Shipton MJ, Thachil J\]\(#\) \(April 2015\). "Vitamin B12 deficiency - A 21st century perspective". \*Clinical Medicine\*. \*\*15\*\* \(2\): 145–50. \[doi:10.7861/clinmedicine.15-2-145\]\(#\). \[PMC 4953733\]\(#\). \[PMID 25824066\]\(#\).](#)
50. [^ \[Silverstein WK, Lin Y, Dharma C, Croxford R, Earle CC, Cheung MC\]\(#\) \(July 15, 2019\). "Prevalence of Inappropriateness of Parenteral Vitamin B12 Administration in Ontario, Canada". \*JAMA Internal Medicine\*. \[doi:10.1001/jamainternmed.2019.1859\]\(#\). \[ISSN 2168-6106\]\(#\). \[PMID 31305876\]\(#\).](#)
51. [^ \[Oussalah A, Levy J, Filhine-Trésarrieu P, Namour F, Guéant JL\]\(#\) \(October 2017\). "\[TCN2 rs1801198 c.776G>C polymorphism with markers of one-carbon metabolism and related diseases: a systematic review and meta-analysis of genetic association studies\]\(#\)". \*The American Journal of Clinical Nutrition\*. \*\*106\*\* \(4\): 1142–1156. \[doi:10.3945/ajcn.117.156349\]\(#\). \[PMC 5611783\]\(#\). \[PMID 28814397\]\(#\).](#)
52. [^ \[Albert MJ, Mathan VI, Baker SJ\]\(#\) \(February 1980\). "Vitamin B12 synthesis by human small intestinal bacteria". \*Nature\*. \*\*283\*\* \(5749\): 781–2. \[doi:10.1038/283781a0\]\(#\). \[PMID 7354869\]\(#\).](#)
53. [^ \[Kelly RJ, Gruner TM, Furlong JM, Sykes AR\]\(#\) \(August 2006\). "Analysis of corrinoids in ovine tissues". \*Biomedical Chromatography\*. \*\*20\*\* \(8\): 806–14. \[doi:10.1002/bmc.604\]\(#\). \[PMID 16345011\]\(#\).](#)
54. [^ \[Schmidt A, Call LM, Macheiner L, Mayer HK\]\(#\) \(May 2019\). "12 in four edible insect species by immunoaffinity and ultra-high performance liquid chromatography". \*Food Chemistry\*. \*\*281\*\*: 124–129. \[doi:10.1016/j.foodchem.2018.12.039\]\(#\). \[PMID 30658738\]\(#\).](#)
55. [^ \[Yamada K, Shimodaira M, Chida S, Yamada N, Matsushima N, Fukuda M, Yamada S\]\(#\) \(2008\). "Degradation of vitamin B12 in dietary supplements". \*International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- und Ernährungsforschung. Journal International de Vitaminologie et de Nutrition\*. \*\*78\*\* \(4–5\): 195–203. \[doi:10.1024/0300-9831.78.45.195\]\(#\). \[PMID 19326342\]\(#\).](#)
56. [^ \[Watanabe F, Katsura H, Takenaka S, Fujita T, Abe K, Tamura Y, Nakatsuka T, Nakano Y\]\(#\) \(November 1999\). "Pseudovitamin B\(12\) is the predominant cobamide of an algal health food, spirulina tablets". \*Journal of Agricultural and Food Chemistry\*. \*\*47\*\* \(11\): 4736–41. \[doi:10.1021/jf990541b\]\(#\). \[PMID 10552882\]\(#\).](#)
57. [^ \[Yamada K, Yamada Y, Fukuda M, Yamada S\]\(#\) \(November 1999\). "Bioavailability of dried asakusanori \(\*porphyra tenera\*\) as a source of Cobalamin \(Vitamin B12\)". \*International Journal for\*](#)

Vitamin and Nutrition Research. *Internationale Zeitschrift Fur Vitamin- und Ernährungsforschung. Journal International de Vitaminologie et de Nutrition.* **69** (6): 412–8. [doi:10.1024/0300-9831.69.6.412](https://doi.org/10.1024/0300-9831.69.6.412). [PMID 10642899](https://pubmed.ncbi.nlm.nih.gov/10642899/).

58. [^](#) [Taga ME, Walker GC \(February 2008\). "Pseudo-B12 joins the cofactor family". \*Journal of Bacteriology.\* \*\*190\*\* \(4\): 1157–9. \[doi:10.1128/JB.01892-07\]\(https://doi.org/10.1128/JB.01892-07\). \[PMC 2238202\]\(https://pubmed.ncbi.nlm.nih.gov/2238202/\). \[PMID 18083805\]\(https://pubmed.ncbi.nlm.nih.gov/18083805/\).](#)
59. [^](#) [DeVault KR, Talley NJ \(September 2009\). "Insights into the future of gastric acid suppression". \*Nat Rev Gastroenterol Hepatol.\* \*\*6\*\* \(9\): 524–532. \[doi:10.1038/nrgastro.2009.125\]\(https://doi.org/10.1038/nrgastro.2009.125\). \[PMID 19713987\]\(https://pubmed.ncbi.nlm.nih.gov/19713987/\).](#)
60. [^](#) [Ahmed, MA \(2016\). "Metformin and Vitamin B12 Deficiency: Where Do We Stand?". \*Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne des Sciences Pharmaceutiques.\* \*\*19\*\* \(3\): 382–398. \[PMID 27806244\]\(https://pubmed.ncbi.nlm.nih.gov/27806244/\).](#)
61. [^](#) [Andrès E, Noel E, Goichot B \(October 2002\). "Metformin-associated vitamin B12 deficiency". \*Archives of Internal Medicine.\* \*\*162\*\* \(19\): 2251–2252. \[doi:10.1001/archinte.162.19.2251-a\]\(https://doi.org/10.1001/archinte.162.19.2251-a\). \[PMID 12390080\]\(https://pubmed.ncbi.nlm.nih.gov/12390080/\).](#)
62. [^](#) [Gilligan MA \(February 2002\). "Metformin and vitamin B12 deficiency". \*Archives of Internal Medicine.\* \*\*162\*\* \(4\): 484–485. \[doi:10.1001/archinte.162.4.484\]\(https://doi.org/10.1001/archinte.162.4.484\). \[PMID 11863489\]\(https://pubmed.ncbi.nlm.nih.gov/11863489/\).](#)
63. [^](#) [Copp S \(December 1, 2007\). "What effect does metformin have on vitamin B<sub>12</sub> levels?". \*UK Medicines Information, NHS.\* Archived from \[the original\]\(#\) on September 27, 2007.](#)
64. [^](#) [Jaouen G, ed. \(2006\). \*Bioorganometallics: Biomolecules, Labeling, Medicine\*. Weinheim: Wiley-VCH. \[ISBN 978-3-527-30990-0\]\(https://doi.org/10.1002/9783527309900\).<sup>\[page needed\]</sup>](#)
65. [^](#) [Obeid R, Fedosov SN, Nexo E \(July 2015\). "Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency". \*Molecular Nutrition & Food Research.\* \*\*59\*\* \(7\): 1364–72. \[doi:10.1002/mnfr.201500019\]\(https://doi.org/10.1002/mnfr.201500019\). \[PMC 4692085\]\(https://pubmed.ncbi.nlm.nih.gov/25820384/\). \[PMID 25820384\]\(https://pubmed.ncbi.nlm.nih.gov/25820384/\).](#)
66. [^](#) [Voet JG, Voet D \(1995\). \*Biochemistry\*. New York: J. Wiley & Sons. p. 675. \[ISBN 978-0-471-58651-7\]\(https://doi.org/10.1002/9780471586517\). \[OCLC 31819701\]\(https://oclc.org/number/oclc/31819701\).](#)
67. [^](#) [Banerjee R, Ragsdale SW \(2003\). "The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes". \*Annual Review of Biochemistry.\* \*\*72\*\*: 209–47. \[doi:10.1146/annurev.biochem.72.121801.161828\]\(https://doi.org/10.1146/annurev.biochem.72.121801.161828\). \[PMID 14527323\]\(https://pubmed.ncbi.nlm.nih.gov/14527323/\).](#)
68. [^](#) [Banerjee RV, Matthews RG \(March 1990\). "Cobalamin-dependent methionine synthase". \*FASEB Journal.\* \*\*4\*\* \(5\): 1450–9. \[doi:10.1096/fasebj.4.5.2407589\]\(https://doi.org/10.1096/fasebj.4.5.2407589\). \[PMID 2407589\]\(https://pubmed.ncbi.nlm.nih.gov/2407589/\).](#)
69. [^](#) [Wickramasinghe SN \(September 1995\). "Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells". \*Baillière's Clinical Haematology.\* \*\*8\*\* \(3\): 441–59. \[doi:10.1016/S0950-3536\\(05\\)80215-X\]\(https://doi.org/10.1016/S0950-3536\(05\)80215-X\). \[PMID 8534956\]\(https://pubmed.ncbi.nlm.nih.gov/8534956/\).](#)
70. [^](#) [Naidich MJ, Ho SU \(October 2005\). "Case 87: Subacute combined degeneration". \*Radiology.\* \*\*237\*\* \(1\): 101–5. \[doi:10.1148/radiol.2371031757\]\(https://doi.org/10.1148/radiol.2371031757\). \[PMID 16183926\]\(https://pubmed.ncbi.nlm.nih.gov/16183926/\).](#)
71. [^](#) ["CerefolinNAC® Caplets" \(PDF\). \*intetlab.com\*.](#)
72. [^](#) [Marks AD \(2009\). \*Basic Medical Biochemistry: A Clinical Approach\* \(3rd ed.\). Lippincott, Williams & Wilkins. p. 757. \[ISBN 978-0781770224\]\(https://doi.org/10.1002/9780781770224\).](#)
73. [^](#) [Allen RH, Seetharam B, Podell E, Alpers DH \(January 1978\). "Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency". \*The Journal of Clinical Investigation.\* \*\*61\*\* \(1\): 47–54. \[doi:10.1172/JCI108924\]\(https://doi.org/10.1172/JCI108924\). \[PMC 372512\]\(https://pubmed.ncbi.nlm.nih.gov/372512/\). \[PMID 22556\]\(https://pubmed.ncbi.nlm.nih.gov/22556/\).](#)
74. [^](#) [Jump up to: <sup>a</sup> <sup>b</sup> Combs GF \(2008\). \*The vitamins: fundamental aspects in nutrition and health\* \(3rd ed.\). Amsterdam: Elsevier Academic Press. \[ISBN 978-0-12-183492-0\]\(https://doi.org/10.1016/B978-0-12-183492-0\). \[OCLC 150255807\]\(https://oclc.org/number/oclc/150255807\).<sup>\[page needed\]</sup>](#)
75. [^](#) [Abels J, Vegter JJ, Woldring MG, Jans JH, Nieweg HO \(October 1959\). "The physiologic mechanism of vitamin B12 absorption". \*Acta Medica Scandinavica.\* \*\*165\*\* \(2\): 105–13. \[doi:10.1111/j.0954-6820.1959.tb14477.x\]\(https://doi.org/10.1111/j.0954-6820.1959.tb14477.x\). \[PMID 13791463\]\(https://pubmed.ncbi.nlm.nih.gov/13791463/\).](#)
76. [^](#) [Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J \(August 1998\). "Effective treatment of cobalamin deficiency with oral cobalamin". \*Blood.\* \*\*92\*\* \(4\): 1191–8. \[PMID 9694707\]\(https://pubmed.ncbi.nlm.nih.gov/9694707/\).](#)
77. [^](#) ["If a person stops consuming the vitamin, the body's stores of this vitamin usually take about 3 to 5 years to exhaust".](#)
78. [^](#) ["B<sub>12</sub>: An essential part of a healthy plant-based diet". \*International Vegetarian Union\*.](#)
79. [^](#) [Martens JH, Barg H, Warren MJ, Jahn D \(March 2002\). "Microbial production of vitamin B12". \*Applied Microbiology and Biotechnology.\* \*\*58\*\* \(3\): 275–285. \[doi:10.1007/s00253-001-0902-7\]\(https://doi.org/10.1007/s00253-001-0902-7\). \[PMID 11935176\]\(https://pubmed.ncbi.nlm.nih.gov/11935176/\).](#)


80. [^ Linnell JC, Matthews DM \(February 1984\). "Cobalamin metabolism and its clinical aspects". \*Clinical Science\*. \*\*66\*\* \(2\): 113–121. doi:10.1042/cs0660113. PMID 6420106.](#)
81. [^ 21 C.F.R. 184.1945](#)
82. [^ De Baets S, Vandedrinc S, Vandamme EJ \(2000\). "Vitamins and Related Biofactors, Microbial Production". In Lederberg J \(ed.\). \*Encyclopedia of Microbiology\*. \*\*4\*\* \(2nd ed.\). New York: Academic Press. pp. 837–853. ISBN 978-0-12-226800-7.](#)
83. [^ Riaz M, Iqbal F, Akram M \(2007\). "Microbial production of vitamin B<sub>12</sub> by methanol utilizing strain of \*Pseudomonas\* species". \*Pakistan Journal of Biochemistry & Molecular Biology\*. \*\*1\*\*. \*\*40\*\*: 5–10.](#)
84. [^ Zhang Y \(January 26, 2009\). "New round of price slashing in vitamin B<sub>12</sub> sector \(Fine and Specialty\)". \*China Chemical Reporter\*. Archived from the original on May 13, 2013.](#)
85. [^ Loeffler G \(2005\). \*Basiswissen Biochemie\*. Heidelberg: Springer. p. 606. ISBN 978-3-540-23885-0.](#)
86. [^ Bertrand EM, Saito MA, Jeon YJ, Neilan BA \(May 2011\). "Vitamin B<sub>12</sub> biosynthesis gene diversity in the Ross Sea: the identification of a new group of putative polar B<sub>12</sub> biosynthesizers". \*Environmental Microbiology\*. \*\*13\*\* \(5\): 1285–98. doi:10.1111/j.1462-2920.2011.02428.x. PMID 21410623.](#)
87. [^ Khan AG, Eswaran SV \(2003\). "Woodward's synthesis of vitamin B<sub>12</sub>". \*Resonance\*. \*\*8\*\* \(6\): 8–16. doi:10.1007/BF02837864.](#)
88. [^ Eschenmoser A, Wintner CE \(June 1977\). "Natural product synthesis and vitamin B<sub>12</sub>". \*Science\*. \*\*196\*\* \(4297\): 1410–20. doi:10.1126/science.867037. PMID 867037.](#)
89. [^ Riether D, Mulzer J \(2003\). "Total Synthesis of Cobyric Acid: Historical Development and Recent Synthetic Innovations". \*European Journal of Organic Chemistry\*. \*\*2003\*\*: 30–45. doi:10.1002/1099-0690\(200301\)2003:1<30::AID-EJOC30>3.0.CO;2-I.](#)
90. [^ "Synthesis of Cyanocobalamin by Robert B. Woodward \(1973\)". www.synarchive.com. Retrieved 2018-02-15.](#)
91. [^ Riether D, Mulzer J \(2003\). "Total Synthesis of Cobyric Acid: Historical Development and Recent Synthetic Innovations". \*European Journal of Organic Chemistry\*. \*\*2003\*\*: 30–45. doi:10.1002/1099-0690\(200301\)2003:1<30::AID-EJOC30>3.0.CO;2-I.](#)
92. [^ "Vegan Sources". VeganHealth.org. Archived from the original on 21 October 2017. Retrieved 21 Dec 2017.](#)
93. [^ Perlman D \(1959\). "Microbial synthesis of cobamides". \*Advances in Applied Microbiology\*. \*\*1\*\*: 87–122. doi:10.1016/S0065-2164\(08\)70476-3. ISBN 9780120026012. PMID 13854292.](#)
94. [^ Martens JH, Barg H, Warren MJ, Jahn D \(March 2002\). "Microbial production of vitamin B<sub>12</sub>". \*Applied Microbiology and Biotechnology\*. \*\*58\*\* \(3\): 275–85. doi:10.1007/s00253-001-0902-7. PMID 11935176.](#)
95. [^ The Nobel Prize in Physiology or Medicine 1934, Nobelprize.org, Nobel Media AB 2014. Retrieved December 2, 2015.](#)
96. [^ "Mary Shorb Lecture in Nutrition". Retrieved March 3, 2016.](#)
97. [^ Jump up to:<sup>a</sup> <sup>b</sup> Shorb MS \(May 10, 2012\). "Annual Lecture". Department of Animal & Avian Sciences, University of Maryland. Archived from the original on December 12, 2012. Retrieved August 2, 2014.](#)
98. [^ Kirkland K \(2010\). \*Biological Sciences: Notable Research and Discoveries. Facts on File\*. p. 87. ISBN 978-0816074396.](#)
99. [^ "The Nobel Prize and the Discovery of Vitamins". www.nobelprize.org. Retrieved 2018-02-15.](#)

# Vitamin D

From Wikipedia, the free encyclopedia

[Jump to navigation](#)[Jump to search](#)

For other uses, see [Vitamin D \(disambiguation\)](#).

Vitamin D	
<i>Drug class</i>	
	
<a href="#">Cholecalciferol</a> (D <sub>3</sub> )	
Class identifiers	
<b>Use</b>	<a href="#">Rickets</a> , <a href="#">osteoporosis</a> , <a href="#">vitamin D deficiency</a>
<b><u>ATC code</u></b>	<a href="#">A11CC</a>
<b><u>Biological target</u></b>	<a href="#">vitamin D receptor</a>
Clinical data	
<b><u>Drugs.com</u></b>	<a href="#">MedFacts Natural Products</a>

External links	
<b>MeSH</b>	<a href="#">D014807</a>
	<a href="#">In Wikidata</a>

**Vitamin D** is a group of fat-soluble [secoosteroids](#) responsible for increasing intestinal absorption of [calcium](#), [magnesium](#), and [phosphate](#), and multiple other biological effects.<sup>[1]</sup> In humans, the most important compounds in this group are vitamin D<sub>3</sub> (also known as [cholecalciferol](#)) and vitamin D<sub>2</sub> ([ergocalciferol](#)).<sup>[2]</sup>

The major natural source of the vitamin is synthesis of cholecalciferol in the skin from [cholesterol](#) through a chemical reaction that is dependent on [sun exposure](#) (specifically [UVB radiation](#)).<sup>[3][4]</sup> Cholecalciferol and ergocalciferol can be ingested from the diet and from supplements.<sup>[2][5][6]</sup> Only a few foods, such as the flesh of fatty fish, contain significant amounts of vitamin D, and fish does not contain enough vitamin D to achieve optimal Vitamin D status without sunlight or supplements.<sup>[7][8]</sup> Dietary recommendations typically assume that all of a person's vitamin D is taken by mouth, as sun exposure in the population is variable and recommendations about the amount of sun exposure that is safe are uncertain in view of the [skin cancer](#) risk.<sup>[7]</sup>

Vitamin D from the diet, or from skin synthesis, is biologically inactive. A protein enzyme must [hydroxylate](#) it to convert it to the active form. This is done in the liver and in the kidneys. As vitamin D can be synthesized in adequate amounts by most mammals exposed to sufficient sunlight, it is not an essential dietary factor, and so not technically a [vitamin](#).<sup>[6]</sup> Instead it could be considered a [hormone](#), with activation of the vitamin D pro-hormone resulting in the active form, [calcitriol](#), which then produces effects via a [nuclear receptor](#) in multiple locations.<sup>[6]</sup>

Cholecalciferol is converted in the liver to [calcifediol](#) (25-hydroxycholecalciferol); [ergocalciferol](#) is converted to 25-hydroxyergocalciferol. These two vitamin D metabolites (called 25-hydroxyvitamin D or 25(OH)D) are measured in serum to determine a person's vitamin D status.<sup>[9][10]</sup> Calcifediol is further hydroxylated by the kidneys to form [calcitriol](#) (also known as 1,25-dihydroxycholecalciferol), the biologically active form of vitamin D.<sup>[11]</sup> Calcitriol circulates as a hormone in the blood, having a major role regulating the concentration of [calcium](#) and [phosphate](#), and promoting the healthy growth and remodeling of bone. Calcitriol also has other effects, including some on cell growth, neuromuscular and immune functions, and reduction of inflammation.<sup>[7]</sup>

Vitamin D has a significant role in [calcium homeostasis](#) and metabolism. Its discovery was due to effort to find the dietary substance lacking in children with [rickets](#) (the childhood form of [osteomalacia](#)).<sup>[12]</sup> Vitamin D supplements are given to treat or to prevent osteomalacia and rickets, but the evidence for other health effects of vitamin D supplementation in the general population is inconsistent.<sup>[13][14]</sup> The effect of vitamin D supplementation on mortality is not clear, with one meta-analysis finding a small decrease in mortality in elderly people,<sup>[15]</sup> and another concluding no clear justification exists for recommending supplementation for preventing many diseases, and that further research of similar design is unneeded in these areas.<sup>[16]</sup>



## Contents

- 1Types
- 2Biology

- 3Deficiency
  - 3.1Bone health
  - 3.2Skin pigmentation
  - 3.3Non-bone diseases
  - 3.4Mortality, all cause
- 4Use of supplements
  - 4.1Mortality, all-cause
  - 4.2Bone health
  - 4.3Cancer
  - 4.4Cardiovascular disease
  - 4.5Immune system
  - 4.6Other conditions
  - 4.7Allowable health claims
- 5Dietary intake
  - 5.1Recommended levels
  - 5.2Sources
  - 5.3Food preparation
- 6Recommended serum levels
- 7Excess
  - 7.1Effect of excess
- 8Biosynthesis
  - 8.1Interactive pathway
  - 8.2Photochemistry
  - 8.3Synthesis in the skin
  - 8.4Evolution
  - 8.5Industrial synthesis
- 9Mechanism of action
  - 9.1Metabolic activation
  - 9.2Inactivation
  - 9.3Difference between substrates
- 10History
- 11Research
- 12References
- 13Further reading
- 14External links

## Types[[edit](#)]

Name	Chemical composition	Structure
Vitamin D <sub>1</sub>	Mixture of molecular compounds of <a href="#">ergocalciferol</a> with <a href="#">lumisterol</a> , 1:1	


<b>Vitamin D<sub>2</sub></b>	<a href="#">ergocalciferol</a> (made from <a href="#">ergosterol</a> )	
<b>Vitamin D<sub>3</sub></b>	<a href="#">cholecalciferol</a> (made from <a href="#">7-dehydrocholesterol</a> in the skin).	
<b>Vitamin D<sub>4</sub></b>	<a href="#">22-dihydroergocalciferol</a>	
	Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg + Vitamin D3 1000 IU + Pyridoxine HCl 3 mg + Folic Acid 1.5 mg Tablets	
<b>Vitamin D<sub>5</sub></b>	<a href="#">sitocalciferol</a> (made from <a href="#">7-dehydrositosterol</a> )	

Several forms ([vitamers](#)) of vitamin D exist. The two major forms are vitamin D<sub>2</sub> or ergocalciferol, and vitamin D<sub>3</sub> or cholecalciferol; vitamin D without a subscript refers to either D<sub>2</sub> or D<sub>3</sub> or both. These are known collectively as calciferol.<sup>[17]</sup> Vitamin D<sub>2</sub> was chemically characterized in 1931. In 1935, the [chemical structure](#) of vitamin D<sub>3</sub> was established and proven to result from the [ultraviolet irradiation](#) of 7-dehydrocholesterol.<sup>[18]</sup>

Chemically, the various forms of vitamin D are [secosteroids](#), i.e., [steroids](#) in which one of the bonds in the steroid rings is broken.<sup>[18]</sup> The structural difference between vitamin D<sub>2</sub> and vitamin D<sub>3</sub> is the side chain of D<sub>2</sub> contains a [double bond](#) between carbons 22 and 23, and a [methyl group](#) on carbon 24.

**Biology**[\[edit\]](#)

---



Calcium regulation in the human body.<sup>[19]</sup> The role of active vitamin D (1,25-dihydroxyvitamin D, calcitriol) is shown in orange.

The active vitamin D metabolite calcitriol mediates its biological effects by binding to the vitamin D receptor (VDR), which is principally located in the nuclei of target cells.<sup>[18]</sup> The binding of calcitriol to the VDR allows the VDR to act as a transcription factor that modulates the gene expression of transport proteins (such as TRPV6 and calbindin), which are involved in calcium absorption in the intestine.<sup>[20]</sup> The vitamin D receptor belongs to the nuclear receptor superfamily of steroid/thyroid hormone receptors, and VDRs are expressed by cells in most organs, including the brain, heart, skin, gonads, prostate, and breast.

VDR activation in the intestine, bone, kidney, and parathyroid gland cells leads to the maintenance of calcium and phosphorus levels in the blood (with the assistance of parathyroid hormone and calcitonin) and to the maintenance of bone content.<sup>[11]</sup>

One of the most important roles of vitamin D is to maintain skeletal calcium balance by promoting calcium absorption in the intestines, promoting bone resorption by increasing osteoclast number, maintaining calcium and phosphate levels for bone formation, and allowing proper functioning of parathyroid hormone to maintain serum calcium levels. Vitamin D deficiency can result in lower bone mineral density and an increased risk of reduced bone density (osteoporosis) or bone fracture because a lack of vitamin D alters mineral metabolism in the body.<sup>[21]</sup> Thus, vitamin D is also critical for bone remodeling through its role as a potent stimulator of bone resorption.<sup>[21]</sup>

The VDR regulates cell proliferation and differentiation. Vitamin D also affects the immune system, and VDRs are expressed in several white blood cells, including monocytes and activated T and B cells.<sup>[22]</sup> In vitro, vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells, and affects the synthesis of neurotrophic factors, nitric oxide synthase, and glutathione.<sup>[23]</sup>

## Deficiency<sup>[edit]</sup>

*Main article:* Vitamin D deficiency

A diet deficient in vitamin D in conjunction with inadequate sun exposure causes osteomalacia (or rickets when it occurs in children), which is a softening of the bones. In the developed world, this is a rare disease.<sup>[24][25]</sup> However, vitamin D deficiency has become a worldwide problem in the elderly and remains common in children and adults.<sup>[26][27]</sup> Low blood calcifediol (25-hydroxy-vitamin D) can result from avoiding the sun.<sup>[28]</sup> Deficiency results in impaired bone mineralization and bone damage which



leads to bone-softening diseases,<sup>[29][30]</sup> including [rickets](#) and [osteomalacia](#). Being deficient in vitamin D can cause intestinal absorption of dietary calcium to fall to 15%.<sup>[1]</sup> When not deficient, an individual usually absorbs between 60-80%.<sup>[1]</sup>

## **Bone health**[\[edit\]](#)

### **Rickets**[\[edit\]](#)

*Main article:* [Rickets](#)

[Rickets](#), a childhood disease, is characterized by impeded growth and soft, weak, deformed [long bones](#) that bend and bow under their weight as children start to walk. This condition is characterized by bow legs,<sup>[30]</sup> which can be caused by calcium or phosphorus deficiency, as well as a lack of vitamin D; today, it is largely found in low-income countries in Africa, Asia, or the Middle East<sup>[31]</sup> and in those with genetic disorders such as pseudovitamin D deficiency rickets.<sup>[32]</sup>

Maternal [vitamin D deficiency](#) may cause overt bone disease from before birth and impairment of bone quality after birth.<sup>[33][34]</sup> Nutritional rickets exists in countries with intense year-round sunlight such as Nigeria and can occur without vitamin D deficiency.<sup>[35][36]</sup>

Although rickets and osteomalacia are now rare in the [UK](#), outbreaks have happened in some immigrant communities in which osteomalacia sufferers included women with seemingly adequate daylight outdoor exposure wearing Western clothing.<sup>[37]</sup> Having darker skin and reduced exposure to sunshine did not produce rickets unless the diet deviated from a Western omnivore pattern characterized by high intakes of meat, fish, and eggs, and low intakes of high-extraction [cereals](#).<sup>[38][39][40]</sup> The dietary risk factors for rickets include abstaining from animal foods.<sup>[37][41]</sup>

Vitamin D deficiency remains the main cause of rickets among young infants in most countries, because breast milk is low in vitamin D and social customs and climatic conditions can prevent adequate sun exposure. In sunny countries such as Nigeria, South Africa, and Bangladesh, where rickets occurs among older toddlers and children, it has been attributed to low dietary calcium intakes, which are characteristic of cereal-based diets with limited access to dairy products.<sup>[40]</sup>

Rickets was formerly a major public health problem among the US population; in [Denver](#), where ultraviolet rays are about 20% stronger than at sea level on the same latitude,<sup>[42]</sup> almost two-thirds of 500 children had mild rickets in the late 1920s.<sup>[43]</sup> An increase in the proportion of animal protein<sup>[41][44]</sup> in the 20th century American diet coupled with increased consumption of milk<sup>[45][46]</sup> fortified with relatively small quantities of vitamin D coincided with a dramatic decline in the number of rickets cases.<sup>[1]</sup> Also, in the United States and Canada, vitamin D-fortified milk, infant vitamin supplements, and vitamin supplements have helped to eradicate the majority of cases of rickets for children with fat malabsorption conditions.<sup>[30]</sup>

### **Osteoporosis and osteomalacia**[\[edit\]](#)

*Main article:* [Osteoporosis](#)

*Main article:* [Osteomalacia](#)

[Osteomalacia](#) is a disease in adults that results from vitamin D deficiency. Characteristics of this disease are softening of the bones, leading to bending of the spine, bowing of the legs, [proximal](#) muscle weakness, bone fragility, and increased risk for fractures.<sup>[47]</sup> Osteomalacia reduces calcium absorption and increases calcium loss from bone, which increases the risk for bone fractures. Osteomalacia is usually present when 25-hydroxyvitamin D levels are less than about 10 ng/mL.<sup>[2]</sup> Although the effects of osteomalacia are thought to contribute to chronic [musculoskeletal pain](#),<sup>[48]</sup> there is no persuasive evidence of lower vitamin D levels in chronic pain sufferers<sup>[49]</sup> or that supplementation alleviates chronic nonspecific musculoskeletal pain.<sup>[50]</sup>

### **Skin pigmentation**[\[edit\]](#)

Dark-skinned people living in temperate climates have been shown to have low vitamin D levels but the significance of this is not certain.<sup>[51][52][53]</sup> Dark-skinned people are less efficient at making vitamin D because melanin in the skin hinders vitamin D synthesis.<sup>[54]</sup>

## Non-bone diseases<sup>[edit]</sup>



**This section is empty.** You can help by [adding to it](#). (May 2019)

## Mortality, all cause<sup>[edit]</sup>



**This section is empty.** You can help by [adding to it](#). (May 2019)

## Use of supplements<sup>[edit]</sup>

The effects of vitamin D supplementation on health are uncertain.<sup>[14][55]</sup> A 2013 review did not find any effect from supplementation on the rates of disease, other than a tentative decrease in mortality in the elderly.<sup>[56]</sup> Vitamin D supplements do not alter the outcomes for [myocardial infarction](#), [stroke](#) or [cerebrovascular disease](#), cancer, [bone fractures](#) or knee [osteoarthritis](#).<sup>[16][57]</sup> Low vitamin D levels may result from disease rather than cause disease.<sup>[56]</sup>

A United States [Institute of Medicine](#) report states: "Outcomes related to [cancer](#), [cardiovascular disease](#) and [hypertension](#), and [diabetes](#) and metabolic syndrome, falls and physical performance, immune functioning and [autoimmune disorders](#), infections, neuropsychological functioning, and [preeclampsia](#) could not be linked reliably with calcium or vitamin D intake and were often conflicting."<sup>[58]:5</sup> Some researchers claim the IOM was too definitive in its recommendations and made a mathematical mistake when calculating the blood level of vitamin D associated with bone health.<sup>[59]</sup> Members of the IOM panel maintain that they used a "standard procedure for dietary recommendations" and that the report is solidly based on the data. Research on vitamin D supplements, including large-scale clinical trials, is continuing.<sup>[59]</sup>

## Mortality, all-cause<sup>[edit]</sup>

Vitamin D<sub>3</sub> supplementation has been tentatively found to lead to a reduced risk of death in the elderly,<sup>[15][56]</sup> but the effect has not been deemed pronounced, or certain enough, to make taking supplements recommendable.<sup>[16]</sup> Other forms (vitamin D<sub>2</sub>, alfacalcidol, and calcitriol) do not appear to have any beneficial effects with regard to the risk of death.<sup>[15]</sup> High blood levels appear to be associated with a lower risk of death, but it is unclear if supplementation can result in this benefit.<sup>[60]</sup> Both an excess and a deficiency in vitamin D appear to cause abnormal functioning and premature aging.<sup>[61][62][63]</sup> The relationship between serum calcifediol level and all-cause mortality is parabolic.<sup>[58]</sup> Harm from vitamin D appears to occur at a lower vitamin D level in the black population than in the white population.<sup>[58]:435</sup>

## Bone health<sup>[edit]</sup>

In general, no good evidence supports the commonly held belief that vitamin D supplements can help prevent [osteoporosis](#).<sup>[16]</sup> Its general use for prevention of this disease in those without vitamin D deficiency is thus likely not needed.<sup>[64]</sup> For older people with osteoporosis, taking vitamin D with calcium may help prevent hip fractures, but it also slightly increases the risk of stomach and kidney problems.<sup>[65]</sup> Supplementation with higher doses of vitamin D, in those older than 65 years, may decrease fracture risk.<sup>[66]</sup> The effect is small or none for people living independently.<sup>[67][68]</sup> Low serum vitamin D levels have been associated with [falls](#), and low [bone mineral density](#).<sup>[69]</sup> Taking extra vitamin D, however, does not appear to change the risk.<sup>[70]</sup> Athletes who are vitamin D deficient are at an increased risk of [stress fractures](#) and/or major breaks, particularly those engaging in contact

sports. The greatest benefit with supplementation is seen in athletes who are deficient (25(OH)D serum levels <30 ng/mL), or severely deficient (25(OH)D serum levels <25 ng/mL). Incremental decreases in risks are observed with rising serum 25(OH)D concentrations plateauing at 50 ng/mL with no additional benefits seen in levels beyond this point.<sup>[71]</sup>



The examples and perspective in this article **may not represent a [worldwide view of the subject](#)**. You may [improve this article](#), discuss the issue on the [talk page](#), or [create a new article](#), as appropriate. *(February 2019)* ([Learn how and when to remove this template message](#))

Because it found mounting evidence for a benefit to bone health, though it had not found good evidence of other benefits, the US [Food and Drug Administration](#) (FDA) has required manufacturers to declare the amount of vitamin D on [nutrition facts labels](#), as "nutrients of public health significance", since May 2016. By a proposed deadline extension, small manufacturers with less than \$10 million in annual food sales will have to comply by January 1, 2021, while larger ones have to comply by January 1, 2020.<sup>[72]</sup> Manufacturers of single-ingredient sugars such as honey and maple syrup and certain cranberry products have until July 1, 2021, to make the changes.<sup>[72]</sup>

## Cancer<sup>[edit]</sup>

Vitamin D supplements have been widely marketed for their claimed anticancer properties.<sup>[73]</sup> Associations have been shown in observational studies between low vitamin D levels and the risk of development of certain cancers.<sup>[74]</sup> It is unclear, however, if taking additional vitamin D in the diet or as supplements affects the risk of [cancer](#). Reviews have described the evidence as being "inconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements"<sup>[58]</sup> and "not sufficiently robust to draw conclusions".<sup>[67]</sup> One 2014 review found that supplements had no significant effect on cancer risk.<sup>[16]</sup>

Another 2014 review concluded that vitamin D<sub>3</sub> may decrease the risk of death from [cancer](#) (one fewer death in 150 people treated over 5 years), but concerns with the quality of the data were noted.<sup>[15]</sup> Insufficient evidence exists to recommend vitamin D supplements for people with cancer, although some evidence suggests that [low vitamin D](#) may be associated with a worse outcome for some cancers,<sup>[75]</sup> and that higher 25-hydroxy vitamin D levels at the time of diagnosis are associated with better outcomes.<sup>[76]</sup>

## Cardiovascular disease<sup>[edit]</sup>

Taking vitamin D supplements does not meaningfully reduce the risk of [stroke](#), [cerebrovascular disease](#), [cardial infarction](#), or [ischemic heart disease](#).<sup>[16][77]</sup> Supplementation may have no effect on [blood pressure](#).<sup>[78]</sup>

## Immune system<sup>[edit]</sup>

### Infectious diseases<sup>[edit]</sup>

In general, vitamin D functions to activate the [innate](#) and dampen the [adaptive immune systems](#).<sup>[79]</sup> Deficiency has been linked to increased risk or severity of [viral infections](#), including [HIV](#).<sup>[80][81]</sup> Low levels of vitamin D appear to be a risk factor for [tuberculosis](#),<sup>[82]</sup> and historically it was used as a treatment.<sup>[83]</sup> Supplementation slightly decreases the risk of acute [respiratory tract infections](#) and the exacerbation of [asthma](#).<sup>[84][85][86]</sup> Evidence is lacking on whether it does so in children under five years of age.<sup>[87]</sup> No clinical trials have been done to assess its effect on preventing other infections, such as [malaria](#).

### Autoimmune diseases<sup>[edit]</sup>

Although tentative data link low levels of vitamin D to [asthma](#), evidence to support a beneficial effect on asthmatics from supplementation is inconclusive.<sup>[88]</sup> Accordingly, supplementation is not currently recommended for treatment or prevention of asthma.<sup>[89]</sup> Vitamin D and [multiple sclerosis](#) incidence

have been linked, but it is not clear what the nature of any causal relationship might be.<sup>[90]</sup> Two systemic reviews concluded that the evidence for vitamin D supplementation being helpful for treating people with multiple sclerosis is inconclusive.<sup>[91][92]</sup>

### **Inflammatory bowel disease**[\[edit\]](#)

Low levels of vitamin D are associated with two major forms of human [Inflammatory bowel disease](#) (IBD): [Crohn's disease](#) and [ulcerative colitis](#).<sup>[93]</sup> However, further studies are required to determine its significance and the potential role of vitamin D axis in IBD.<sup>[93][94]</sup>

### **Other conditions**[\[edit\]](#)

**Diabetes** -- A systematic review of 2014 concluded that the available studies show no evidence of vitamin D3 supplementation having an effect on glucose homeostasis or [diabetes](#) prevention.<sup>[95]</sup> A review article of 2016 reported that while there is increasing evidence that vitamin D deficiency may be a risk factor for diabetes, over-all evidence regarding vitamin D levels and diabetes mellitus is contradictory, requiring further studies.<sup>[96]</sup>

**Depression** -- Clinical trials of vitamin D supplementation for depressive symptoms have generally been of low quality and show no overall effect, although subgroup analysis showed supplementation for participants with clinically significant depressive symptoms or depressive disorder had a moderate effect.<sup>[97]</sup>

**Cognition and dementia** -- A systematic review of clinical studies found an association between low vitamin D levels with [cognitive impairment](#) and a higher risk of developing [Alzheimer's disease](#). However, lower vitamin D concentrations are also associated with poor nutrition and spending less time outdoors. Therefore, alternative explanations for the increase in cognitive impairment exist and hence a direct causal relationship between vitamin D levels and cognition could not be established.<sup>[98]</sup>

**Pregnancy** -- Low levels of vitamin D in pregnancy are associated with [gestational diabetes](#), [pre-eclampsia](#), and small (for gestational age) infants.<sup>[99]</sup> Although taking vitamin D supplements during pregnancy raises blood levels of vitamin D in the mother at term,<sup>[100]</sup> the extent of benefits for the mother or baby is unclear.<sup>[99][100][101]</sup> Pregnant women who take an adequate amount of vitamin D during gestation may experience a lower risk of pre-eclampsia<sup>[100]</sup> and positive immune effects.<sup>[102]</sup> A 2018 review found that supplements may reduce the risk of undersized babies and of their poor rate of growth.<sup>[103]</sup> Pregnant women often do not take the recommended amount of vitamin D.<sup>[102]</sup>

**Weight loss** -- Though hypothesized that vitamin D supplementation may be an effective treatment for [obesity](#) apart from [calorie restriction](#), one systematic review found no association of supplementation with body weight or [fat mass](#).<sup>[104]</sup> A 2016 [meta-analysis](#) found that circulating vitamin D status was improved by weight loss, indicating that fat mass may be inversely associated with blood levels of vitamin D.<sup>[105]</sup>

### **Allowable health claims**[\[edit\]](#)

Governmental regulatory agencies stipulate for the food and dietary supplement industries certain health claims as allowable as statements on packaging.

#### [European Food Safety Authority](#)

- normal function of the immune system<sup>[106]</sup>
- normal inflammatory response<sup>[106]</sup>
- normal muscle function<sup>[106]</sup>
- reduced risk of falling in people over age 60<sup>[107]</sup>

US [Food and Drug Administration](#) (FDA)

- "Adequate calcium and vitamin D, as part of a well balanced diet, along with physical activity, may reduce the risk of osteoporosis."<sup>[108]</sup>

[Health Canada](#)

- Adequate calcium and regular exercise may help to achieve strong bones in children and adolescents and may reduce the risk of osteoporosis in older adults. An adequate intake of vitamin D is also necessary<sup>[109]</sup>

Other possible agencies with claim guidance: Japan FOSHU<sup>[110]</sup> and Australia-New Zealand.<sup>[111]</sup>

Dietary intake<sup>[edit]</sup>

Recommended levels<sup>[edit]</sup>

United States		
Age group	RDA (IU/day)	(µg/day) <sup>[58]</sup>
Infants 0–6 months	400*	10
Infants 6–12 months	400*	10
1–70 years	600	15
71+ years	800	20
Pregnant/Lactating	600	15
Age group	Tolerable upper intake level (IU/day)	(µg/day)
Infants 0–6 months	1,000	25
Infants 6–12 months	1,500	37.5
1–3 years	2,500	62.5
4–8 years	3,000	75

9+ years	4,000	100
Pregnant/lactating	4,000	100 <sup>[58]</sup>
<b>Canada</b>		
Age group	RDA (IU)	Tolerable upper intake (IU) <sup>[112]</sup>
Infants 0–6 months	400*	1,000
Infants 7–12 months	400*	1,500
Children 1–3 years	600	2,500
Children 4–8 years	600	3,000
Children and Adults 9–70 years	600	4,000
Adults > 70 years	800	4,000
Pregnancy & Lactation	600	4,000
<b>Australia and New Zealand</b>		
Age group	Adequate Intake (µg)	Upper Level of Intake (µg) <sup>[113]</sup>
Infants 0–12 months	5*	25
Children 1–18 years	5*	80
Adults 19–50 years	5*	80

Adults 51–70 years	10*	80
Adults > 70 years	15*	80
<b>European Food Safety Authority</b>		
Age group	Adequate Intake (µg) <sup>[114]</sup>	Tolerable upper limit (µg) <sup>[115]</sup>
Infants 0–12 months	10	25
Children 1–10 years	15	50
Children 11–17 years	15	100
Adults	15	100
Pregnancy & Lactation	15	100
* Adequate intake, no RDA/RDI yet established		

Conversion: 1 µg = 40 IU.

Various institutions have proposed different recommendations for the amount of [daily intake](#) of vitamin D. These vary according to precise definition, age, pregnancy or lactation, and the extent assumptions are made regarding skin synthesis of vitamin D.<sup>[58][112][113][114]</sup>

### United States<sup>[edit]</sup>

The [dietary reference intake](#) for vitamin D issued in 2010 by the Institute of Medicine (IoM) (renamed [National Academy of Medicine](#) in 2015), superseded previous recommendations which were expressed in terms of Adequate Intake. The recommendations were formed assuming the individual has no skin synthesis of vitamin D because of inadequate sun exposure. The reference intake for vitamin D refers to total intake from food, beverages and supplements, and assumes that calcium requirements are being met.<sup>[58]:5</sup> The [tolerable upper intake level](#) (UL) is defined as "the highest average daily intake of a nutrient that is likely to pose no risk of adverse health effects for nearly all persons in the general population."<sup>[58]:403</sup> Although ULs are believed to be safe, information on the long-term effects is incomplete and these levels of intake are not recommended for long-term consumption.<sup>[58]:403:433</sup>

For U.S food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For vitamin D labeling purposes, 100% of the Daily Value was 400 IU (10 µg), but on May 27, 2016, it was revised to 800 IU (20 µg) to bring it into agreement with the

RDA.<sup>[116]</sup> The deadline to be in compliance was extended to January 1, 2020 for large companies and January 1, 2021 for small companies.<sup>[72]</sup>

### Canada<sup>[edit]</sup>

[Health Canada](#) published recommended dietary allowances (RDA) and tolerable upper intake levels for vitamin D in 2012<sup>[112]</sup> based on the Institute of Medicine report.<sup>[58]</sup>

### Australia and New Zealand<sup>[edit]</sup>

Australia and New Zealand published nutrient reference values including guidelines for dietary vitamin D intake in 2005.<sup>[113]</sup> About a third of Australians have vitamin D deficiency.<sup>[117]</sup>

### European Union<sup>[edit]</sup>

The [European Food Safety Authority](#) (EFSA) in 2016<sup>[114]</sup> reviewed the current evidence, finding the relationship between serum 25(OH)D concentration and musculoskeletal health outcomes is widely variable. They considered that average requirements and population reference intakes values for vitamin D cannot be derived, and that a serum 25(OH)D concentration of 50 nmol/L was a suitable target value. For all people over the age of 1, including women who are pregnant or lactating, they set an adequate intake of 15 µg/day (600 IU).<sup>[114]</sup>

The EFSA reviewed safe levels of intake in 2012,<sup>[115]</sup> setting the tolerable upper limit for adults at 100 µg/day (4000 IU), a similar conclusion as the IOM.

The UK [National Health Service](#) recommends babies and young children aged six months to five years, pregnant or breastfeeding women, and sun-deprived elderly people should take daily vitamin supplements to ensure sufficient vitamin D intake.<sup>[118]</sup> In July 2016, [Public Health England](#) recommended that everyone consider taking a daily supplement containing 10 µg of vitamin D during autumn and winter because of inadequate sunlight for vitamin D synthesis.<sup>[119]</sup>

The [Swedish National Food Agency](#) recommends a daily intake of 10 µg (400 IU) of vitamin D3 for children and adults up to 75 years, and 20 µg (800 IU) for adults 75 and older.<sup>[120]</sup>

Non-government organisations in Europe have made their own recommendations. The German Society for Nutrition recommends 20 µg.<sup>[121]</sup> The European Menopause and Andropause Society recommends postmenopausal women consume 15 µg (600 IU) until age 70, and 20 µg (800 IU) from age 71. This dose should be increased to 100 µg (4,000 IU) in some patients with very low vitamin D status or in case of co-morbid conditions.<sup>[122]</sup>

### Sources<sup>[edit]</sup>

Although vitamin D is not present naturally in most foods,<sup>[26]</sup> it is commonly [added](#) as a [fortification](#) in manufactured foods. In some countries, staple foods are [artificially fortified](#) with vitamin D.<sup>[123]</sup>

### Natural sources<sup>[edit]</sup>

*Main article: [Ergocalciferol § Biosynthesis](#)*

In general, vitamin D<sub>2</sub> is found in [fungi](#) and vitamin D<sub>3</sub> is found in animals.<sup>[124][125]</sup> Vitamin D<sub>2</sub> is produced by ultraviolet irradiation of [ergosterol](#) found in many fungi. The vitamin D<sub>2</sub> content in mushrooms and *Cladonia arbuscula*, a lichen, increase with exposure to ultraviolet light.<sup>[126][127]</sup> This process is emulated by industrial ultraviolet lamps, concentrating vitamin D<sub>2</sub> levels to higher levels.<sup>[125]</sup>

The [United States Department of Agriculture](#) reports D<sub>2</sub> and D<sub>3</sub> content combined in one value.

### Fungal sources



Source		µg/g	IU/g
<i>C. arbuscula</i> ( <a href="#">lichen</a> ), <a href="#">thalli</a> , dry <sup>[126]</sup>	<b>vitamin D<sub>3</sub></b>	0.67–2.04	27–82
	<b>vitamin D<sub>2</sub></b>	0.22–0.55	8.8–22
<b><u>Agaricus bisporus</u> (common mushroom): D<sub>2</sub> + D<sub>3</sub></b>			
<b>Portobello</b>	Raw	0.003	0.1
	Exposed to ultraviolet light	0.112	4.46
<b>Crimini</b>	Raw	0.001	0.03
	Exposed to ultraviolet light	0.319	12.76

#### Animal sources<sup>[128]</sup>

Source	IU/g	Irregular
Cooked <a href="#">egg</a> yolk	0.7	44 IU for a 61g egg
Beef liver, cooked, braised	0.5	
Fish liver oils, such as <a href="#">cod liver oil</a>	100	450 IU per <a href="#">teaspoon</a> (4.5 g)
<b>Fatty fish species</b>		
<a href="#">Salmon</a> , pink, cooked, dry heat	5.2	

<a href="#">Mackerel</a> , Pacific and jack, mixed species, cooked, dry heat	4.6	
<a href="#">Tuna</a> , canned in oil	2.7	
<a href="#">Sardines, canned in oil</a> , drained	1.9	

### Food fortification [\[edit\]](#)

Manufactured foods fortified with vitamin D include some fruit juices and fruit juice drinks, [meal replacement energy bars](#), [soy protein](#)-based beverages, certain cheese and cheese products, [flour](#) products, [infant formulas](#), many [breakfast cereals](#), and [milk](#).<sup>[129][130]</sup>

In 2016 in the United States, the [Food and Drug Administration](#) (FDA) amended food additive regulations for milk fortification,<sup>[131]</sup> stating that vitamin D<sub>3</sub> levels not exceed 42 IU vitamin D per 100 g (400 IU per US [quart](#)) of dairy milk, 84 IU of vitamin D<sub>2</sub> per 100 g (800 IU per quart) of [plant milks](#), and 89 IU per 100 g (800 IU per quart) in plant-based [yogurts](#) or in soy beverage products.<sup>[132][133][134]</sup> Plant milks are defined as beverages made from soy, almond, rice, among other plant sources intended as alternatives to dairy milk.<sup>[citation needed]</sup>


While some studies have found that vitamin D<sub>3</sub> raises 25(OH)D blood levels faster and remains active in the body longer,<sup>[135][136]</sup> others contend that vitamin D<sub>2</sub> sources are equally bioavailable and effective as D<sub>3</sub> for raising and sustaining 25(OH)D.<sup>[125][137][138]</sup>

### Food preparation [\[edit\]](#)

Vitamin D content in typical foods is reduced variably by cooking. Boiled, fried and baked foods retained 69–89% of original vitamin D.<sup>[139]</sup>

## Recommended serum levels [\[edit\]](#)

See also: [Reference ranges for blood tests § Vitamins](#), and [Hypervitaminosis D § Ethnic differences](#)



Global vitamin D serum levels among adults (nmol/L).<sup>[140][141]</sup>

■ > 75

■ 50-74

■ 25-49

Recommendations on recommended 25(OH)D serum levels vary across authorities, and vary based on factors like age.<sup>[7]</sup> US labs generally report 25(OH)D levels in ng/mL.<sup>[citation needed]</sup> Other countries often use nmol/L.<sup>[citation needed]</sup> One ng/mL is approximately equal to 2.5 nmol/L.<sup>[citation needed]</sup>

A 2014 review concluded that the most advantageous serum levels for 25(OH)D for all outcomes appeared to be close to 30 ng/mL (75 nmol/L).<sup>[142]</sup> The optimal vitamin D levels are still controversial and another review concluded that ranges from 30 to 40 ng/mL (75 to 100 nmol/L) were to be recommended for athletes.<sup>[143]</sup> Part of the controversy is because numerous studies have found differences in serum levels of 25(OH)D between ethnic groups; studies point to genetic as well as environmental reasons behind these variations.<sup>[144]</sup> Supplementation to achieve these standard levels could cause harmful vascular [calcification](#).<sup>[53]</sup>

A 2012 [meta-analysis](#) showed that the risk of [cardiovascular diseases](#) increases when blood levels of vitamin D are lowest in a range of 8 to 24 ng/mL (20 to 60 nmol/L), although results among the studies analyzed were inconsistent.<sup>[145]</sup>

In 2011 an [IOM](#) committee concluded a serum 25(OH)D level of 20 ng/mL (50 nmol/L) is needed for bone and overall health. The dietary reference intakes for vitamin D are chosen with a margin of safety and 'overshoot' the targeted serum value to ensure the specified levels of intake achieve the desired serum 25(OH)D levels in almost all persons. No contributions to serum 25(OH)D level are assumed from sun exposure and the recommendations are fully applicable to people with [dark skin](#) or negligible exposure to sunlight. The Institute found serum 25(OH)D concentrations above 30 ng/mL (75 nmol/L) are "not consistently associated with increased benefit". Serum 25(OH)D levels above 50 ng/mL (125 nmol/L) may be cause for concern. However, some people with serum 25(OH)D between 30 and 50 ng/mL (75 nmol/L-125 nmol/L) will also have inadequate vitamin D.<sup>[58]</sup>

## Excess<sup>[edit]</sup>

Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +

Further information: [hypervitaminosis D](#) [tablets](#)

Vitamin D toxicity is rare.<sup>[27]</sup> It is caused by supplementing with high doses of vitamin D rather than sunlight. The threshold for vitamin D toxicity has not been established; however, according to some research, the tolerable upper intake level (UL) is 4,000 IU/day for ages 9–71<sup>[146]</sup> (100 µg/day), while other research concludes that, in healthy adults, sustained intake of more than 1250 µg/day (50,000 IU) can produce overt [toxicity](#) after several months and can increase serum 25-hydroxyvitamin D levels to 150 ng/mL and greater.<sup>[27][147]</sup> Those with certain medical conditions, such as primary [hyperparathyroidism](#),<sup>[148]</sup> are far more sensitive to vitamin D and develop [hypercalcemia](#) in response to any increase in vitamin D nutrition, while maternal hypercalcemia during pregnancy may increase fetal sensitivity to effects of vitamin D and lead to a syndrome of mental retardation and facial deformities.<sup>[148][149]</sup>

A review published in 2015 noted that adverse effects have been reported only at 25(OH)D serum concentrations above 200 nmol/L.<sup>[143]</sup>

Published cases of toxicity involving hypercalcemia in which the vitamin D dose and the 25-hydroxyvitamin D levels are known all involve an intake of ≥40,000 IU (1,000 µg) per day.<sup>[148]</sup>

Pregnant or breastfeeding women should consult a doctor before taking a vitamin D supplement. The FDA advised manufacturers of liquid vitamin D supplements that droppers accompanying these products should be clearly and accurately marked for 400 [international units](#) (1 IU is the biological equivalent of 25 ng cholecalciferol/ergocalciferol). In addition, for products intended for infants, the FDA recommends the dropper hold no more than 400 IU.<sup>[150]</sup> For infants (birth to 12 months), the tolerable upper limit (maximum amount that can be tolerated without harm) is set at 25 µg/day (1,000 IU). One thousand micrograms per day in infants has produced toxicity within one month.<sup>[147]</sup> After being commissioned by the Canadian and American governments, the [Institute of Medicine](#) (IOM) as of 30 November 2010, has increased the tolerable upper limit (UL) to 2,500 IU per day for ages 1–3 years, 3,000 IU per day for ages 4–8 years and 4,000 IU per day for ages 9–71+ years (including pregnant or lactating women).<sup>[146]</sup>

Calcitriol itself is auto-regulated in a [negative feedback](#) cycle, and is also affected by [parathyroid hormone](#), [fibroblast growth factor 23](#), [cytokines](#), calcium, and phosphate.<sup>[151]</sup>

## Effect of excess [\[edit\]](#)

Vitamin D overdose causes hypercalcemia, which is a strong indication of vitamin D toxicity – this can be noted with an increase in urination and thirst. If hypercalcemia is not treated, it results in excess deposits of calcium in soft tissues and organs such as the kidneys, liver, and heart, resulting in pain and organ damage. <sup>[27][30][47]</sup>

The main symptoms of vitamin D overdose which are those of hypercalcemia including [anorexia](#), nausea, and vomiting. These may be followed by [polyuria](#), [polydipsia](#), weakness, insomnia, nervousness, [pruritus](#) and ultimately [renal failure](#). Furthermore, [proteinuria](#), [urinary casts](#), [azotemia](#), and [metastatic calcification](#) (especially in the kidneys) may develop. <sup>[147]</sup> Other symptoms of vitamin D toxicity include mental retardation in young children, abnormal bone growth and formation, diarrhea, irritability, weight loss, and severe depression. <sup>[27][47]</sup>

Vitamin D toxicity is treated by discontinuing vitamin D supplementation and restricting calcium intake. Kidney damage may be irreversible. Exposure to sunlight for extended periods of time does not normally cause vitamin D toxicity. The concentrations of vitamin D precursors produced in the skin reach an [equilibrium](#), and any further vitamin D produced is degraded. <sup>[148]</sup>

## Biosynthesis [\[edit\]](#)


---

Synthesis of vitamin D in nature is dependent on the presence of UV radiation and subsequent activation in liver and in kidney. Many animals synthesize vitamin D<sub>3</sub> from [7-dehydrocholesterol](#), and many fungi synthesize vitamin D<sub>2</sub> from [ergosterol](#). <sup>[124][125]</sup>

## Interactive pathway [\[edit\]](#)


Click on icon in lower right corner to open. *Click on genes, proteins and metabolites below to link to respective articles.* <sup>[8.1]</sup>

[[File:



# *Formylin<sup>TM</sup> Plus*

Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
Folic Acid 1.5 mg Tablets




alt=Vitamin D Synthesis Pathway ([view](#) / [edit](#))

Vitamin D Synthesis Pathway ([view](#) / [edit](#))

1. [^](#) The interactive pathway map can be edited at WikiPathways: "[VitaminDSynthesis\\_WP1531](#)".

## Photochemistry[[edit](#)]



The photochemistry of vitamin D biosynthesis in animal and fungi


Thermal isomerization of [previtamin D<sub>3</sub>](#) to vitamin D<sub>3</sub>

The transformation that converts 7-dehydrocholesterol to vitamin D<sub>3</sub> occurs in two steps.<sup>[152][153]</sup> First, 7-dehydrocholesterol is [photolyzed](#) by ultraviolet light in a 6-electron [conrotatory](#) ring-opening [electrocyclic reaction](#); the product is [previtamin D<sub>3</sub>](#). Second, previtamin D<sub>3</sub> spontaneously [isomerizes](#) to vitamin D<sub>3</sub> ([cholecalciferol](#)) in an [antarafacial sigmatropic \[1,7\] hydride shift](#). At room temperature, the transformation of previtamin D<sub>3</sub> to vitamin D<sub>3</sub> in an organic solvent takes about 12 days to complete. The conversion of previtamin D<sub>3</sub> to vitamin D<sub>3</sub> in the skin is about 10 times faster than in an organic solvent.<sup>[154]</sup>

The conversion from ergosterol to vitamin D<sub>2</sub> follows a similar procedure, forming previtamin D<sub>2</sub> by photolysis, which isomerizes to vitamin D<sub>2</sub>.<sup>[155]</sup> The transformation of previtamin D<sub>2</sub> to vitamin D<sub>2</sub> in methanol has a rate comparable to that of previtamin D<sub>3</sub>. The process is faster in white button mushrooms.<sup>[125](fig. 3)</sup>

## Synthesis in the skin[[edit](#)]





In the epidermal strata of the skin, vitamin D production is greatest in the stratum basale (colored red in the illustration) and stratum spinosum (colored light brown).

Vitamin D<sub>3</sub> is produced photochemically from 7-dehydrocholesterol in the skin of most vertebrate animals, including humans.<sup>[156]</sup> The precursor of vitamin D<sub>3</sub>, 7-dehydrocholesterol is produced in relatively large quantities. 7-Dehydrocholesterol reacts with [UVB light](#) at [wavelengths](#) of 290–315 nm.<sup>[157]</sup> These wavelengths are present in sunlight, as well as in the light emitted by the UV lamps in [tanning beds](#) (which produce ultraviolet primarily in the [UVA](#) spectrum, but typically produce 4% to 10% of the total UV emissions as UVB). Exposure to light through windows is insufficient because glass almost completely blocks UVB light.<sup>[158][159]</sup>

Adequate amounts of vitamin D can be produced with moderate sun exposure to the face, arms and legs, averaging 5–30 minutes twice per week, or approximately 25% of the time for minimal sunburn. The darker the skin, and the weaker the sunlight, the more minutes of exposure are needed. Vitamin D overdose is impossible from UV exposure; the skin reaches an equilibrium where the vitamin degrades as fast as it is created.<sup>[127][160][161]</sup>

[Sunscreen](#) absorbs or reflects ultraviolet light and prevents much of it from reaching the skin.<sup>[162]</sup> Sunscreen with a sun protection factor (SPF) of 8 based on the UVB spectrum decreases vitamin D synthetic capacity by 95%, and SPF 15 decreases it by 98%.<sup>[58]</sup>

The skin consists of two primary layers: the inner layer called the [dermis](#), composed largely of [connective tissue](#), and the outer, thinner [epidermis](#).<sup>[163]</sup> Thick epidermis in the soles and palms consists of five strata; from outer to inner, they are: the [stratum corneum](#), [stratum lucidum](#), [stratum granulosum](#), [stratum spinosum](#), and [stratum basale](#). Vitamin D is produced in the [keratinocytes](#)<sup>[164]</sup> of two innermost strata, the stratum basale and stratum spinosum.<sup>[162]</sup>

## Evolution<sup>[edit]</sup>

Vitamin D can be synthesized only by a photochemical process. Phytoplankton in the ocean (such as [coccolithophore](#) and *Emiliana huxleyi*) have been photosynthesizing vitamin D for more than 500 million years. Primitive vertebrates in the ocean could absorb calcium from the ocean into their skeletons and eat plankton rich in vitamin D.

Land vertebrates required another source of vitamin D other than plants for their calcified skeletons. They had to either ingest it or be exposed to sunlight to photosynthesize it in their skin.<sup>[124][154]</sup> Land vertebrates have been photosynthesizing vitamin D for more than 350 million years.<sup>[165]</sup>

In birds and fur-bearing mammals, fur or feathers block UV rays from reaching the skin. Instead, vitamin D is created from oily secretions of the skin deposited onto the feathers or fur, and is


obtained orally during grooming.<sup>[166]</sup> However, some animals, such as the [naked mole-rat](#), are naturally [cholecalciferol-deficient](#), as serum 25-OH vitamin D levels are undetectable.<sup>[167]</sup>

## Industrial synthesis<sup>[edit]</sup>

Vitamin D<sub>3</sub> (cholecalciferol) is produced industrially by exposing [7-dehydrocholesterol](#) to UVB light, followed by purification.<sup>[168]</sup> The 7-dehydrocholesterol is a natural substance in fish organs, especially the liver,<sup>[169]</sup> or in wool grease ([lanolin](#)) from sheep. Vitamin D<sub>2</sub> (ergocalciferol) is produced in a similar way using ergosterol from yeast or mushrooms as a starting material.<sup>[168][125]</sup>

## Mechanism of action<sup>[edit]</sup>

### Metabolic activation<sup>[edit]</sup>



Vitamin D is carried in the bloodstream to the liver, where it is converted into the [prohormone calcifediol](#). Circulating calcifediol may then be converted into [calcitriol](#), the biologically active form of vitamin D, in the kidneys.<sup>[170]</sup>

Whether it is made in the skin or ingested, vitamin D is [hydroxylated](#) in the [liver](#) at position 25 (upper right of the molecule) to form 25-hydroxycholecalciferol (calcifediol or 25(OH)D).<sup>[171]</sup> This reaction is catalyzed by the [microsomal](#) enzyme [vitamin D 25-hydroxylase](#), the product of the *CYP2R1* human gene, and expressed by [hepatocytes](#).<sup>[172]</sup> Once made, the product is released into the [plasma](#), where it is bound to an  $\alpha$ -globulin carrier protein named the [vitamin D-binding protein](#).<sup>[173]</sup>

Calcifediol is transported to the proximal tubules of the kidneys, where it is hydroxylated at the 1- $\alpha$  position (lower right of the molecule) to form calcitriol (1,25-dihydroxycholecalciferol, 1,25(OH)<sub>2</sub>D). The conversion of calcifediol to calcitriol is catalyzed by the enzyme [25-hydroxyvitamin D<sub>3</sub> 1-alpha-hydroxylase](#), which is the product of the *CYP27B1* human gene. The activity of CYP27B1 is increased by [parathyroid hormone](#), and also by low calcium or phosphate.<sup>[6][170]</sup>

Following the final converting step in the kidney, calcitriol is released into the circulation. By binding to vitamin D-binding protein, calcitriol is transported throughout the body, including to the classical target organs of intestine, kidney and bone.<sup>[18]</sup> Calcitriol is the most potent natural [ligand](#) of the [vitamin D receptor](#), which mediates most of the physiological actions of vitamin D.<sup>[6][170]</sup>

In addition to the kidneys, calcitriol is also synthesized by certain other cells including [monocyte-macrophages](#) in the [immune system](#). When synthesized by monocyte-macrophages, calcitriol acts

locally as a [cytokine](#), modulating body defenses against microbial invaders by stimulating the [innate immune system](#).<sup>[170]</sup>

## Inactivation<sup>[edit]</sup>

The activity of calcifediol and calcitriol can be reduced by hydroxylation at position 24 by [vitamin D3 24-hydroxylase](#), forming secalciferol and calcitetrol, respectively.<sup>[171]</sup>

## Difference between substrates<sup>[edit]</sup>

Vitamin D<sub>2</sub> (ergocalciferol) and vitamin D<sub>3</sub> (cholecalciferol) share a similar mechanism of action as outlined above.<sup>[171]</sup> Metabolites produced by vitamin D<sub>2</sub> are sometimes named with an *er-* or *ergo* prefix to differentiate them from the D<sub>3</sub>-based counterparts.<sup>[174]</sup>

- Metabolites produced from vitamin D<sub>2</sub> tend to bind less well to the vitamin D-binding protein.
- Vitamin D<sub>3</sub> can alternatively be hydroxylated to calcifediol by [sterol 27-hydroxylase](#) (CYP27A1), but vitamin D<sub>2</sub> cannot.
- Ergocalciferol can be directly hydroxylated at position 24. This hydroxylation also leads to a greater degree of inactivation: while calcitriol's activity decreases to 60% of original after 24-hydroxylation, <sup>[175]</sup> ercalcitriol suffers a 10-fold decrease in activity on conversion to ercalcitetrol.<sup>[176]</sup>

## History<sup>[edit]</sup>

Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +

American researchers [Elmer McCollum](#) and [Marguerite Davis](#) in 1914<sup>[12]</sup> discovered a substance in [cod liver oil](#) which later was called "vitamin A". British doctor [Edward Mellanby](#) noticed dogs that were fed cod liver oil did not develop rickets and concluded vitamin A, or a closely associated factor, could prevent the disease. In 1922, Elmer McCollum tested modified cod liver oil in which the vitamin A had been destroyed.<sup>[12]</sup> The modified oil cured the sick dogs, so McCollum concluded the factor in cod liver oil which cured rickets was distinct from vitamin A. He called it vitamin D because it was the fourth vitamin to be named.<sup>[177][178][179]</sup> It was not initially realized that, unlike other vitamins, vitamin D can be synthesised by humans through exposure to UV light.

In 1925,<sup>[12]</sup> it was established that when 7-dehydrocholesterol is irradiated with light, a form of a [fat-soluble](#) vitamin is produced (now known as D<sub>3</sub>). [Alfred Fabian Hess](#) stated: "Light equals vitamin D."<sup>[180]</sup> [Adolf Windaus](#), at the [University of Göttingen](#) in Germany, received the [Nobel Prize in Chemistry](#) in 1928 for his work on the constitution of sterols and their connection with vitamins.<sup>[181]</sup> In 1929, a group at [NIMR](#) in Hampstead, London, were working on the structure of vitamin D, which was still unknown, as well as the structure of steroids. A meeting took place with [J.B.S. Haldane](#), [J.D. Bernal](#), and [Dorothy Crowfoot](#) to discuss possible structures, which contributed to bringing a team together. X-ray crystallography demonstrated the sterol molecules were flat, not as proposed by the German team led by Windaus. In 1932, Otto Rosenheim and Harold King published a paper putting forward structures for sterols and bile acids which found immediate acceptance.<sup>[182]</sup> The informal academic collaboration between the team members [Robert Benedict Bourdillon](#), Otto Rosenheim, Harold King, and [Kenneth Callow](#) was very productive and led to the isolation and characterization of vitamin D.<sup>[183]</sup> At this time, the policy of the [Medical Research Council](#) was not to patent discoveries, believing the results of medical research should be open to everybody. In the 1930s, Windaus clarified further the chemical structure of vitamin D.<sup>[184]</sup>

In 1923, American biochemist [Harry Steenbock](#) at the [University of Wisconsin](#) demonstrated that irradiation by ultraviolet light increased the vitamin D content of foods and other organic materials.<sup>[185]</sup> After irradiating rodent food, Steenbock discovered the rodents were cured of rickets. A vitamin D deficiency is a known cause of rickets. Using \$300 of his own money, Steenbock patented his invention. His irradiation technique was used for foodstuffs, most memorably for milk. By the expiration of his patent in 1945, rickets had been all but eliminated in the US.<sup>[186]</sup>

In 1969, after studying nuclear fragments of intestinal cells, a specific binding protein for vitamin D called the [vitamin D receptor](#) was identified by Mark Haussler and [Tony Norman](#).<sup>[187]</sup> In 1971–72, the further metabolism of vitamin D to active forms was discovered. In the liver, vitamin D was found to be converted to calcifediol. Calcifediol is then converted by the kidneys to calcitriol, the biologically active form of vitamin D.<sup>[11]</sup> Calcitriol circulates as a hormone in the blood, regulating the concentration of calcium and phosphate in the bloodstream and promoting the healthy growth and remodeling of bone. The vitamin D metabolites, calcifediol and calcitriol, were identified by competing teams led by [Michael F. Holick](#) in the laboratory of [Hector DeLuca](#) and by Tony Norman and colleagues.<sup>[188][189][190]</sup>

## Research<sup>[edit]</sup>

---

There is considerable research activity looking at effects of vitamin D and its metabolites in animal models, cell systems, gene expression studies, epidemiology and clinical therapeutics. These different types of studies can produce conflicting evidence as to the benefits of interventions with vitamin D.<sup>[191]</sup> One school of thought contends the human physiology is fine-tuned to an intake of 4,000–12,000 IU/day from sun exposure with concomitant serum 25-hydroxyvitamin D levels of 40 to 80 ng/mL<sup>[192]</sup> and this is required for optimal health. Proponents of this view, who include some members of the panel that drafted a now-superseded 1997 report on vitamin D from the IOM, contend the IOM's warning about serum concentrations above 50 ng/mL lacks biological plausibility. They suggest, for some people, reducing the risk of preventable disease requires a higher level of vitamin D than that recommended by the IOM.<sup>[192][193]</sup>

The United States [National Institutes of Health](#) Office of Dietary Supplements established a Vitamin D Initiative in 2014 to track current research and provide education to consumers.<sup>[194]</sup> In their 2016 review, they recognize that a growing body of research suggests that vitamin D might play some role in the prevention and treatment of types 1 and 2 diabetes, glucose intolerance, hypertension, multiple sclerosis, and other medical conditions. They state further: "however, most evidence for these roles comes from in vitro, animal, and epidemiological studies, not the randomized clinical trials considered to be more definitive. Until such trials are conducted, the implications of the available evidence for public health and patient care will be debated".<sup>[7]</sup>

Some preliminary studies link low vitamin D levels with disease later in life.<sup>[195]</sup> Evidence as of 2013 is insufficient to determine whether vitamin D affects the risk of cancer.<sup>[196]</sup> One meta-analysis found a decrease in mortality in elderly people.<sup>[15]</sup> Another meta-analysis covering over 350,000 people concluded that vitamin D supplementation in unselected community-dwelling individuals does not reduce skeletal (total fracture) or non-skeletal outcomes (myocardial infarction, ischemic heart disease, stroke, cerebrovascular disease, cancer) by more than 15%, and that further research trials with similar design are unlikely to change these conclusions.<sup>[16]</sup> A 2019 meta-analysis found that there may be an increased risk of stroke when taking both calcium and vitamin D.<sup>[197]</sup>

Vitamin D deficiency is widespread in the European population.<sup>[198]</sup> European research is assessing vitamin D intake levels in association with disease rates and policies of dietary recommendations, food fortification, vitamin D supplementation, and small amounts of sun exposure.<sup>[130]</sup>

Apart from VDR activation, various alternative mechanisms of action are under study, such as inhibition of [signal transduction](#) by [hedgehog](#), a hormone involved in [morphogenesis](#).<sup>[199]</sup>

## References<sup>[edit]</sup>

---

- <sup>^</sup> [Jump up to: <sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup>](#) Holick MF (December 2004). *"Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease"*. *The American Journal of Clinical Nutrition*. **80** (6 Suppl): 1678S–88S. doi:10.1093/ajcn/80.6.1678S. PMID 15585788.

2. ^ Jump up to:<sup>a b c d</sup> Holick MF (March 2006). "High prevalence of vitamin D inadequacy and implications for health". *Mayo Clinic Proceedings*. **81** (3): 353–73. doi:10.4065/81.3.353. PMID 16529140.
3. ^ MacDonald, James (July 18, 2019). "How Does the Body Make Vitamin D from Sunlight?". *JSTOR Daily*. Retrieved July 22, 2019.
4. ^ Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT, Anderson RR, et al. (October 10, 1980). "Photosynthesis of previtamin D3 in human skin and the physiologic consequences". *Science*. **210** (4466): 203–5. doi:10.1126/science.6251551. ISSN 0036-8075. JSTOR 1685024. PMID 6251551.
5. ^ Calvo MS, Whiting SJ, Barton CN (February 2005). "Vitamin D intake: a global perspective of current status". *The Journal of Nutrition*. **135** (2): 310–6. doi:10.1093/jn/135.2.310. PMID 15671233.
6. ^ Jump up to:<sup>a b c d e f</sup> Norman AW (August 2008). "From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health". *The American Journal of Clinical Nutrition*. **88** (2): 491S–499S. doi:10.1093/ajcn/88.2.491S. PMID 18689389.
7. ^ Jump up to:<sup>a b c d e</sup> "Vitamin D Fact Sheet for Health Professionals". National Institutes of Health (NIH). February 11, 2016. Retrieved June 6, 2017. <sup>Ⓢ</sup> This article incorporates text from this source, which is in the public domain.
8. ^ <https://academic.oup.com/ajcn/article/102/4/837/4564566>
9. ^ "Vitamin D Tests". *Lab Tests Online (USA)*. American Association for Clinical Chemistry. Retrieved June 23, 2013.
10. ^ Hollis BW (January 1996). "Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it". *Calcified Tissue International*. **58** (1): 4–5. doi:10.1007/BF02509538. PMID 8825231.
11. ^ Jump up to:<sup>a b</sup> Holick MF, Schnoes HK, DeLuca HF, Suda T, Cousins RJ (July 1971). "Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine". *Biochemistry*. **10** (14): 2799–804. doi:10.1021/bi00790a023. PMID 4326883.
12. ^ Jump up to:<sup>a b c d</sup> Wolf G (June 2004). "The discovery of vitamin D: the contribution of Adolf Windaus". *The Journal of Nutrition*. **134** (6): 1299–302. doi:10.1093/jn/134.6.1299. PMID 15173387.
13. ^ Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. (March 2010). "Systematic review: Vitamin D and cardiometabolic outcomes". *Annals of Internal Medicine*. **152** (5): 307–14. doi:10.7326/0003-4819-152-5-201003020-00009. PMC 3211092. PMID 20194237.
14. ^ Jump up to:<sup>a b</sup> Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al. (August 2009). "Vitamin D and calcium: a systematic review of health outcomes". *Evidence Report/Technology Assessment (183)*: 1–420. PMC 4781105. PMID 20629479.
15. ^ Jump up to:<sup>a b c d e f g</sup> Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. (January 2014). "Vitamin D supplementation for prevention of mortality in adults". *The Cochrane Database of Systematic Reviews (Systematic review)*. **1** (1): CD007470. doi:10.1002/14651858.CD007470.pub3. PMID 24414552.
16. ^ Jump up to:<sup>a b c d e f g h</sup> Bolland MJ, Grey A, Gamble GD, Reid IR (April 2014). "The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis". *The Lancet Diabetes & Endocrinology (Meta-analysis)*. **2** (4): 307–20. doi:10.1016/S2213-8587(13)70212-2. PMID 24703049.
17. ^ *Dorland's Illustrated Medical Dictionary*, under Vitamin (Table of Vitamins)
18. ^ Jump up to:<sup>a b c d</sup> "About Vitamin D". University of California, Riverside. November 2011. Retrieved January 24, 2015.
19. ^ Boron WF, Boulpaep EL (March 29, 2016). *Medical Physiology E-Book*. Elsevier Health Sciences. ISBN 978-1-4557-3328-6.
20. ^ Bouillon R, Van Cromphaut S, Carmeliet G (February 2003). "Intestinal calcium absorption: Molecular vitamin D mediated mechanisms". *Journal of Cellular Biochemistry*. **88** (2): 332–9. doi:10.1002/jcb.10360. PMID 12520535.
21. ^ Jump up to:<sup>a b</sup> Bell TD, Demay MB, Burnett-Bowie SA (September 2010). "The biology and pathology of vitamin D control in bone". *Journal of Cellular Biochemistry*. **111** (1): 7–13. doi:10.1002/jcb.22661. PMC 4020510. PMID 20506379.
22. ^ Watkins RR, Lemonovich TL, Salata RA (May 2015). "An update on the association of vitamin D deficiency with common infectious diseases". *Canadian Journal of Physiology and Pharmacology*. **93** (5): 363–8. doi:10.1139/cjpp-2014-0352. PMID 25741906.

23. [^ Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK \(February 1996\). "Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells". \*Brain Research. Molecular Brain Research\*. \*\*36\*\* \(1\): 193–6. doi:10.1016/0169-328X\(95\)00314-I. PMID 9011759.](#)
24. [^ "Rickets". \*National Health Service\*. March 8, 2012. Retrieved July 9, 2012.](#)
25. [^ \*MedlinePlus Encyclopedia\* Rickets](#)
26. [^ Eriksen EF, Glerup H \(2002\). "Vitamin D deficiency and aging: implications for general health and osteoporosis". \*Biogerontology\*. \*\*3\*\* \(1–2\): 73–7. doi:10.1023/A:1015263514765. PMID 12014847.](#)
27. [^ Jump up to:<sup>a b c d e f</sup> Holick MF \(July 2007\). "Vitamin D deficiency". \*The New England Journal of Medicine\*. \*\*357\*\* \(3\): 266–81. doi:10.1056/NEJMra070553. PMID 17634462.](#)
28. [^ Schoenmakers I, Goldberg GR, Prentice A \(June 2008\). "\*Abundant sunshine and vitamin D deficiency\*". \*The British Journal of Nutrition\*. \*\*99\*\* \(6\): 1171–3. doi:10.1017/S0007114508898662. PMC 2758994. PMID 18234141.](#)
29. [^ Grant WB, Holick MF \(June 2005\). "Benefits and requirements of vitamin D for optimal health: a review". \*Alternative Medicine Review\*. \*\*10\*\* \(2\): 94–111. PMID 15989379.](#)
30. [^ Jump up to:<sup>a b c d</sup> Brown JE, Isaacs J, Krinke B, Lechtenberg E, Murtaugh M \(June 28, 2013\). \*Nutrition Through the Life Cycle\*. Cengage Learning. ISBN 978-1-285-82025-5.](#)
31. [^ Lerch C, Meissner T \(October 2007\). Lerch C \(ed.\). "Interventions for the prevention of nutritional rickets in term born children". \*The Cochrane Database of Systematic Reviews\*\(4\): CD006164. doi:10.1002/14651858.CD006164.pub2. PMID 17943890.](#)
32. [^ Zargar AH, Mithal A, Wani AI, Laway BA, Masoodi SR, Bashir MI, et al. \(June 2000\). "\*Pseudovitamin D deficiency rickets--a report from the Indian subcontinent\*". \*Postgraduate Medical Journal\*. \*\*76\*\* \(896\): 369–72. doi:10.1136/pmj.76.896.369. PMC 1741602. PMID 10824056.](#)
33. [^ Elidrissy AT \(September 2016\). "The Return of Congenital Rickets, Are We Missing Occult Cases?". \*Calcified Tissue International \(Review\)\*. \*\*99\*\* \(3\): 227–36. doi:10.1007/s00223-016-0146-2. PMID 27245342.](#)
34. [^ Paterson CR, Ayoub D \(October 2015\). "Congenital rickets due to vitamin D deficiency in the mothers". \*Clinical Nutrition \(Review\)\*. \*\*34\*\* \(5\): 793–8. doi:10.1016/j.clnu.2014.12.006. PMID 25552383.](#)
35. [^ Oramasionwu GE, Thacher TD, Pam SD, Pettifor JM, Abrams SA \(August 2008\). "Adaptation of calcium absorption during treatment of nutritional rickets in Nigerian children". \*The British Journal of Nutrition\*. \*\*100\*\* \(2\): 387–92. doi:10.1017/S0007114507901233. PMID 18197991.](#)
36. [^ Fischer PR, Rahman A, Cimma JP, Kyaw-Myint TO, Kabir AR, Talukder K, et al. \(October 1999\). "Nutritional rickets without vitamin D deficiency in Bangladesh". \*Journal of Tropical Pediatrics\*. \*\*45\*\* \(5\): 291–3. doi:10.1093/tropej/45.5.291. PMID 10584471.](#)
37. [^ Jump up to:<sup>a b</sup> Dunnigan MG, Henderson JB \(November 1997\). "An epidemiological model of privational rickets and osteomalacia". \*The Proceedings of the Nutrition Society\*. \*\*56\*\* \(3\): 939–56. doi:10.1079/PNS19970100. PMID 9483661.](#)
38. [^ Robertson I, Ford JA, McIntosh WB, Dunnigan MG \(January 1981\). "The role of cereals in the aetiology of nutritional rickets: the lesson of the Irish National Nutrition Survey 1943-8". \*The British Journal of Nutrition\*. \*\*45\*\* \(1\): 17–22. doi:10.1079/BJN19810073. PMID 6970590.](#)
39. [^ Clements MR \(1989\). "The problem of rickets in UK Asians". \*Journal of Human Nutrition and Dietetics\*. \*\*2\*\* \(2\): 105–116. doi:10.1111/j.1365-277X.1989.tb00015.x.](#)
40. [^ Jump up to:<sup>a b</sup> Pettifor JM \(December 2004\). "Nutritional rickets: deficiency of vitamin D, calcium, or both?". \*The American Journal of Clinical Nutrition\*. \*\*80\*\* \(6 Suppl\): 1725S–9S. doi:10.1093/ajcn/80.6.1725S. PMID 15585795.](#)
41. [^ Jump up to:<sup>a b</sup> Dunnigan MG, Henderson JB, Hole DJ, Barbara Mawer E, Berry JL \(December 2005\). "Meat consumption reduces the risk of nutritional rickets and osteomalacia". \*The British Journal of Nutrition\*. \*\*94\*\* \(6\): 983–91. doi:10.1079/BJN20051558. PMID 16351777.](#)
42. [^ "\*Cell Biology and Cancer Curriculum Supplement\*". Office of Science Education. Archived from the original on June 8, 2010. Retrieved August 24, 2010. This article incorporates text from this source, which is in the public domain.](#)
43. [^ Weick MT \(November 1967\). "A history of rickets in the United States". \*The American Journal of Clinical Nutrition\*. \*\*20\*\* \(11\): 1234–41. doi:10.1093/ajcn/20.11.1234. PMID 4862158.](#)
44. [^ Garrison RH, Somer E \(1997\). \*The Nutrition Desk Reference\*. McGraw-Hill. ISBN 978-0-87983-826-3.](#)
45. [^ Dupuis EM \(February 1, 2002\). \*Nature's Perfect Food: How Milk Became America's Drink\*. NYU Press. ISBN 978-0-8147-1938-1.](#)

46. [^ Teegarden D, Lyle RM, Proulx WR, Johnston CC, Weaver CM \(May 1999\). "Previous milk consumption is associated with greater bone density in young women". \*The American Journal of Clinical Nutrition\*. \*\*69\*\* \(5\): 1014–7. doi:10.1093/ajcn/69.5.1014. PMID 10232644.](#)
47. [^ Jump up to:<sup>a b c</sup> Insel P, Ross D, Bernstein M, McMahon K \(March 18, 2015\). \*Discovering Nutrition\*. Jones & Bartlett Publishers. ISBN 978-1-284-06465-0.](#)
48. [^ Holick MF \(2003\). "Vitamin D: A millenium perspective". \*Journal of Cellular Biochemistry\*. \*\*88\*\* \(2\): 296–307. doi:10.1002/jcb.10338. PMID 12520530.](#)
49. [^ Straube S, Andrew Moore R, Derry S, McQuay HJ \(2009\). "Vitamin D and chronic pain". \*Pain\*. \*\*141\*\* \(1–2\): 10–13. doi:10.1016/j.pain.2008.11.010. PMID 19084336.](#)
50. [^ Gaikwad M, Vanlint S, Mittinity M, Moseley GL, Stocks N \(2016\). "Does vitamin D supplementation alleviate chronic nonspecific musculoskeletal pain? A systematic review and meta-analysis". \*Clinical Rheumatology\*. \*\*36\*\* \(5\): 1201–1208. doi:10.1007/s10067-016-3205-1. PMID 26861032.](#)
51. [^ Lowe NM, Bhojani I \(2017\). "Special considerations for vitamin D in the south Asian population in the UK". \*Therapeutic Advances in Musculoskeletal Disease\*. \*\*9\*\* \(6\): 137–144. doi:10.1177/1759720X17704430. PMC 5466148. PMID 28620422.](#)
52. [^ O'Connor MY, Thoreson CK, Ramsey NL, Ricks M, Sumner AE \(2013\). "The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature". \*Progress in Cardiovascular Diseases\*. \*\*56\*\* \(3\): 261–269. doi:10.1016/j.pcad.2013.10.015. PMC 3894250. PMID 24267433.](#)
53. [^ Jump up to:<sup>a b</sup> Freedman BI, Register TC \(2012\). "Effect of race and genetics on vitamin D metabolism, bone and vascular health". \*Nature Reviews Nephrology\*. \*\*8\*\* \(8\): 459–466. doi:10.1038/nrneph.2012.112. PMID 22688752.](#)
54. [^ Khalid AT, Moore CG, Hall C, Olabopo F, Rozario NL, Holick MF, et al. \(2017\). "Utility of sun-reactive skin typing and melanin index for discerning vitamin D deficiency". \*Pediatric Research\*. \*\*82\*\* \(3\): 444–451. doi:10.1038/pr.2017.114. PMC 5570640. PMID 28467404.](#)
55. [^ Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP \(April 2014\). "Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials". \*BMJ\*. \*\*348\*\*: g2035. doi:10.1136/bmj.g2035. PMC 3972415. PMID 24690624.](#)
56. [^ Jump up to:<sup>a b c</sup> Autier P, Boniol M, Pizot C, Mullie P \(January 2014\). "Vitamin D status and ill health: a systematic review". \*The Lancet Diabetes & Endocrinology\*. \*\*2\*\* \(1\): 76–89. doi:10.1016/S2213-8587\(13\)70165-7. PMID 24622671.](#)
57. [^ Hussain S, Singh A, Akhtar M, Najmi AK \(September 2017\). "Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials". \*Rheumatology International\*. \*\*37\*\* \(9\): 1489–1498. doi:10.1007/s00296-017-3719-0. PMID 28421358.](#)
58. [^ Jump up to:<sup>a b c d e f g h i j k l m</sup> Institute of Medicine \(IoM\) \(2011\). "8, Implications and Special Concerns". In Ross AC, Taylor CL, Yaktine AL, Del Valle HB \(eds.\). \*Dietary Reference Intakes for Calcium and Vitamin D\*. The National Academies Collection: Reports funded by National Institutes of Health. National Academies Press. doi:10.17226/13050. ISBN 978-0-309-16394-1. PMID 21796828.](#)
59. [^ Jump up to:<sup>a b</sup> Maxmen A \(July 2011\). "Nutrition advice: the vitamin D-lemma". \*Nature\*. \*\*475\*\* \(7354\): 23–5. doi:10.1038/475023a. PMID 21734684.](#)
60. [^ Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot LD, et al. \(June 2014\). "Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States". \*BMJ\*. \*\*348\*\* \(jun17 16\): g3656. doi:10.1136/bmj.g3656. PMC 4061380. PMID 24938302.](#)
61. [^ Tuohimaa P \(March 2009\). "Vitamin D and aging". \*The Journal of Steroid Biochemistry and Molecular Biology\*. \*\*114\*\* \(1–2\): 78–84. doi:10.1016/j.jsbmb.2008.12.020. PMID 19444937.](#)
62. [^ Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A \(December 2009\). "Vitamin D, nervous system and aging". \*Psychoneuroendocrinology\*. \*\*34\*\* Suppl 1: S278–86. doi:10.1016/j.psyneuen.2009.07.003. PMID 19660871.](#)
63. [^ Manya H, Akasaka-Manya K, Endo T \(July 2010\). "Klotho protein deficiency and aging". \*Geriatrics & Gerontology International\*. \*\*10\*\* Suppl 1 \(Suppl 1\): S80–7. doi:10.1111/j.1447-0594.2010.00596.x. PMID 20590845.](#)
64. [^ Reid IR, Bolland MJ, Grey A \(January 2014\). "Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis". \*Lancet\*. \*\*383\*\* \(9912\): 146–55. doi:10.1016/s0140-6736\(13\)61647-5. PMID 24119980.](#)

65. [^ Avenell A, Mak JC, O'Connell D \(April 2014\). "Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men". The Cochrane Database of Systematic Reviews. 4 \(4\): CD000227. doi:10.1002/14651858.CD000227.pub4. PMID 24729336.](#)
66. [^ Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, et al. \(July 2012\). "A pooled analysis of vitamin D dose requirements for fracture prevention" \(PDF\). The New England Journal of Medicine. 367 \(1\): 40–9. doi:10.1056/NEJMoa1109617. hdl:1871/48765. PMID 22762317.](#)
67. [^ Jump up to:<sup>a b</sup> Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA \(December 2011\). "Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 155 \(12\): 827–38. doi:10.7326/0003-4819-155-12-201112200-00005. PMID 22184690.](#)
68. [^ Zhao JG, Zeng XT, Wang J, Liu L \(December 2017\). "Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis". JAMA. 318 \(24\): 2466–2482. doi:10.1001/jama.2017.19344. PMC 5820727. PMID 29279934.](#)
69. [^ Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, et al. \(August 2007\). "Effectiveness and safety of vitamin D in relation to bone health". Evidence Report/Technology Assessment \(158\): 1–235. PMC 4781354. PMID 18088161.](#)
70. [^ Bolland MJ, Grey A, Gamble GD, Reid IR \(July 2014\). "Vitamin D supplementation and falls: a trial sequential meta-analysis". The Lancet Diabetes & Endocrinology. 2 \(7\): 573–80. doi:10.1016/S2213-8587\(14\)70068-3. PMID 24768505.](#)
71. [^ Shuler FD, Wingate MK, Moore GH, Giangarra C \(November 2012\). "Sports health benefits of vitamin d". Sports Health. 4 \(6\): 496–501. doi:10.1177/1941738112461621. PMC 3497950. PMID 24179588.](#)
72. [^ Jump up to:<sup>a b c</sup> "Changes to the Nutrition Facts Label". Food and Drug Administration \(FDA\). June 18, 2019. Retrieved July 16, 2019. This article incorporates text from this source, which is in the public domain.](#)
73. [^ Byers T \(July 2010\). "Anticancer vitamins du Jour--The ABCED's so far". American Journal of Epidemiology \(Review\). 172 \(1\): 1–3. doi:10.1093/aje/kwq112. PMC 2892535. PMID 20562190.](#)
74. [^ Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ \(May 2014\). "The role of vitamin D in reducing cancer risk and progression". Nature Reviews. Cancer. 14 \(5\): 342–57. doi:10.1038/nrc3691. PMID 24705652.](#)
75. [^ Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, et al. \(2011\). "Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review". The Oncologist. 16 \(9\): 1215–27. doi:10.1634/theoncologist.2011-0098. PMC 3228169. PMID 21835895.](#)
76. [^ Li M, Chen P, Li J, Chu R, Xie D, Wang H \(July 2014\). "Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 99 \(7\): 2327–36. doi:10.1210/jc.2013-4320. PMID 24780061.](#)
77. [^ Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, et al. \(June 19, 2019\). "Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis". JAMA Cardiology. doi:10.1001/jamacardio.2019.1870. ISSN 2380-6583. PMC 6584896. PMID 31215980.](#)
78. [^ Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. \(May 2015\). "Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data". JAMA Internal Medicine. 175 \(5\): 745–54. doi:10.1001/jamainternmed.2015.0237. PMC 5966296. PMID 25775274.](#)
79. [^ Hewison M \(2011\). Vitamin D and innate and adaptive immunity. Vitamins & Hormones. 86. pp. 23–62. doi:10.1016/B978-0-12-386960-9.00002-2. ISBN 9780123869609. PMID 21419266.](#)
80. [^ Beard JA, Bearden A, Striker R \(2011\). "Vitamin D and the anti-viral state". Journal of Clinical Virology. 50 \(3\): 194–200. doi:10.1016/j.jcv.2010.12.006. PMC 3308600. PMID 21242105.](#)
81. [^ Spector SA \(2011\). "Vitamin D and HIV: letting the sun shine in". Topics in Antiviral Medicine. 19 \(1\): 6–10. PMC 6148856. PMID 21852710.](#)
82. [^ Nnoaham KE, Clarke A \(2008\). "Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis". International Journal of Epidemiology. 37 \(1\): 113–119. doi:10.1093/ije/dym247. PMID 18245055.](#)



83. [^ Luong KV, Nguyen LT \(2011\). "Impact of vitamin D in the treatment of tuberculosis". \*The American Journal of the Medical Sciences\*. \*\*341\*\* \(6\): 493–498. doi:10.1097/MAJ.0b013e3182070f47. PMID 21289501.](#)
84. [^ Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD \(2013\). "Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". \*PLOS ONE\*. \*\*8\*\* \(6\): e65835. Bibcode:2013PLoS...865835B. doi:10.1371/journal.pone.0065835. PMC 3686844. PMID 23840373.](#)
85. [^ Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. \(2017\). "Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data". \*BMJ\*. \*\*356\*\*: i6583. doi:10.1136/bmj.i6583. PMC 5310969. PMID 28202713.](#)
86. [^ Autier P, Mullie P, Macacu A, Dragomir M, Boniol M, Coppens K, et al. \(2017\). "Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials". \*The Lancet. Diabetes & Endocrinology\*. \*\*5\*\* \(12\): 986–1004. doi:10.1016/S2213-8587\(17\)30357-1. PMID 29102433.](#)
87. [^ Yakoob MY, Salam RA, Khan FR, Bhutta ZA \(2016\). "Vitamin D supplementation for preventing infections in children under five years of age". \*The Cochrane Database of Systematic Reviews\*. \*\*11\*\*: CD008824. doi:10.1002/14651858.cd008824.pub2. PMC 5450876. PMID 27826955.](#)
88. [^ Hart PH \(June 2012\). "Vitamin D supplementation, moderate sun exposure, and control of immune diseases". \*Discovery Medicine\*. \*\*13\*\* \(73\): 397–404. PMID 22742645.](#)
89. [^ Paul G, Brehm JM, Alcorn JF, Holguín F, Aujla SJ, Celedón JC \(2012\). "Vitamin D and asthma". \*American Journal of Respiratory and Critical Care Medicine\*. \*\*185\*\* \(2\): 124–132. doi:10.1164/rccm.201108-1502CI. PMC 3297088. PMID 22016447.](#)
90. [^ Pakpoor J, Ramagopalan S \(2014\). "Evidence for an Association Between Vitamin D and Multiple Sclerosis". \*Emerging and Evolving Topics in Multiple Sclerosis Pathogenesis and Treatments. Current Topics in Behavioral Neurosciences\*. \*\*26\*\*. pp. 105–115. doi:10.1007/7854\\_2014\\_358. ISBN 978-3-319-25541-5. PMID 25502544. The evidence for vitamin D as a treatment for MS is inconclusive.](#)
91. [^ Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J \(2013\). "A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis". \*Neuroepidemiology \(Systematic Review\)\*. \*\*40\*\* \(3\): 147–153. doi:10.1159/000345122. PMC 3649517. PMID 23257784. The available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS.](#)
92. [^ Thomas JS, Ellen MM \(2018\). "A review of vitamin D supplementation as disease-modifying therapy". \*Multiple Sclerosis Journal \(Systematic Review\)\*. \*\*24\*\* \(1\): 6–11. doi:10.1177/1352458517738131. PMID 29307295. Several preliminary studies have reported results which have shown some promise, but none has yet provided significant evidence of a clinically meaningful improvement.](#)
93. [^ Jump up to:<sup>a</sup> <sup>b</sup> Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F \(November 2015\). "Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis". \*Inflammatory Bowel Diseases\*. \*\*21\*\* \(11\): 2708–2717. doi:10.1097/MIB.0000000000000546. PMC 4615394. PMID 26348447.](#)
94. [^ Del Pinto R, Ferri C, Cominelli F \(November 2017\). "Vitamin D Axis in Inflammatory Bowel Diseases: Role, Current Uses and Future Perspectives". \*International Journal of Molecular Sciences\*. \*\*18\*\* \(11\): 2360. doi:10.3390/ijms18112360. PMC 5713329. PMID 29112157.](#)
95. [^ Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. \(October 2014\). "Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis". \*The Journal of Clinical Endocrinology and Metabolism \(Review\)\*. \*\*99\*\* \(10\): 3551–60. doi:10.1210/jc.2014-2136. PMC 4483466. PMID 25062463.](#)
96. [^ Nakashima A, Yokoyama K, Yokoo T, Urashima M \(March 2016\). "Role of vitamin D in diabetes mellitus and chronic kidney disease". \*World Journal of Diabetes \(Review\)\*. \*\*7\*\*\(5\): 89–100. doi:10.4239/wjd.v7.i5.89. PMC 4781904. PMID 26981182.](#)
97. [^ Shaffer JA, Edmondson D, Wasson LT, Falzon L, Homma K, Ezeokoli N, et al. \(April 2014\). "Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials". \*Psychosomatic Medicine\*. \*\*76\*\* \(3\): 190–6. doi:10.1097/psy.0000000000000044. PMC 4008710. PMID 24632894.](#)

98. <sup>^</sup> [Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. \(September 2012\). "Vitamin D, cognition, and dementia: a systematic review and meta-analysis". \*Neurology\*. \*\*79\*\* \(13\): 1397–405. doi:10.1212/WNL.0b013e31826c197f. PMC 3448747. PMID 23008220.](#)
99. <sup>^</sup> [Jump up to:<sup>a b c</sup> Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM \(March 2013\). "Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies". \*BMJ\*. \*\*346\*\*: f1169. doi:10.1136/bmj.f1169. PMID 23533188.](#)
100. <sup>^</sup> [Jump up to:<sup>a b c</sup> Palacios C, De-Regil LM, Lombardo LK, Peña-Rosas JP \(November 2016\). "Vitamin D supplementation during pregnancy: Updated meta-analysis on maternal outcomes". \*The Journal of Steroid Biochemistry and Molecular Biology\*. \*\*164\*\*: 148–155. doi:10.1016/j.jsmb.2016.02.008. PMC 5357731. PMID 26877200.](#)
101. <sup>^</sup> [Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E \(November 2017\). "Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials". \*BMJ\*. \*\*359\*\*: j5237. doi:10.1136/bmj.j5237. PMC 5706533. PMID 29187358.](#)
102. <sup>^</sup> [Jump up to:<sup>a b</sup> Wagner CL, Taylor SN, Dawodu A, Johnson DD, Hollis BW \(March 2012\). "Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus". \*Nutrients\*. \*\*4\*\* \(3\): 208–30. doi:10.3390/nu4030208. PMC 3347028. PMID 22666547.](#)
103. <sup>^</sup> [Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ \(May 2018\). "Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis". \*JAMA Pediatrics\*. \*\*172\*\* \(7\): 635–645. doi:10.1001/jamapediatrics.2018.0302. PMC 6137512. PMID 29813153.](#)
104. <sup>^</sup> [Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J \(June 2014\). "Vitamin D supplementation and body weight status: a systematic review and meta-analysis of randomized controlled trials". \*Obesity Reviews\*. \*\*15\*\* \(6\): 528–37. doi:10.1111/obr.12162. PMID 24528624.](#)
105. <sup>^</sup> [Mallard SR, Howe AS, Houghton LA \(October 2016\). "Vitamin D status and weight loss: a systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials". \*The American Journal of Clinical Nutrition\*. \*\*104\*\* \(4\): 1151–1159. doi:10.3945/ajcn.116.136879. PMID 27604772.](#)
106. <sup>^</sup> [Jump up to:<sup>a b c</sup> European Food Safety Authority \(EFSA\) Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(2010\). "Scientific opinion on the substantiation of health claims related to vitamin D and normal function of the immune system and inflammatory response \(ID 154, 159\), maintenance of normal muscle function \(ID 155\) and maintenance of normal cardiovascular function \(ID 159\) pursuant to Article 13\(1\) of Regulation \(EC\) No 1924/2006". \*EFSA Journal\*. \*\*8\*\* \(2\): 1468–85. doi:10.2903/j.efsa.2010.1468.](#)
107. <sup>^</sup> [European Food Safety Authority \(EFSA\) Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(2011\). "Scientific opinion on the substantiation of a health claim related to vitamin D and risk of falling pursuant to Article 14 of Regulation \(EC\) No 1924/2006". \*EFSA Journal\*. \*\*9\*\* \(9\): 2382–2400. doi:10.2903/j.efsa.2011.2382.](#)
108. <sup>^</sup> ["Guidance for Industry: Food Labeling Guide". \*Food and Drug Administration\* \(FDA\). January 2013. !\[\]\(694fcb4611893e9db5249daba48abfc1\_img.jpg\) This article incorporates text from this source, which is in the \[public domain\]\(#\).](#)
109. <sup>^</sup> ["Health Canada Scientific Summary on the U. S. Health Claim Regarding Calcium and Osteoporosis". Bureau of Nutritional Sciences Food Directorate, Health Products and Food Branch Health Canada. May 1, 2000.](#)
110. <sup>^</sup> ["Regulatory Systems of Health Claims in Japan" \(PDF\). Japan Consumer Affairs Agency, Food Labelling Division. June 1, 2011. Archived from \[the original\]\(#\) \(PDF\) on March 6, 2012. Retrieved January 29, 2012.](#)
111. <sup>^</sup> ["Vitamin D". Nutrient Reference Values for Australia and New Zealand. Australian Ministry of Health. September 9, 2005. Archived from \[the original\]\(#\) on February 27, 2012.](#)
112. <sup>^</sup> [Jump up to:<sup>a b c</sup> "Vitamin D and Calcium: Updated Dietary Reference Intakes". Nutrition and Healthy Eating. Health Canada. December 5, 2008. Retrieved April 28, 2018.](#)
113. <sup>^</sup> [Jump up to:<sup>a b c</sup> "Nutrient reference values for Australia and New Zealand" \(PDF\). National Health and Medical Research Council. September 9, 2005. Retrieved April 28, 2018.](#)
114. <sup>^</sup> [Jump up to:<sup>a b c d</sup> EFSA Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(June 29, 2016\). "Dietary reference values for vitamin D". \*EFSA Journal\*. \*\*14\*\* \(10\): e04547. doi:10.2903/j.efsa.2016.4547.](#)

115. ^ Jump up to:<sup>a b</sup> EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2012). "[Scientific Opinion on the Tolerable Upper Intake Level of vitamin D](#)". *EFSA Journal* (Submitted manuscript). **10** (7). doi:10.2903/j.efsa.2012.2813.
116. ^ "[Federal Register May 27, 2016 Food Labeling: Revision of the Nutrition and Supplement Facts Labels. FR page 33982](#)" (PDF).<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
117. ^ Salleh A (June 12, 2012). "[Vitamin D food fortification on the table](#)". Australian Broadcasting Corporation.
118. ^ "[Vitamins and minerals – Vitamin D](#)". *National Health Service*. February 18, 2015. Retrieved July 21, 2016.
119. ^ "[PHE publishes new advice on vitamin D](#)". Public Health England. July 21, 2016. Retrieved July 21, 2016.
120. ^ "[Vitamin D \(translated\)](#)" (in Swedish). *Swedish National Food Agency*. Retrieved October 19, 2018.
121. ^ [Vitamin-D-Bedarf bei fehlender endogener Synthese](#) Deutsche Gesellschaft für Ernährung, January 2012
122. ^ Pérez-López FR, Brincat M, Erel CT, Tremollieres F, Gambacciani M, Lambrinouadaki I, et al. (January 2012). "EMAS position statement: Vitamin D and postmenopausal health". *Maturitas*. **71** (1): 83–8. doi:10.1016/j.maturitas.2011.11.002. PMID 22100145.
123. ^ Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes (1997). *DRI, Dietary reference intakes: for calcium, phosphorus, magnesium, vitamin D, and fluoride*. Washington, D.C: National Academy Press. p. 250. doi:10.17226/5776. ISBN 978-0-309-06350-0. PMID 23115811.
124. ^ Jump up to:<sup>a b c</sup> Holick MF (1992). "Evolutionary biology and pathology of vitamin D". *J. Nutr. Sci. Vitaminol. Spec No*: 79–83. doi:10.3177/jnsv.38.Special\_79. PMID 1297827.
125. ^ Jump up to:<sup>a b c d e f</sup> Keegan RJ, Lu Z, Bogusz JM, Williams JE, Holick MF (January 2013). "[Photobiology of vitamin D in mushrooms and its bioavailability in humans](#)". *Dermato-Endocrinology*. **5** (1): 165–76. doi:10.4161/derm.23321. PMC 3897585. PMID 24494050.
126. ^ Jump up to:<sup>a b</sup> Wang T, Bengtsson G, Kärnefelt I, Björn LO (September 2001). "[Provitamins and vitamins D<sub>2</sub> and D<sub>3</sub> in \*Cladina\* spp. over a latitudinal gradient: possible correlation with UV levels](#)". *Journal of Photochemistry and Photobiology. B, Biology* (Submitted manuscript). **62** (1–2): 118–22. doi:10.1016/S1011-1344(01)00160-9. PMID 11693362.
127. ^ Haytowitz DB (2009). "[Vitamin D in mushrooms](#)" (PDF). Nutrient Data Laboratory, US Department of Agriculture. Retrieved April 16, 2018.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
128. ^ "[Search, National Nutrient Database for Standard Reference Release 27](#)". US Department of Agriculture, Agricultural Research Service. 2014. Retrieved June 12, 2015.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
129. ^ de Lourdes Samaniego-Vaesken M, Alonso-Apperte E, Varela-Moreiras G (2012). "[Vitamin food fortification today](#)". *Food & Nutrition Research*. **56**: 5459. doi:10.3402/fnr.v56i0.5459. PMC 3319130. PMID 22481896.
130. ^ Jump up to:<sup>a b</sup> Spiro A, Buttriss JL (December 2014). "[Vitamin D: An overview of vitamin D status and intake in Europe](#)". *Nutrition Bulletin*. **39** (4): 322–350. doi:10.1111/nbu.12108. PMC 4288313. PMID 25635171.
131. ^ "[Vitamin D for Milk and Milk Alternatives](#)". *Food and Drug Administration* (FDA). July 15, 2016. Retrieved February 22, 2017.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
132. ^ "[Federal Register: Food Additives Permitted for Direct Addition to Food for Human Consumption: Vitamin D2](#)". Food and Drug Administration, US Department of Health and Human Services. July 18, 2016. Retrieved February 22, 2017.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
133. ^ "[§172.379 Vitamin D2](#)". *Electronic Code of Federal Regulations*. Retrieved July 16, 2019.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).
134. ^ "[§172.380 Vitamin D3](#)". *Electronic Code of Federal Regulations*. Retrieved July 16, 2019.<sup>Ⓢ</sup> This article incorporates text from this source, which is in the [public domain](#).

135. [^](#) [Tripkovic L](#) (2013). "Vitamin D<sub>2</sub> vs. vitamin D<sub>3</sub>: Are they one and the same?". *Nutrition Bulletin*. **38** (2): 243–248. [doi:10.1111/nbu.12029](#).
136. [^](#) [Alshahrani F, Aljohani N](#) (September 2013). "[Vitamin D: deficiency, sufficiency and toxicity](#)". *Nutrients*. **5** (9): 3605–16. [doi:10.3390/nu5093605](#). [PMC 3798924](#). [PMID 24067388](#).
137. [^](#) [Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF](#) (March 2013). "[Serum concentrations of 1,25-dihydroxyvitamin D<sub>2</sub> and 1,25-dihydroxyvitamin D<sub>3</sub> in response to vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation](#)". *The Journal of Clinical Endocrinology and Metabolism*. **98** (3): 973–9. [doi:10.1210/jc.2012-2114](#). [PMC 3590486](#). [PMID 23386645](#).
138. [^](#) [Borel P, Caillaud D, Cano NJ](#) (2015). "Vitamin D bioavailability: state of the art". *Critical Reviews in Food Science and Nutrition*. **55** (9): 1193–205. [doi:10.1080/10408398.2012.688897](#). [PMID 24915331](#).
139. [^](#) [Jakobsen J, Knuthsen P](#) (April 2014). "Stability of vitamin D in foodstuffs during cooking". *Food Chemistry*. **148**: 170–5. [doi:10.1016/j.foodchem.2013.10.043](#). [PMID 24262542](#).
140. [^](#) [Wahl DA, Cooper C, Ebeling PR, Eggersdorfer M, Hilger J, Hoffmann K, et al.](#) (August 29, 2012). "A global representation of vitamin D status in healthy populations". *Archives of Osteoporosis*. **7** (1–2): 155–72. [doi:10.1007/s11657-012-0093-0](#). [hdl:11343/220606](#). [PMID 23225293](#).
141. [^](#) [Wahl DA, Cooper C, Ebeling PR, Eggersdorfer M, Hilger J, Hoffmann K, et al.](#) (February 1, 2013). "A global representation of vitamin D status in healthy populations: reply to comment by Saadi". *Archives of Osteoporosis*. **8** (1–2): 122. [doi:10.1007/s11657-013-0122-7](#). [PMID 23371520](#).
142. [^](#) [Bischoff-Ferrari HA](#) (2014). Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. *Advances in Experimental Medicine and Biology* (Review). **810**. pp. 500–25. [doi:10.1007/978-0-387-77574-6\\_5](#). [ISBN 978-0-387-77573-9](#). [PMID 25207384](#).
143. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup>](#) [Dahlquist DT, Dieter BP, Koehle MS](#) (2015). "[Plausible ergogenic effects of vitamin D on athletic performance and recovery](#)". *Journal of the International Society of Sports Nutrition* (Review). **12**: 33. [doi:10.1186/s12970-015-0093-8](#). [PMC 4539891](#). [PMID 26288575](#).
144. [^](#) [Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, et al.](#) (September 2008). "[Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans](#)". *The Journal of Clinical Endocrinology and Metabolism*. **93** (9): 3381–8. [doi:10.1210/jc.2007-2702](#). [PMC 2567851](#). [PMID 18593774](#).
145. [^](#) [Wang L, Song Y, Manson JE, Piltz S, März W, Michaëlsson K, et al.](#) (2012). "[Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies](#)". *Circulation: Cardiovascular Quality and Outcomes*. **5** (6): 819–29. [doi:10.1161/CIRCOUTCOMES.112.967604](#). [PMC 3510675](#). [PMID 23149428](#).
146. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup>](#) [Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al.](#) (January 2011). "[The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know](#)". *The Journal of Clinical Endocrinology and Metabolism*. **96** (1): 53–8. [doi:10.1210/jc.2010-2704](#). [PMC 3046611](#). [PMID 21118827](#).
147. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup>](#) [Vitamin D at Merck Manual of Diagnosis and Therapy Professional Edition](#)
148. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup>](#) [Vieth R](#) (May 1999). "[Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety](#)" (PDF). *The American Journal of Clinical Nutrition*. **69** (5): 842–56. [doi:10.1093/ajcn/69.5.842](#). [PMID 10232622](#).
149. [^](#) [Tolerable Upper Intake Limits for Vitamins And Minerals](#) (PDF). [European Food Safety Authority](#). December 2006. [ISBN 978-92-9199-014-6](#).
150. [^](#) "[FDA Cautions on Accurate Vitamin D Supplementation for Infants](#)" (Press release). [Food and Drug Administration \(FDA\)](#). June 15, 2010. Archived from [the original](#) on January 12, 2017.  This article incorporates text from this source, which is in the [public domain](#).
151. [^](#) [Olmos-Ortiz A, Avila E, Durand-Carbajal M, Díaz L](#) (January 2015). "[Regulation of calcitriol biosynthesis and activity: focus on gestational vitamin D deficiency and adverse pregnancy outcomes](#)". *Nutrients*. **7** (1): 443–80. [doi:10.3390/nu7010443](#). [PMC 4303849](#). [PMID 25584965](#).
152. [^](#) [Holick MF](#) (April 1987). "Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables". *Federation Proceedings*. **46** (5): 1876–82. [PMID 3030826](#).
153. [^](#) [Deluca HF](#) (January 2014). "[History of the discovery of vitamin D and its active metabolites](#)". *BoneKEy Reports*. **3**: 479. [doi:10.1038/bonekey.2013.213](#). [PMC 3899558](#). [PMID 24466410](#).



154. ^ Jump up to:<sup>a</sup> <sup>b</sup> Holick MF (March 2004). "Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis". *The American Journal of Clinical Nutrition*. **79**(3): 362–71. doi:10.1093/ajcn/79.3.362. PMID 14985208.
155. ^ Eyley SC, Williams DH (1975). "Photolytic production of vitamin D. The preparative value of a photo-sensitiser". *Journal of the Chemical Society, Chemical Communications* (20): 858a. doi:10.1039/C3975000858A.
156. ^ Crissey SD, Ange KD, Jacobsen KL, Slifka KA, Bowen PE, Stacewicz-Sapuntzakis M, et al. (January 2003). "Serum concentrations of lipids, vitamin d metabolites, retinol, retinyl esters, tocopherols and selected carotenoids in twelve captive wild felid species at four zoos". *The Journal of Nutrition*. **133** (1): 160–6. doi:10.1093/jn/133.1.160. PMID 12514284.
157. ^ Holick MF (2018). "Chapter 4: Photobiology of Vitamin D". In Feldman D, Wesley Pike J, Bouillon R, Giovannucci E, Goltzman D, Hewison M (eds.). *Vitamin D: Volume 1: Biochemistry, Physiology and Diagnostics* (4th ed.). London, UK: Academic Press. ISBN 978-0-12-809965-0.
158. ^ Ray CC (May 17, 2005). "Q&A Sunshine Vitamin D". *The New York Times*. Archived from the original on February 21, 2013. Retrieved March 8, 2013.
159. ^ Bolton J. "UV FAQs". International Ultraviolet Association. Archived from the original on May 30, 2013.
160. ^ Holick MF (February 2002). "Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health". *Current Opinion in Endocrinology, Diabetes and Obesity*. **9** (1): 87–98. doi:10.1097/00060793-200202000-00011.
161. ^ Holick MF (September 2002). "Sunlight and vitamin D: both good for cardiovascular health". *Journal of General Internal Medicine*. **17** (9): 733–5. doi:10.1046/j.1525-1497.2002.20731.x. PMC 1495109. PMID 12220371.
162. ^ Jump up to:<sup>a</sup> <sup>b</sup> Holick MF, Smith E, Pincus S (December 1987). "Skin as the site of vitamin D synthesis and target tissue for 1,25-dihydroxyvitamin D3. Use of calcitriol (1,25-dihydroxyvitamin D3) for treatment of psoriasis". *Archives of Dermatology*. **123** (12): 1677–1683a. doi:10.1001/archderm.1987.01660360108022. PMID 2825606.
163. ^ "Anatomy of the skin". National Cancer Institute, US National Institutes of Health, Bethesda. 2016. Retrieved December 19, 2016.
164. ^ "Vitamin D and Skin Health". LINUS PAULING INSTITUTE Micronutrient Information Center. Oregon State University. November 7, 2016. Retrieved March 30, 2017.
165. ^ Holick MF (April 1, 2010). *The Vitamin D Solution: A 3-Step Strategy to Cure Our Most Common Health Problems*. Penguin Publishing Group. ISBN 978-1-101-22293-5.
166. ^ Agarwal SC, Stout SD (June 28, 2011). *Bone Loss and Osteoporosis: An Anthropological Perspective*. Springer Science & Business Media. ISBN 978-1-4419-8891-1. Archived(PDF) from the original on January 29, 2006. The high 25(OH)D concentrations, and relatively high vitamin D requirements of apes and monkeys are understandable in light of their biology—their body surface area relative to mass is generally greater than for humans, and they are inveterate groomers, consuming by mouth the vitamin D generated from the oils secreted by skin into fur. Although much of the vitamin D produced within human skin is absorbed directly, birds and furbearing animals acquire most of their vitamin D orally, as they groom themselves (Bicknell and Prescott, 1946; Carpenter and Zhao, 1999). Vitamin D is generated from the oily secretions of skin into fur. The oral consumption of UV-exposed dermal excretion is the way many animals acquire the "nutrient," vitamin D. Although Fraser (1983) has argued that dermal absorption of vitamin D may be more natural, what we know from animals indicates that oral consumption is equally physiological. Since vitamin D can be extracted from UV-exposed human sweat and skin secretions (Bicknell and Prescott, 1946), it is also reasonable to think that early humans obtained some of their vitamin D by mouth as well, by licking the skin.
167. ^ Yahav S, Buffenstein R (January 1993). "Cholecalciferol supplementation alters gut function and improves digestibility in an underground inhabitant, the naked mole rat (*Heterocephalus glaber*), when fed on a carrot diet". *The British Journal of Nutrition*. **69** (1): 233–41. doi:10.1079/BJN19930025. PMID 8384476.
168. ^ Jump up to:<sup>a</sup> <sup>b</sup> Holick MF (November 2005). "The vitamin D epidemic and its health consequences" (PDF). *The Journal of Nutrition*. **135** (11): 2739S–48S. doi:10.1093/jn/135.11.2739S. PMID 16251641. [Vitamin D3] is produced commercially by extracting 7-dehydrocholesterol from wool fat, followed by UVB irradiation and purification [...] [Vitamin D2] is commercially made by irradiating and then purifying the ergosterol extracted from yeast

169. <sup>^</sup> Takeuchi A, Okano T, Sayamoto M, Sawamura S, Kobayashi T, Motosugi M, et al. (February 1986). "Tissue distribution of 7-dehydrocholesterol, vitamin D3 and 25-hydroxyvitamin D3 in several species of fishes". *Journal of Nutritional Science and Vitaminology*. **32** (1): 13–22. doi:10.3177/jnsv.32.13. PMID 3012050.
170. <sup>^</sup> Jump up to:<sup>a b c d</sup> Adams JS, Hewison M (February 2010). "Update in vitamin D". *The Journal of Clinical Endocrinology and Metabolism*. **95** (2): 471–8. doi:10.1210/jc.2009-1773. PMC 2840860. PMID 20133466.
171. <sup>^</sup> Jump up to:<sup>a b c</sup> Bikle DD (March 20, 2014). "Vitamin D metabolism, mechanism of action, and clinical applications". *Chemistry & Biology*. **21** (3): 319–29. doi:10.1016/j.chembiol.2013.12.016. PMC 3968073. PMID 24529992.
172. <sup>^</sup> Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (May 2004). "Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase". *Proceedings of the National Academy of Sciences of the United States of America*. **101**(20): 7711–5. Bibcode:2004PNAS..101.7711C. doi:10.1073/pnas.0402490101. PMC 419671. PMID 15128933.
173. <sup>^</sup> Laing CJ, Cooke NE (2004). "Section I: Ch. 8: Vitamin D Binding Protein". In Feldman D, Glorieux FH, Pike JW (eds.). *Vitamin D*. 1 (2 ed.). Academic Press. pp. 117–134. ISBN 978-0122526879.
174. <sup>^</sup> "IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN): Nomenclature of vitamin D. Recommendations 1981". *European Journal of Biochemistry*. **124** (2): 223–7. May 17, 1982. doi:10.1111/j.1432-1033.1982.tb06581.x. PMID 7094913.
175. <sup>^</sup> Holick MF, Kleiner-Bossaller A, Schnoes HK, Kasten PM, Boyle IT, DeLuca HF (October 1973). "1,24,25-Trihydroxyvitamin D3. A metabolite of vitamin D3 effective on intestine". *The Journal of Biological Chemistry*. **248** (19): 6691–6. PMID 4355503.
176. <sup>^</sup> Horst RL, Reinhardt TA, Ramberg CF, Koszewski NJ, Napoli JL (July 1986). "24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process". *The Journal of Biological Chemistry*. **261** (20): 9250–6. PMID 3013880.
177. <sup>^</sup> Carere S (July 25, 2007). "Age-old children's disease back in force". *Toronto Star*. Archived from the original on May 17, 2008. Retrieved August 24, 2010.
178. <sup>^</sup> Conis E (July 24, 2006). "Fortified foods took out rickets". *Los Angeles Times*. Retrieved August 24, 2010.
179. <sup>^</sup> McClean FC, Budy AM (January 28, 1964). "Vitamin A, Vitamin D, Cartilage, Bones, and Teeth". *Vitamins and Hormones*. **21**. Academic Press. pp. 51–52. ISBN 978-0-12-709821-0.
180. <sup>^</sup> "History of Vitamin D". University of California at Riverside. 2011. Retrieved May 9, 2014.
181. <sup>^</sup> "Adolf Windaus – Biography". Nobelprize.org. March 25, 2010. Retrieved March 25, 2010.
182. <sup>^</sup> Rosenheim O, King H (1932). "The Ring-system of sterols and bile acids. Part II". *J. Chem. Technol. Biotechnol*. **51** (47): 954–7. doi:10.1002/jctb.5000514702.
183. <sup>^</sup> Askew FA, Bourdillon RB, Bruce HM, Callow RK, St. L. Philpot J, Webster TA (1932). "Crystalline Vitamin D". *Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character*. **109** (764): 488–506. doi:10.1098/rspb.1932.0008. JSTOR 81571.
184. <sup>^</sup> Hirsch AL (2011). "Industrial aspects of vitamin D". In Feldman DJ, Pike JW, Adams JS (eds.). *Vitamin D*. London; Waltham, MA: Academic Press. p. 73. ISBN 978-0-12-387035-3.
185. <sup>^</sup> Ziedonis AA, Mowery DC, Nelson RR, Bhaven NS (2004). "Ivory tower and industrial innovation: university-industry technology transfer before and after the Bayh-Dole Act in the United States". Stanford, Calif: Stanford Business Books. pp. 39–40. ISBN 978-0-8047-4920-6.
186. <sup>^</sup> Marshall J (September 2010). Elbridge a Stuart: Founder of Carnation Company. Kessinger Publishing. ISBN 978-1-164-49678-6.
187. <sup>^</sup> Haussler MR, Norman AW (January 1969). "Chromosomal receptor for a vitamin D metabolite". *Proceedings of the National Academy of Sciences of the United States of America*. **62** (1): 155–62. Bibcode:1969PNAS...62..155H. doi:10.1073/pnas.62.1.155. PMC 285968. PMID 5253652.
188. <sup>^</sup> Holick MF, Schnoes HK, DeLuca HF (April 1971). "Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine". *Proceedings of the National Academy of Sciences of the United States of America*. **68** (4): 803–4. Bibcode:1971PNAS...68..803H. doi:10.1073/pnas.68.4.803. PMC 389047. PMID 4323790.
189. <sup>^</sup> Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V, Popják G (July 1971). "1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the

- intestine". *Science*. **173** (3991): 51–  
4. [Bibcode:1971Sci...173...51N](#). [doi:10.1126/science.173.3991.51](#). [PMID 4325863](#).
190. [^](#) Holick MF, DeLuca HF, Avioli LV (January 1972). "Isolation and identification of 25-hydroxycholecalciferol from human plasma". *Archives of Internal Medicine*. **129** (1): 56–61. [doi:10.1001/archinte.1972.00320010060005](#). [PMID 4332591](#).
191. [^](#) Dankers W, Colin EM, van Hamburg JP, Lubberts E (2016). "[Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential](#)". *Front Immunol*. **7**: 697. [doi:10.3389/fimmu.2016.00697](#). [PMC 5247472](#). [PMID 28163705](#).
192. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup>](#) Heaney RP, Holick MF (March 2011). "Why the IOM recommendations for vitamin D are deficient". *Journal of Bone and Mineral Research*. **26** (3): 455–7. [doi:10.1002/jbmr.328](#). [PMID 21337617](#).
193. [^](#) Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. (July 2011). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline". *The Journal of Clinical Endocrinology and Metabolism*. **96** (7): 1911–30. [doi:10.1210/jc.2011-0385](#). [PMID 21646368](#).
194. [^](#) "[ODS Vitamin D Initiative](#)". Bethesda, MD: Office of Dietary Supplements, US National Institutes of Health. 2014.
195. [^](#) Pyrzak B, Witkowska-Sędek E, Krajewska M, Demkow U, Kucharska AM (2015). "Metabolic and immunological consequences of vitamin D deficiency in obese children". *Body Metabolism and Exercise. Advances in Experimental Medicine and Biology*. **840**. pp. 13–9. [doi:10.1007/5584\\_2014\\_81](#). [ISBN 978-3-319-10249-8](#). [PMID 25315624](#).
196. [^](#) "[How is vitamin D being studied now in clinical cancer research?](#)". Bethesda, MD: National Cancer Institute, US National Institutes of Health. October 21, 2013.
197. [^](#) Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, et al. (July 9, 2019). "Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes". *Annals of Internal Medicine*. [doi:10.7326/m19-0341](#). [ISSN 0003-4819](#). [PMID 31284304](#).
198. [^](#) Cashman KD, Dowling KG, Škrabáková Z, Gonzalez-Gross M, Valtueña J, De Henauw S, et al. (April 2016). "[Vitamin D deficiency in Europe: pandemic?](#)". *The American Journal of Clinical Nutrition*. **103** (4): 1033–44. [doi:10.3945/ajcn.115.120873](#). [PMC 5527850](#). [PMID 26864360](#).
199. [^](#) Sarkar FH, Li Y, Wang Z, Kong D (September 2010). "[The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer](#)". *Cancer Metastasis Reviews*. **29**(3): 383–94. [doi:10.1007/s10555-010-9233-4](#). [PMC 2974632](#). [PMID 20711635](#).

# Pyridoxine

From Wikipedia, the free encyclopedia  
[Jump to navigation](#)[Jump to search](#)

<p style="text-align: center;"><b>Pyridoxine</b></p> <div style="text-align: center;"> </div> <p style="text-align: center;">Pyridoxine</p>	
<b>Clinical data</b>	
<b>Synonyms</b>	vitamin B <sub>6</sub> , <sup>[1]</sup> pyridoxol <sup>[2]</sup> pyridoxine hydrochloride
<b><a href="#">AHFS/Drugs.com</a></b>	<a href="#">Monograph</a>
<b><a href="#">Pregnancy category</a></b>	US: <a href="#">A</a> (No risk in human studies) and C
<b><a href="#">Routes of administration</a></b>	by mouth, IV, IM, subQ
<b><a href="#">ATC code</a></b>	<a href="#">A11HA02</a> (WHO)
<b>Legal status</b>	
<b><a href="#">Legal status</a></b>	US: <a href="#">OTC</a>



Identifiers	
<a href="#">IUPAC name</a> <sup>[show]</sup>	
<a href="#">CAS Number</a>	<a href="#">65-23-6</a>
<a href="#">DrugBank</a>	<a href="#">DB00165</a>
<a href="#">ChemSpider</a>	<a href="#">1025</a>
<a href="#">UNII</a>	<a href="#">KV2JZ1BI6Z</a>
<a href="#">KEGG</a>	<a href="#">D08454</a>
<a href="#">ChEBI</a>	<a href="#">CHEBI:16709</a>
<a href="#">ChEMBL</a>	<a href="#">ChEMBL1364</a>
<a href="#">CompTox Dashboard</a> (EPA)	<a href="#">DTXSID4023541</a>
<a href="#">ECHA InfoCard</a>	<a href="#">100.000.548</a>
Chemical and physical data	
<a href="#">Formula</a>	C <sub>8</sub> H <sub>11</sub> NO <sub>3</sub>
<a href="#">Molar mass</a>	169.180 g·mol <sup>-1</sup>
<a href="#">3D model (JSmol)</a>	<a href="#">Interactive image</a>
<a href="#">Melting point</a>	159 to 162 °C (318 to 324 °F)
<a href="#">SMILES</a> <sup>[show]</sup>	
<a href="#">InChI</a> <sup>[show]</sup>	

**Pyridoxine**, also known as **vitamin B<sub>6</sub>**, is a form of [vitamin B<sub>6</sub>](#) found commonly in food and used as [dietary supplement](#).<sup>[1]</sup> As a supplement it is used to treat and prevent [pyridoxine deficiency](#), [sideroblastic anaemia](#), [pyridoxine-dependent epilepsy](#), certain [metabolic disorders](#), problems from [isoniazid](#), and certain types of [mushroom poisoning](#).<sup>[3][1]</sup> It is used by mouth or by injection.<sup>[3]</sup>

It is usually well tolerated.<sup>[3]</sup> Occasionally side effects include headache, numbness, and sleepiness.<sup>[3]</sup> Normal doses are safe during [pregnancy](#) and [breastfeeding](#).<sup>[3]</sup> Pyridoxine is in the [vitamin B](#) family of vitamins.<sup>[3]</sup> It is required by the body to make [amino acids](#), [carbohydrates](#), and [lipids](#).<sup>[3]</sup> Sources in the diet include [fruit](#), [vegetables](#), and [grain](#).<sup>[4]</sup>

Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939.<sup>[5][6]</sup> It is on the [World Health Organization's List of Essential Medicines](#), the most effective and safe medicines needed in a [health system](#).<sup>[7]</sup> Pyridoxine is available as a [generic medication](#) and [over the counter](#).<sup>[3]</sup> The wholesale cost in the [developing world](#) is about US\$0.59–3.54 per month.<sup>[8]</sup> Foods, such as [breakfast cereal](#) have pyridoxine added in some countries.<sup>[4]</sup>



## Contents

- 1Medical uses
- 2Side effects
- 3Mechanism
- 4History and culture
- 5References
- 6External links

### Medical uses[[edit](#)]

---

As a supplement it is used to treat and prevent [pyridoxine deficiency](#), [sideroblastic anaemia](#), [pyridoxine-dependent epilepsy](#), certain [metabolic disorders](#), problems from [isoniazid](#), and certain types of [mushroom poisoning](#).<sup>[3][1]</sup> Pyridoxine-dependent epilepsy is a type of rare epilepsy that does not improve with typical antiseizure medications.<sup>[2]</sup> Pyridoxine is used by mouth or by injection.<sup>[3]</sup>

Pyridoxine in combination with [doxylamine](#) is used as a treatment for [morning sickness](#) in pregnant women. It has been used in [hydrazine](#) exposure with unclear effect.<sup>[10]</sup>

### Side effects[[edit](#)]

---

It is usually well tolerated.<sup>[3]</sup> Occasionally side effects include headache, numbness, and sleepiness.<sup>[3]</sup> Normal doses are safe during [pregnancy](#) and [breastfeeding](#).<sup>[3]</sup>

### Mechanism[[edit](#)]

---

Pyridoxine is in the [vitamin B](#) family of vitamins.<sup>[3]</sup> It is required by the body to make [amino acids](#), [carbohydrates](#), and [lipids](#).<sup>[3]</sup> Sources in the diet include [fruit](#), [vegetables](#), and [grain](#).<sup>[4]</sup> It is also required for muscle phosphorylase activity associated with glycogen metabolism.

### History and culture[[edit](#)]

---

Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939.<sup>[5][6]</sup> It is on the [World Health Organization's List of Essential Medicines](#), the most effective and safe medicines needed in a [health system](#).<sup>[7]</sup> Pyridoxine is available as a [generic medication](#) and [over the counter](#).<sup>[3]</sup> The wholesale cost in the [developing world](#) is about US\$0.59–3.54 per month.<sup>[8]</sup> Foods, such as [breakfast cereal](#) have pyridoxine added in some countries.<sup>[4]</sup>

### References[[edit](#)]


---

- <sup>1</sup>  ^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> *WHO Model Formulary 2008 (PDF)*. World Health Organization. 2009. p. 496. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- <sup>2</sup>   Dryhurst, Glenn (2012). *Electrochemistry of Biological Molecules*. Elsevier. p. 562. ISBN 9780323144520. Archived from the original on 2016-12-30.
- <sup>3</sup>  ^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> <sup>g</sup> <sup>h</sup> <sup>i</sup> <sup>j</sup> <sup>k</sup> <sup>l</sup> <sup>m</sup> <sup>n</sup> <sup>o</sup> <sup>p</sup> *"Pyridoxine Hydrochloride"*. The American Society of Health-System Pharmacists. Archived from the original on 30 December 2016. Retrieved 8 December 2016.
- <sup>4</sup>  ^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> *"Office of Dietary Supplements - Dietary Supplement Fact Sheet: Vitamin B6"*. ods.od.nih.gov. 11 February 2016. Archived from the original on 12 December 2016. Retrieved 30 December 2016.
- <sup>5</sup>  ^ Jump up to:<sup>a</sup> <sup>b</sup> *Squires, Victor R. (2011). *The Role of Food, Agriculture, Forestry and Fisheries in Human Nutrition - Volume IV*. EOLSS Publications. p. 121. ISBN 9781848261952.*

6. ^ Jump up to:<sup>a</sup> <sup>b</sup> Harris, Harry (2012). *Advances in Human Genetics 6*. Springer Science & Business Media. p. 39. ISBN 9781461582649.
7. ^ Jump up to:<sup>a</sup> <sup>b</sup> "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
8. ^ Jump up to:<sup>a</sup> <sup>b</sup> "Vitamin B6". International Drug Price Indicator Guide. Retrieved 8 December 2016.
9. <sup>a</sup> Abend, NS; Loddenkemper, T (July 2014). "Management of pediatric status epilepticus". *Current Treatment Options in Neurology*. **16** (7): 301. doi:10.1007/s11940-014-0301-x. PMC 4110742. PMID 24909106.
10. <sup>a</sup> "Hydrazine (EHC 68, 1987)". www.inchem.org. Retrieved 2018-11-20.

## External links[edit]

---

-  Media related to [Pyridoxine](#) at Wikimedia Commons
- [Pyridoxine mass spectrum](#)

**Formylin<sup>TM</sup> Plus**



Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
Folic Acid 1.5 mg Tablets

# Folate

From Wikipedia, the free encyclopedia

(Redirected from [Folic acid](#))

[Jump to navigation](#)[Jump to search](#)

<b>Folic acid</b>	
 	
<b>Clinical data</b>	
<b>Pronunciation</b>	<span><span>/<span><span>ˈ</span><span>f</span><span>oʊ</span><span>l</span><span>ɪ</span><span>k</span></span>,<span> </span><span><span>ˈ</span><span>f</span><span>ɒ</span><span>l</span><span>ɪ</span><span>k</span></span>/</span></span>
<b>Synonyms</b>	FA, N-(4-{{(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl}amino}benzoyl)-L-glutamic acid, pteroyl-L-glutamic acid, vitamin B <sub>9</sub> , <sup>[1]</sup> vitamin B <sub>11</sub> , <sup>[2]</sup> vitamin M, <sup>[3]</sup> folacin, pteroyl-L-glutamate
<b><a href="#">AHFS/Drugs.com</a></b>	<a href="#">Monograph</a>
<b><a href="#">MedlinePlus</a></b>	<a href="#">a682591</a>
<b><a href="#">Pregnancy category</a></b>	US: <span><span><span></span></span></span> <b>A</b> (No risk in human studies)
<b><a href="#">Routes of</a></b>	By mouth, IM, IV, sub-Q

<b><u>administration</u></b>	
<b><u>ATC code</u></b>	<a href="#">B03BB01</a> (WHO)
<b>Legal status</b>	
<b><u>Legal status</u></b>	US: <a href="#">OTC</a>
<b><u>Pharmacokinetic data</u></b>	
<b><u>Bioavailability</u></b>	50–100% <sup>[4]</sup>
<b><u>Metabolism</u></b>	Liver <sup>[4]</sup>
<b><u>Excretion</u></b>	Urine <sup>[4]</sup>
<b>Identifiers</b>	
<b><u>IUPAC name</u></b> <sup>[show]</sup>	<i>Formylin<sup>TM</sup> Plus</i>
<b><u>CAS Number</u></b>	<a href="#">59-30-3</a>
<b><u>PubChem CID</u></b>	<a href="#">6037</a>
<b><u>IUPHAR/BPS</u></b>	<a href="#">4563</a>
<b><u>DrugBank</u></b>	<a href="#">DB00158</a> ✓
<b><u>ChemSpider</u></b>	<a href="#">5815</a>
<b><u>UNII</u></b>	<a href="#">935E97BOY8</a>
<b><u>KEGG</u></b>	<a href="#">C00504</a>
<b><u>ChEBI</u></b>	<a href="#">CHEBI:27470</a>
<b><u>ChEMBL</u></b>	<a href="#">ChEMBL1622</a>
<b><u>CompTox</u></b>	<a href="#">DTXSID0022519</a> ✎
<b><u>Dashboard</u></b> (EPA)	
<b><u>ECHA InfoCard</u></b>	<a href="#">100.000.381</a> ✎
<b>Chemical and physical data</b>	
<b><u>Formula</u></b>	C <sub>19</sub> H <sub>19</sub> N <sub>7</sub> O <sub>6</sub>
<b><u>Molar mass</u></b>	441.404 g·mol <sup>-1</sup>
<b><u>3D model (JSmol)</u></b>	<a href="#">Interactive image</a>
<b><u>Density</u></b>	1.6±0.1 <sup>[6]</sup> g/cm <sup>3</sup>
<b><u>Melting point</u></b>	250 °C (482 °F) (decomposition)

**Solubility in water** 1.6 mg/L (25 °C) mg/mL (20 °C)

**SMILES**[\[show\]](#)

**InChI**[\[show\]](#)

**Folate**, distinct forms of which are known as **folic acid**, **folacin**, and **vitamin B<sub>9</sub>**,<sup>[7]</sup> is one of the **B vitamins**.<sup>[4]</sup> It may be taken by mouth or by injection.<sup>[4]</sup> The recommended adult daily intake of folate in the U.S. is 400 **micrograms** from foods or **dietary supplements**.<sup>[8]</sup> Folate in the form of folic acid is used to treat **anemia** caused by **folate deficiency**.<sup>[4]</sup> Folic acid is also used as a **supplement** by women during **pregnancy** to reduce the risk of **neural tube defects** (NTDs) in the baby.<sup>[4][9]</sup> Low levels in early **pregnancy** are believed to be the cause of more than half of babies born with NTDs.<sup>[8]</sup> More than 80 countries use **fortification of certain foods** with folic acid as a measure to decrease the rate of NTDs.<sup>[10]</sup> Long-term supplementation is also associated with small reductions in the risk of **stroke** and **cardiovascular disease**.<sup>[11]</sup>

No common side effects are known.<sup>[4]</sup> There are concerns that large amounts of folic acid might hide **vitamin B<sub>12</sub> deficiency**.<sup>[8]</sup> Folate is **essential** for the body to make **DNA**, **RNA**, and metabolise **amino acids**, which are required for **cell division**.<sup>[8]</sup> As humans cannot make folate, it is required from the diet, making it an **essential vitamin**.<sup>[12]</sup>

Not consuming enough folate can lead to **folate deficiency**.<sup>[8]</sup> This may result in a type of anemia in which **low numbers of large red blood cells** occur.<sup>[8]</sup> Symptoms may include **feeling tired**, **heart palpitations**, **shortness of breath**, open sores on the tongue, and changes in the color of the skin or hair.<sup>[8]</sup> Folate deficiency in children may develop within a month of poor dietary intake.<sup>[13]</sup> In adults, normal total body folate is between 10 and 30 mg with blood levels of greater than 7 nmol/L (3 ng/mL).<sup>[8]</sup>

Folic acid was discovered between 1931 and 1943.<sup>[14]</sup> It is on the **World Health Organization's List of Essential Medicines**, the most effective and safe medicines needed in a health system.<sup>[15]</sup> The wholesale cost of supplements in the **developing world** is between US\$0.001 and 0.005 per dose as of 2014.<sup>[16]</sup> The term "folic" is from the Latin word *folium* (which means leaf) because it was found in dark-green leafy vegetables.<sup>[17]</sup> Folates occur naturally in many foods.<sup>[7][8]</sup> In 2016, it was the 96th most prescribed medication in the United States, with more than 8 million prescriptions.<sup>[18]</sup>



## Contents

- 1 Definition
- 2 Health effects
  - 2.1 Pregnancy
  - 2.2 Fertility
  - 2.3 Heart disease
  - 2.4 Stroke
  - 2.5 Cancer
  - 2.6 Neurological
  - 2.7 Age-related macular degeneration
  - 2.8 Folic acid, B<sub>12</sub> and iron
  - 2.9 Folate deficiency
  - 2.10 Malaria
- 3 Dietary recommendations
  - 3.1 Safety

- 3.2 Food labeling
- 3.3 Sources
- 4 Biological roles
  - 4.1 C1-derivatives of folate
  - 4.2 DNA production
  - 4.3 Amino acid processing
  - 4.4 Conversion to biologically active derivatives
- 5 Drugs that interfere with folate reactions
- 6 Food fortification
  - 6.1 Australia and New Zealand
  - 6.2 Canada
  - 6.3 United Kingdom
  - 6.4 United States
- 7 History
- 8 See also
- 9 References



## Definition [\[edit\]](#)

"Folate" is the term used to name the many forms of the vitamin—namely folic acid and its [congeners](#), including tetrahydrofolic acid (the activated form of the vitamin), [methyltetrahydrofolate](#) (the primary form found in the serum), methenyltetrahydrofolate, folinic acid, and folacin.<sup>[7][19][20][21]</sup> Other names include vitamin B<sub>9</sub>,<sup>[1]</sup> vitamin B<sub>c</sub>,<sup>[2]</sup> vitamin M,<sup>[3]</sup> and pteroyl-L-glutamate.

## Health effects [\[edit\]](#)

Folate is necessary for the production and maintenance of new [cells](#), for [DNA synthesis](#) and [RNA synthesis](#) through [methylation](#), and for preventing changes to DNA.<sup>[22]</sup> It is especially important during periods of frequent cell division and growth, such as infancy and pregnancy. Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of their greater frequency of cell division. RNA transcription and subsequent protein synthesis are less affected by folate deficiency, as the mRNA can be recycled and used again (as opposed to DNA synthesis, where a new genomic copy must be created). Since folate deficiency limits cell division, [erythropoiesis](#) (production of red blood cells) is hindered. This leads to [megaloblastic anemia](#), which is characterized by large, immature red blood cells. This pathology results from persistently thwarted attempts at normal DNA replication, DNA repair, and cell division, and produces abnormally large red cells called megaloblasts (and hypersegmented neutrophils) with abundant cytoplasm capable of RNA and protein synthesis, but with clumping and fragmentation of nuclear chromatin. Some of these large cells, although immature (reticulocytes), are released early from the marrow in an attempt to compensate for the anemia.<sup>[23]</sup> Both adults and children need folate to make normal red and white blood cells and prevent anemia.<sup>[24]</sup> Deficiency of folate in pregnant women has been implicated in NTDs; therefore, many developed countries have implemented mandatory folic acid fortification in cereals, etc. NTDs occur early in pregnancy (first month), therefore women must have abundant folate upon conception. Folate is required to make red blood cells and white blood cells and folate deficiency may lead to anemia, which causes fatigue, weakness, and inability to concentrate.<sup>[25]</sup>

## Pregnancy [\[edit\]](#)

Folate intake during pregnancy has been linked to a lessened risk of neural tube defects (NTDs), and for this reason there is a recommendation that any woman planning to become pregnant consume a folate-containing dietary supplement before and during pregnancy.<sup>[26]</sup> Compliance with

this recommendation is not complete, and many women become pregnant without this being a planned pregnancy, or may not realize that they are pregnant until well into the first trimester, which is the critical period for reducing risk of NTDs. Countries have implemented either mandatory or voluntary food fortification of wheat flour and other grains, or else have no such program and depend on public health and healthcare practitioner advice to women of childbearing age. A meta-analysis of global birth prevalence of spina bifida showed that when mandatory fortification was compared to countries with voluntary fortification or no fortification program, there was a 30% reduction in live births with spina bifida.<sup>[27]</sup> The [United States Preventive Services Task Force](#) recommends folic acid as the supplement or fortification ingredient, as forms of folate other than folic acid have not been studied.<sup>[20]</sup>

A meta-analysis of folate supplementation during pregnancy reported a 28% lower risk of newborn [congenital heart defects](#).<sup>[28]</sup> Prenatal supplementation with folic acid did not appear to reduce the risk of preterm births.<sup>[29][30]</sup> One [systematic review](#) indicated no effect of folic acid on mortality, growth, body composition, respiratory, or cognitive outcomes of children from birth to 9 years old.<sup>[31]</sup> There was no correlation between maternal folic acid supplementation and an increased risk for childhood asthma.<sup>[32]</sup>

### **Fertility**[\[edit\]](#)

Folate is necessary for fertility in both men and women. It contributes to [spermatogenesis](#). Therefore, receiving sufficient amounts through the diet is necessary to avoid low fertility.<sup>[33]</sup> Also, polymorphisms in genes of enzymes involved in folate metabolism could be one reason for fertility complications in some women with [unexplained infertility](#).<sup>[34]</sup>

### **Heart disease**[\[edit\]](#)

Taking folic acid over years reduced the risk of cardiovascular disease by 4%,<sup>[11]</sup> where another study found it did not affect cardiovascular disease, even while reducing [homocysteine](#) levels.<sup>[35]</sup> Several studies provided preliminary evidence that folate-rich diets were associated with reduced risk of cardiovascular diseases by lowering blood levels of homocysteine.<sup>[7]</sup>

### **Stroke**[\[edit\]](#)

Long-term supplementation with folic acid reduced the risk of stroke by 10%, which may be due to the role folate plays in regulating homocysteine concentration.<sup>[11]</sup> A meta-analysis indicated the risk of stroke appeared to be reduced only in some individuals, so a definite recommendation regarding supplementation beyond the current RDA has not been established.<sup>[36]</sup> Asian populations had greater protection against stroke with folate supplementation than did European or North American subjects.<sup>[11]</sup> Observed stroke reduction is consistent with the reduction in [pulse pressure](#) produced by folate supplementation of 5 mg per day, since hypertension is a key risk factor for stroke. Folic supplements are inexpensive and relatively safe to use, which is why people who have had strokes or who have [hyperhomocysteinemia](#) are encouraged to consume daily B vitamins including folic acid.<sup>[37]</sup>

### **Cancer**[\[edit\]](#)

Studies on folic acid intake from food and folate supplementation with regards to cancer risk are based on the adequacy of chronic intake. Chronically insufficient intake of folate may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, cervical, and prostate cancers.<sup>[7][38][39]</sup> Other studies showed that excessive dietary supplementation with folic acid may modestly increase the risk of certain cancers, but only [prostate cancer](#) was significant.<sup>[40][41]</sup> A subsequent meta-analysis found no relationship between taking folate supplements and cancer risk of any type.<sup>[42]</sup>

### **Antifolate chemotherapy**[\[edit\]](#)



Folate is important for cells and tissues that divide rapidly.<sup>[22]</sup> Cancer cells divide rapidly, and drugs that interfere with folate metabolism are used to treat cancer. The antifolate drug [methotrexate](#) is often used to treat cancer because it inhibits the production of the active form of THF from the inactive dihydrofolate (DHF). However, methotrexate can be toxic,<sup>[43][44][45]</sup> producing side effects, such as inflammation in the digestive tract that make eating normally more difficult. Also, bone marrow depression (inducing leukopenia and thrombocytopenia) and acute kidney and liver failure have been reported.

[Folinic acid](#), under the drug name [leucovorin](#), a form of folate (formyl-THF), can help "rescue" or reverse the toxic effects of methotrexate.<sup>[46]</sup> Folinic acid is *not* the same as folic acid. Folic acid supplements have little established role in cancer chemotherapy.<sup>[47][48]</sup> Cases of severe adverse effects of accidental substitution of folic acid for folinic acid have been reported in people receiving methotrexate cancer chemotherapy. Anyone receiving methotrexate should follow medical advice on the use of folic or folinic acid supplements. The supplement of folinic acid in people undergoing methotrexate treatment is to give cells dividing less rapidly enough folate to maintain normal cell functions. The amount of folate given is depleted by rapidly dividing cells (cancer) quickly, so does not negate the effects of methotrexate.

### Neurological<sup>[edit]</sup>

Some evidence links a shortage of folate with [clinical depression](#).<sup>[49]</sup> Limited evidence from [randomized controlled trials](#) showed using folic acid in addition to [selective serotonin reuptake inhibitors](#) (SSRIs) may have benefits.<sup>[50]</sup> Research found a link between depression and low levels of folate.<sup>[51][52]</sup> Folate may reduce homocysteine levels, which are associated with cognitive functions.<sup>[7]</sup>

The exact mechanisms involved in the development of schizophrenia and depression are not entirely clear, but the bioactive folate, [methyltetrahydrofolate](#) (5-MTHF), a direct target of methyl donors such as [S-adenosyl methionine](#) (SAME), recycles the inactive [dihydrobiopterin](#) (BH<sub>2</sub>) into [tetrahydrobiopterin](#) (BH<sub>4</sub>), the necessary [cofactor](#) in various steps of [monoamine synthesis](#), including that of [dopamine](#). BH<sub>4</sub> serves a regulatory role in monoamine neurotransmission and is required to mediate the actions of most antidepressants. 5-MTHF also plays both direct & indirect roles in [DNA methylation](#), NO<sub>2</sub> synthesis, and one-carbon metabolism.<sup>[53]</sup>

### Age-related macular degeneration<sup>[edit]</sup>

A sub-study of the *Women's Antioxidant and Folic Acid Cardiovascular Study* published in 2009 reported use of a nutritional supplement containing folic acid at 2,500 µg/day, [pyridoxine](#) at 50 mg/day, and vitamin B<sub>12</sub> at 1,000 µg/day decreased the risk of developing [age-related macular degeneration](#) by 34.7%. The amount of folic acid used in this clinical trial – 2,500 µg/day – was higher than the tolerable upper intake level of 1,000 µg.<sup>[54]</sup>

### Folic acid, B<sub>12</sub> and iron<sup>[edit]</sup>

A complex interaction occurs between folic acid, [vitamin B<sub>12</sub>](#), and iron. A deficiency of one may be "masked" by excess of another, so the three must always be in balance.<sup>[55][56][57]</sup>

### Folate deficiency<sup>[edit]</sup>

Main article: [Folate deficiency](#)

Folate deficiency can be caused by unhealthy diets that do not include enough vegetables and other folate-rich foods; diseases in which folates are not well absorbed in the digestive system (such as [Crohn's disease](#) or [celiac disease](#)); some genetic disorders that affect levels of folate; and certain medicines (such as phenytoin, sulfasalazine, or trimethoprim-sulfamethoxazole).<sup>[58]</sup> Folate deficiency is accelerated by alcohol consumption, possibly by interference with folate transport.<sup>[59]</sup>

Folate deficiency may lead to [glossitis](#), diarrhea, depression, confusion, anemia, and fetal neural tube and brain defects.<sup>[60]</sup> Other symptoms include fatigue, gray hair, mouth sores, poor growth, and swollen tongue.<sup>[58]</sup> Folate deficiency is diagnosed by analyzing a [Complete blood count](#) (CBC) and

plasma vitamin B<sub>12</sub> and folate levels. A serum folate of 3 µg/L or lower indicates deficiency.<sup>[60]</sup> Serum folate level reflects folate status, but erythrocyte folate level better reflects tissue stores after intake. An erythrocyte folate level of 140 µg/L or lower indicates inadequate folate status. Serum folate reacts more rapidly to folate intake than erythrocyte folate.<sup>[61]</sup>

Increased homocysteine levels suggest tissue folate deficiency, but homocysteine is also affected by vitamin B<sub>12</sub> and vitamin B<sub>6</sub>, renal function, and genetics. One way to differentiate between folate (vitamin B<sub>9</sub>) deficiency from vitamin B<sub>12</sub> deficiency is by testing for [methylmalonic acid](#) (MMA) levels. Normal MMA levels indicate folate deficiency and elevated MMA levels indicate vitamin B<sub>12</sub> deficiency.<sup>[60]</sup> Folate deficiency is treated with supplemental oral folic acid of 400 to 1000 µg per day. This treatment is very successful in replenishing tissues, even if deficiency was caused by malabsorption. People with megaloblastic anemia need to be tested for vitamin B<sub>12</sub> deficiency before treatment with folic acid, because if the person has vitamin B<sub>12</sub> deficiency, folic acid supplementation can remove the anemia, but can also worsen neurologic problems.<sup>[60]</sup> Cobalamin deficiency may lead to folate deficiency, which, in turn, increases homocysteine levels and may result in the development of cardiovascular disease or birth defects.<sup>[62]</sup>

## Malaria<sup>[edit]</sup>

Some studies show iron–folic acid supplementation in children under five may result in increased mortality due to [malaria](#); this has prompted the World Health Organization to alter their iron–folic acid supplementation policies for children in malaria-prone areas, such as India.<sup>[63]</sup>

## Dietary recommendations<sup>[edit]</sup>

Because of the difference in bioavailability between supplemented folic acid and the different forms of folate found in food, the dietary folate equivalent (DFE) system was established. One DFE is defined as 1 µg of dietary folate. One µg of folic acid supplement counts as 1.7 µg DFE. The reason for the difference is that at least 85% of folic acid is estimated to be bioavailable when taken with food, whereas only about 50% of folate naturally present in food is bioavailable.<sup>[8]</sup>

### National Institutes of Health (U.S.) nutritional recommendations<sup>[8]</sup> (µg DFE per day for RDA, µg folic acid for UL)

Age	Infants		Children and adults		Pregnant women		Lactating women	
	(AI)	(UL)	(RDA)	(UL)	(RDA)	(UL)	(RDA)	(UL)
0–6 months	65	None set	–	–	–	–	–	–
7–12 months	80	None set	–	–	–	–	–	–
1–3 years	–	–	150	300	–	–	–	–

4–8 years	–	–	200	400	–	–	–	–
9–13 years	–	–	300	600	–	–	–	–
14–18	–	–	400	800	600	800	500	800
19+	–	–	400	1000	600	1000	500	1000

The U.S. Institute of Medicine (IOM) updated [Recommended Dietary Allowances](#) (RDAs) and [Tolerable upper intake levels](#) (ULs) for folate in 2001. Collectively the EARs, RDAs, AIs, and ULs are referred to as [Dietary Reference Intakes](#) (DRIs).<sup>[61][60]</sup> The [European Food Safety Authority](#) (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. For women and men over age 18 the PRI is set at 330 µg/day. PRI for pregnancy is 600 µg/day, for lactation 500 µg/day. For children ages 1–17 years the PRIs increase with age from 120 to 270 µg/day. These values differ somewhat from the U.S. RDAs.<sup>[64]</sup> The United Kingdom's Dietary Reference Value for folate, set by the Committee on Medical Aspects of Food and Nutrition Policy (COMA) in 1991, is 200 µg/day for adults.<sup>[65]</sup>

### Safety[[edit](#)]

The risk of toxicity from folic acid is low, because folate is a water-soluble vitamin and is regularly removed from the body through urine. One potential issue associated with high doses of folic acid is that it has a masking effect on the diagnosis of [pernicious anaemia](#) due to vitamin B<sub>12</sub> deficiency.<sup>[60]</sup> An additional concern raised was that low vitamin B<sub>12</sub> status in combination with high folic acid intake appeared to increase the risk of cognitive impairment in the elderly.<sup>[66]</sup> The IOM sets ULs for vitamins and minerals when evidence is sufficient. The adult UL of 1000 µg for folate (and lower for children) refers to folic acid used as a supplement, as no health risks have been associated with high intake of folate from food sources. The EFSA reviewed the safety question and agreed with United States that the UL be set at 1000 µg.<sup>[67]</sup> The Japan National Institute of Health and Nutrition set the adult UL at 1,300 or 1,400 µg depending on age.<sup>[68]</sup>

### Food labeling[[edit](#)]

For U.S. food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For folate labeling purposes 100% of the Daily Value was 400 µg. As of the 27 May 2016 update, it was kept unchanged at 400 µg.<sup>[69]</sup> A table of the old and new adult Daily Values is provided at [Reference Daily Intake](#). The original deadline to be in compliance was 28 July 2018, but on 29 September 2017 the FDA released a proposed rule that extended the deadline to 1 January 2020 for large companies and 1 January 2021 for small companies.<sup>[70]</sup> European Union regulations require that labels declare energy, protein, fat, saturated fat, carbohydrates, sugars, and salt. Voluntary nutrients may be shown if present in significant amounts. Instead of Daily Values, amounts are shown as percent of Reference Intakes (RIs). For folate, 100% RI was set at 200 µg in 2011.<sup>[71]</sup>

### Sources[[edit](#)]

The [United States Department of Agriculture](#) (USDA), [Agricultural Research Service](#), maintains a food composition database from which folate content in hundreds of foods can be searched as

shown in the table.<sup>[72]</sup> The Food Fortification Initiative lists all countries in the world that conduct fortification programs,<sup>[73]</sup> and within each country, what nutrients are added to which foods, and whether those programs are voluntary or mandatory. In the US, mandatory fortification of enriched breads, cereals, flours, corn meal, pastas, rice, and other grain products began in January 1998. As of December 21, 2018, 81 countries required food fortification with one or more vitamins.<sup>[74]</sup> The most commonly fortified vitamin – as used in 62 countries – is folate; the most commonly fortified food is wheat flour, followed by maize flour and rice. From country to country, added folic acid amounts range from 0.4 to 5.1 µg/100 g, but the great majority are in a more narrow range of 1.5 to 2.5 µg/100 g.<sup>[74]</sup> Folate naturally found in food is susceptible to destruction from high heat cooking, especially in the presence of acidic foods and sauces. It is soluble in water, and so may be lost from foods boiled in water.<sup>[75]</sup> For foods that are normally consumed cooked, values in the table are for folate naturally occurring in cooked foods.

<b>Plant sources<sup>[72]</sup></b>	<b>Amount as Folate (µg / 100g)</b>
<a href="#"><u>Peanuts</u></a>	246
<a href="#"><u>Sunflower seed kernels</u></a>	238
<a href="#"><u>Lentils</u></a>	181
<a href="#"><u>Chickpeas</u></a>	172
<a href="#"><u>Asparagus</u></a>	149
<a href="#"><u>Spinach</u></a>	146
<a href="#"><u>Lettuce</u></a>	136
<a href="#"><u>Peanuts (oil-roasted)</u></a>	125
<a href="#"><u>Soybeans</u></a>	111
<a href="#"><u>Broccoli</u></a>	108

*Formylin<sup>TM</sup> Plus*  
 Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
 Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
 Folic Acid 1.5 mg Tablets

<a href="#">Walnuts</a>	98
<b>Plant sources<sup>[72]</sup></b>	<b>Amount as Folate (µg / 100g)</b>
<a href="#">Peanut butter</a>	92
<a href="#">Hazelnuts</a>	88
<a href="#">Avocados</a>	81
<a href="#">Beets</a>	80
<a href="#">Kale</a>	65
<a href="#">Bread (not fortified)</a>	65
<a href="#">Cabbage</a>	46
<a href="#">Red bell peppers</a>	46
<a href="#">Cauliflower</a>	44
<a href="#">Tofu</a>	29
<a href="#">Potatoes</a>	28
<b>Animal sources<sup>[72]</sup></b>	<b>Amount as Folate (µg / 100g)</b>

*Formylin<sup>TM</sup> Plus*

Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
 Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
 Folic Acid 1.5 mg Tablets

<a href="#">Chicken liver</a>	578
<a href="#">Calf liver</a>	331
<a href="#">Cheese</a>	20-60
<a href="#">Chicken eggs</a>	44
<a href="#">Salmon</a>	35
<a href="#">Chicken</a>	12
<a href="#">Beef</a>	12
<a href="#">Pork</a>	8
<a href="#">Yogurt</a>	8-11
<a href="#">Milk, whole</a>	5
<a href="#">Butter, salted</a>	3


**Formylin™ Plus**

Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
Folic Acid 1.5 mg Tablets


## Biological roles[[edit](#)]

The formation of [tetrahydrofolate](#) (FH<sub>4</sub>, also THF) begins when folic acid (F) is [reduced](#) to [dihydrofolate](#) (DHF) (FH<sub>2</sub>), which is then reduced to THF. [Dihydrofolate reductase](#) catalyses the last step.<sup>[76]</sup> Vitamin B<sub>3</sub> in the form of [NADPH](#) is a cofactor for both steps. Thus, hydride is transferred from NADPH to the C6 position of the pteridine ring.<sup>[77]</sup>

### C1-derivatives of folate[[edit](#)]



[10-Formyl-THF](#)




### 5,10-methylenetetrahydrofolic acid

Folate is a carrier of C1 groups (methyl, methylene, formyl). **Methylene-THF** ( $\text{CH}_2\text{FH}_4$ ) is formed from THF by the addition of a **methylene bridge** from one of three carbon donors: **formate**, **serine**, or **glycine**. For example, **serine hydroxymethyltransferase** catalyzes the conversion of THF to  $\text{CH}_2$ -THF, extracting the C1 unit from L-serine giving **glycine**. This reaction provides the largest part of the one-carbon units available to the cell.<sup>[78]</sup> **Methyl tetrahydrofolate** ( $\text{CH}_3$ -THF, or methyl-THF) forms by reduction of methylene-THF by NADPH. Also, histidine can donate a single carbon to THF to form methenyl-THF. **10-Formyl-THF** forms from two pathways. It results from **oxidation** of methylene-THF. It also forms from formate donating formyl group to THF.

### DNA production<sup>[edit]</sup>

Folate derivatives participate in the biosynthesis of both purines and pyrimidines. Formyl folate is required for two of the steps in the biosynthesis of **inosine monophosphate**, the precursor to GMP and AMP. Methylene tetrahydrofolate donates the C1 center required for the biosynthesis of **dTMP** (2'-deoxythymidine-5'-phosphate) from **dUMP** (2'-deoxyuridine-5'-phosphate). The conversion is catalyzed by **thymidylate synthase**.




Metabolism of folic acid to recycle **homocysteine** into **methionine**


### Amino acid processing<sup>[edit]</sup>

Methyl-THF converts vitamin  $\text{B}_{12}$  to methyl- $\text{B}_{12}$  (**methylcobalamin**). Methyl- $\text{B}_{12}$  converts homocysteine, in a reaction catalyzed by **homocysteine methyltransferase**, to **methionine**. A defect in homocysteine methyltransferase or a deficiency of  $\text{B}_{12}$  may lead to a so-called "methyl-trap" of THF, in which THF converts to methyl-THF, causing a deficiency in folate.<sup>[79]</sup> Thus, a deficiency in  $\text{B}_{12}$  can cause accumulation of methyl-THF, mimicking folate deficiency. **Methionyl-tRNA formyltransferase catalyzes** the conversion of **L-methionyl-tRNA<sup>Met</sup>** into **N-formylmethionyl-tRNA<sup>Met</sup>**.

Folate metabolism



**Formylin<sup>TM</sup> Plus**  
Methylcobalamin 1500 mcg + Alpha Lipoic Acid 100 mg +  
Vitamin D3 1000 IU + Pyridoxine HCl 3 mg +  
Folic Acid 1.5 mg Tablets



[Formiminoglutamic acid](#) is an intermediate in the conversion of [histidine](#) to glutamic acid, catalyzed by THF.

### Conversion to biologically active derivatives[\[edit\]](#)

All the biological functions of folic acid are performed by [tetrahydrofolate](#) and other derivatives. Their biological availability to the body depends upon [dihydrofolate reductase](#) action in the liver. This action is unusually slow in humans, being less than 2% of that in rats (and with an almost-5-fold variation in enzymatic activity), leading to the accumulation of unmetabolized folic acid.<sup>[80]</sup> It has been suggested this low activity limits the conversion of folic acid into its biologically active forms "when folic acid is consumed at levels higher than the Tolerable Upper Intake Level (1 mg/d for adults)."<sup>[80]</sup>

### Drugs that interfere with folate reactions[\[edit\]](#)

A number of drugs interfere with the biosynthesis of folic acid and THF. Among them are the [dihydrofolate reductase inhibitors](#) such as [trimethoprim](#), [pyrimethamine](#), and [methotrexate](#); the [sulfonamides](#) (competitive inhibitors of [4-aminobenzoic acid](#) in the reactions of [dihydropteroate synthetase](#)). [Valproic acid](#), one of the most commonly prescribed anticonvulsants that is also used to treat certain psychological conditions, is a known inhibitor of folic acid, and as such, has been shown to cause [neural tube defects](#) and cases of [spina bifida](#) and cognitive impairment in the newborn. Because of this considerable risk, those mothers who must continue to use valproic acid or its derivatives during pregnancy to control their condition (as opposed to stopping the drug or switching to another drug or to a lesser dose) should take folic acid supplements under the direction and guidance of their health care providers.

### Food fortification[\[edit\]](#)

See also: [Food fortification](#)



*Folic acid fortification* is a process where folic acid is added to flour with the intention of promoting public health through increasing blood folate levels in the populace. In the U.S., food is fortified with folic acid, only one of the many naturally occurring forms of folate, and a substance contributing only a minor amount to the folates in natural foods.<sup>[66]</sup> After the discovery of the link between insufficient folic acid and [neural tube defects](#), governments and health organizations worldwide made recommendations concerning folic acid [supplementation](#) for women intending to become pregnant. Because the neural tube closes in the first four weeks of gestation, often before many women even know they are pregnant, many countries in time decided to implement mandatory food fortification programs. A meta-analysis of global birth prevalence of spina bifida showed that when mandatory fortification was compared to countries with voluntary fortification or no fortification program, there was a 30% reduction in live births with spina bifida.<sup>[27]</sup> Folic acid is added to grain products in more than 80 countries,<sup>[10]</sup> and these fortified products make up a significant source of the population's folate intake.<sup>[81]</sup> Fortification is controversial, with issues having been raised concerning individual liberty,<sup>[66]</sup> as well as the health concerns described in the [Toxicity](#) section. In the U.S., there is concern that the federal government mandates fortification but does not provide monitoring of potential undesirable effects of fortification.<sup>[66]</sup> The Food Fortification Initiative lists all countries in the world that conduct fortification programs,<sup>[73]</sup> and within each country, what nutrients are added to which foods. As of December 21, 2018, 81 countries required food fortification with one or more vitamins.<sup>[74]</sup> The most commonly fortified vitamin – as used in 62 countries – is folate; the most commonly fortified food is wheat flour.<sup>[74]</sup>

## **Australia and New Zealand**[\[edit\]](#)

[Australia](#) and [New Zealand](#) jointly agreed to wheat flour fortification through the [Food Standards Australia New Zealand](#) in 2007. The requirement was set at 135 µg of folate per 100 g of bread. Australia implemented the program in 2009.<sup>[82]</sup> New Zealand was also planning to fortify bread (excluding organic and unleavened varieties) starting in 2009, but then opted to wait until more research was done. The Association of Bakers and the [Green Party](#) had opposed mandatory fortification, describing it as "mass medication."<sup>[83][84]</sup> Food Safety Minister [Kate Wilkinson](#) reviewed the decision to fortify in July 2009, citing as reasons to oppose claims for links between over consumption of folate with increased risk of cancer.<sup>[85]</sup> In 2012 the delayed mandatory fortification program was revoked and replaced by a voluntary program, with the hope of achieving a 50% bread fortification target.<sup>[86]</sup>

## **Canada**[\[edit\]](#)

According to a Canadian survey, 58% of women said they took a folic acid containing multivitamin or a folic acid supplement as early as three months before becoming pregnant. Women in higher income households and with more years of school education were more likely to use folic acid supplements before pregnancy, as were women with planned pregnancies and those over the age of 25. Canadian public health efforts focused on promoting awareness of the importance of folic acid supplementation for all women of childbearing age and decreasing socio-economic inequalities by providing practical folic acid support to vulnerable groups of women.<sup>[87]</sup> Folic acid [food fortification](#) became mandatory in 1998, with the fortification of 150 µg of folic acid per 100 grams of [enriched flour](#) and uncooked [cereal](#) grains.<sup>[88]</sup> The results of folic acid fortification on the rate of neural tube defects in [Canada](#) have been positive, showing a 46% reduction in prevalence of NTDs; the magnitude of reduction was proportional to the prefortification rate of NTDs, essentially removing geographical variations in rates of NTDs seen in Canada before fortification.<sup>[89]</sup>

## **United Kingdom**[\[edit\]](#)

While the [Food Standards Agency](#) recommended folic acid fortification,<sup>[90][91][92]</sup> and wheat flour is fortified with iron,<sup>[93]</sup> folic acid fortification of wheat flour is allowed voluntarily rather than required. A 2018 review by authors based in the United Kingdom strongly recommended that mandatory fortification be reconsidered as a means of reducing the risk of neural tube defects.<sup>[10]</sup>

## United States<sup>[edit]</sup>



In the United States many grain products are fortified with folic acid.

In 1996, the United States [Food and Drug Administration](#) (FDA) published regulations requiring the addition of folic acid to enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products.<sup>[94][95]</sup> This ruling took effect on 1 January 1998, and was specifically targeted to reduce the risk of neural tube birth defects in newborns.<sup>[96]</sup> There were concerns expressed that the amount of folate added was insufficient.<sup>[97]</sup>

The fortification program was expected to raise a person's folic acid intake level by 70–130 µg/day;<sup>[98]</sup> however, an increase of almost double that amount was actually observed.<sup>[99]</sup> This could be from the fact that many foods are over-fortified by 160–175% over the required amount.<sup>[99]</sup> Much of the elder population take [supplements](#) that add 400 µg to their daily folic acid intake. This is a concern because 70–80% of the population have detectable levels of unmetabolized folic acid in their [blood](#), a consequence of folic acid supplementation and fortification, and high intakes are thought to accelerate the growth of preneoplastic lesions that could lead to cancer.<sup>[100]</sup>

The U.S. National Center for Health Statistics conducts biannual National Health and Nutrition Examination Survey (NHANES) to assess the health and nutritional status of adults and children in the United States. Some results are reported as What We Eat In America. The 2013–2014 survey reported that for adults ages 20 years and older, men consumed on average of 249 µg/d folate from food plus 207/d µg of folic acid from consumption of fortified foods, for a combined total of 601 µg/d of dietary folate equivalents (DFEs; because each microgram of folic acid counts as 1.7 µg of food folate). For women, the values are 199, 153 and 459 µg/d, respectively. This means that fortification led to a bigger increase in folic acid intake than first projected, and that more than half the adults are consuming more than the RDA of 400 µg (as DFEs)> Even so, fewer than half of pregnant women are exceeding the pregnancy RDA of 600 µg/d.<sup>[101]</sup>

The [Centers for Disease Control and Prevention](#) in [Atlanta, Georgia](#) used data from 23 birth defect registries covering about half of United States births, and extrapolated their findings to the rest of the country. These data indicate that since the addition of folic acid in grain-based foods as mandated by the FDA, the rate of neural tube defects dropped by 25% in the United States.<sup>[102]</sup> Before folic acid fortification, about 4,100 pregnancies were affected by a neural tube defect each year in the United States. After fortification, this number declined to around 3,000.<sup>[103]</sup>

## History<sup>[edit]</sup>

---

In the 1920s, scientists believed folate deficiency and anemia were the same condition.<sup>[104]</sup> In 1931, researcher [Lucy Wills](#) made a key observation that led to the identification of folate as the nutrient required to prevent [anemia](#) during pregnancy. Wills demonstrated that anemia could be reversed with [brewer's yeast](#).<sup>[14][105]</sup> In the late 1930s, folate was identified as the corrective substance in brewer's yeast. It was first isolated via extraction from [spinach](#) leaves by [Herschel K. Mitchell](#), [Esmond E. Snell](#), and [Roger J. Williams](#) in 1941.<sup>[106]</sup> Bob Stokstad isolated the pure crystalline form in 1943, and was able to determine its chemical structure while working at the Lederle Laboratories of the American Cyanamid Company.<sup>[79]</sup> This historical research project, of obtaining folic acid in a pure crystalline form in 1945, was done by the team called the "folic acid boys," under the supervision and guidance of Director of Research Dr. [Yellapragada Subbarow](#), at the Lederle Lab, Pearl River, NY.<sup>[107]</sup>

This research subsequently led to the synthesis of the antifolate [aminopterin](#), the first-ever anticancer drug, the clinical efficacy was proven by [Sidney Farber](#) in 1948. In the 1950s and 1960s, scientists began to discover the biochemical mechanisms of action for folate.<sup>[104]</sup> In 1960, experts first linked folate deficiency to neural tube defects.<sup>[104]</sup> In the late 1990s, U.S. scientists realized, despite the availability of folate in foods and in supplements, there was still a challenge for people to meet their daily folate requirements, which is when the US implemented the folate fortification program.<sup>[104]</sup>

## See also<sup>[edit]</sup>

---

- [Levomefolic acid](#)
- [Pteridine](#): Substituted pteridines are intermediates in the biosynthesis of [dihydrofolic acid](#) in many microorganisms.

## References<sup>[edit]</sup>

---

- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup></sup> *Fenech, Michael (May 2012). "Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity". *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. **733** (1–2): 21–33. doi:10.1016/j.mrfmmm.2011.11.003. PMID 22093367.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup></sup> *"Definition of vitamin Bc". *Medical-dictionary.thefreedictionary.com*. Retrieved 9 September 2012.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup></sup> *Darby WJ, Jones E (1945). "Treatment of sprue with synthetic L. casei factor (folic acid, vitamin M)". *Proc. Soc. Exp. Biol. Med.* **60** (2): 259–262. doi:10.3181/00379727-60-15154P. PMID 21006310.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> <sup>g</sup> <sup>h</sup></sup> *"Folic Acid". *Drugs.com*. American Society of Health-System Pharmacists. 1 January 2010. Archived from the original on 8 September 2017. Retrieved 1 September 2016.*
- <sup>^</sup> *"Folic Acid". *The PubChem Project*. Archived from the original on 7 April 2014.*
- <sup>^</sup> *"Folic Acid". *ChemSrc*.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup></sup> *"Folate". *Micronutrient Information Center, Linus Pauling Institute, Oregon State University*. 2014. Retrieved 17 March 2018.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> <sup>g</sup> <sup>h</sup> <sup>i</sup> <sup>k</sup> <sup>l</sup></sup> *"Fact Sheet for Health Professionals - Folate". *National Institutes of Health*. Archived from the original on 2 April 2011.*
- <sup>^</sup> *Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FA, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP, Silverstein M, Tseng CW (2017). "Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement". *JAMA*. **317** (2): 183–189. doi:10.1001/jama.2016.19438. PMID 28097362.*
- <sup>^</sup> <sup>Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup></sup> *Wald NJ, Morris JK, Blakemore C (2018). "Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate". *Public Health Rev.* **39**: 2. doi:10.1186/s40985-018-0079-6. PMC 5809909. PMID 29450103.*

11. <sup>^</sup> [Jump up to:<sup>a b c d</sup>](#) Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB (2016). "[Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials](#)" (PDF). *J Am Heart Assoc.* **5** (8): e003768. doi:10.1161/JAHA.116.003768. PMC 5015297. PMID 27528407.
12. <sup>^</sup> [Pommerville, Glendale Community College Jeffrey C.](#) (2009). *Alcamo's Fundamentals of Microbiology: Body Systems*. Jones & Bartlett Publishers. p. 511. ISBN 9780763787127. Archived from the original on 8 September 2017.
13. <sup>^</sup> [Marino, BS; Fine, KS](#) (2009). *Blueprints Pediatrics*. Lippincott Williams & Wilkins. p. 131. ISBN 9780781782517. Archived from the original on 8 September 2017.
14. <sup>^</sup> [Jump up to:<sup>a b</sup>](#) Pond, Wilson G.; Nichols, Buford L.; Brown, Dan L. (2009). *Adequate Food for All: Culture, Science, and Technology of Food in the 21st Century*. CRC Press. p. 148. ISBN 9781420077544. Folic acid's discovery started in 1931...
15. <sup>^</sup> ["WHO Model List of Essential Medicines \(19th List\)"](#) (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
16. <sup>^</sup> ["Folic Acid"](#). International Drug Price Indicator Guide. Retrieved 1 September 2016.
17. <sup>^</sup> [Chambers Concise Dictionary](#). Allied Publishers. 2004. p. 451. ISBN 9788186062364. Archived from the original on 8 September 2017.
18. <sup>^</sup> ["The Top 300 of 2019"](#). clincalc.com. Retrieved 22 December 2018.
19. <sup>^</sup> ["Folic Acid"](#). NIH LiverTox. 2 June 2017. Archived from the original on 7 January 2017.
20. <sup>^</sup> [Jump up to:<sup>a b</sup>](#) ["FAQ's Folic Acid"](#). CDC. 16 December 2016. Archived from the original on 10 July 2017. Retrieved 7 July 2017.
21. <sup>^</sup> ["Nomenclature and symbols for folic acid and related compounds"](#). IUPAC-IUB Joint Commission on Biochemical Nomenclature. Archived from the original on 6 February 2007.
22. <sup>^</sup> [Jump up to:<sup>a b</sup>](#) Kamen B (October 1997). "Folate and antifolate pharmacology". *Semin. Oncol.* **24** (5 Suppl 18): S18–30–S18–39. PMID 9420019.
23. <sup>^</sup> [Lieberman M, Marks AD, Smith C](#) (2007). *Marks' Essential Medical Biochemistry, First edition*. Hagerstown, MD: Lippincott Williams & Wilkins. ISBN 978-0-7817-9340-7.<sup>[page needed]</sup>
24. <sup>^</sup> [Zittoun J](#) (1993). "Anemias due to disorder of folate, vitamin B<sub>12</sub> and transcobalamin metabolism". *La Revue du Praticien (in French)*. **43** (11): 1358–1363. PMID 8235383.
25. <sup>^</sup> ["Folate and Your Health – HealthLinkBC File #68g"](#). Healthlink British Columbia. Archived from the original on 9 July 2012. Retrieved 9 September 2012.
26. <sup>^</sup> [Wilson RD, et al.](#) (2015). "Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies". *J Obstet Gynaecol Can.* **37** (6): 534–552. doi:10.1016/s1701-2163(15)30230-9. PMID 26334606.
27. <sup>^</sup> [Jump up to:<sup>a b</sup>](#) Atta CA, Fiest KM, Frolkis AD, Jette N, Pringsheim T, St Germaine-Smith C, Rajapakse T, Kaplan GG, Metcalfe A (2016). "[Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta-Analysis](#)". *Am J Public Health.* **106** (1): e24–e34. doi:10.2105/AJPH.2015.302902. PMC 4695937. PMID 26562127.
28. <sup>^</sup> [Feng Y, Wang S, Chen R, Tong X, Wu Z, Mo X](#) (2015). "[Maternal folic acid supplementation and the risk of congenital heart defects in offspring: a meta-analysis of epidemiological observational studies](#)". *Sci Rep.* **5**: 8506. Bibcode:2015NatSR...5E8506F. doi:10.1038/srep08506. PMC 4330542. PMID 25687545.
29. <sup>^</sup> [Fekete K, Berti C, Trovato M, Lohner S, Dullemeijer C, Souverein OW, Cetin I, Decsi T](#) (2012). "[Effect of folate intake on health outcomes in pregnancy: a systematic review and meta-analysis on birth weight, placental weight and length of gestation](#)". *Nutr J.* **11**: 75. doi:10.1186/1475-2891-11-75. PMC 3499376. PMID 22992251.
30. <sup>^</sup> [Saccone G, Berghella V](#) (2016). "Folic acid supplementation in pregnancy to prevent preterm birth: a systematic review and meta-analysis of randomized controlled trials". *Eur. J. Obstet. Gynecol. Reprod. Biol.* **199**: 76–81. doi:10.1016/j.ejogrb.2016.01.042. PMID 26901401.
31. <sup>^</sup> [Devakumar D, Fall CH, Sachdev HS, Margetts BM, Osmond C, Wells JC, Costello A, Osrin D](#) (2016). "[Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis](#)". *BMC Med.* **14**: 90. doi:10.1186/s12916-016-0633-3. PMC 4910255. PMID 27306908.
32. <sup>^</sup> [Crider KS, Cordero AM, Qi YP, Mulinare J, Dowling NF, Berry RJ](#) (2013). "[Prenatal folic acid and risk of asthma in children: a systematic review and meta-analysis](#)". *Am. J. Clin. Nutr.* **98** (5): 1272–

1281. [doi:10.3945/ajcn.113.065623](https://doi.org/10.3945/ajcn.113.065623). [PMC 5369603](https://pubmed.ncbi.nlm.nih.gov/3369603/). [PMID 24004895](https://pubmed.ncbi.nlm.nih.gov/24004895/). Archived from the original on 8 September 2017.
33. [^ Ebisch IM, Thomas CM, Peters WH, Braat DD, Steegers-Theunissen RP \(2007\). "The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility". \*Hum. Reprod. Update.\* \*\*13\*\* \(2\): 163–174. \[doi:10.1093/humupd/dml054\]\(https://doi.org/10.1093/humupd/dml054\). \[PMID 17099205\]\(https://pubmed.ncbi.nlm.nih.gov/17099205/\).](#)
  34. [^ Altmäe S, Stavreus-Evers A, Ruiz JR, et al. \(2010\). "Variations in folate pathway genes are associated with unexplained female infertility". \*Fertil. Steril.\* \*\*94\*\* \(1\): 130–137. \[doi:10.1016/j.fertnstert.2009.02.025\]\(https://doi.org/10.1016/j.fertnstert.2009.02.025\). \[PMID 19324355\]\(https://pubmed.ncbi.nlm.nih.gov/19324355/\).](#)
  35. [^ Bazzano LA \(2011\). "No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced". \*Evid Based Med.\* \*\*16\*\* \(4\): 117–118. \[doi:10.1136/ebm1204\]\(https://doi.org/10.1136/ebm1204\). \[PMID 21402567\]\(https://pubmed.ncbi.nlm.nih.gov/21402567/\).](#)
  36. [^ Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X \(2007\). "Efficacy of folic acid supplementation in stroke prevention: a meta-analysis". \*Lancet.\* \*\*369\*\* \(9576\): 1876–1882. \[doi:10.1016/S0140-6736\\(07\\)60854-X\]\(https://doi.org/10.1016/S0140-6736\(07\)60854-X\). \[PMID 17544768\]\(https://pubmed.ncbi.nlm.nih.gov/17544768/\).](#)
  37. [^ Terwecoren A, Steen E, Benoit D, Boon P, Hemelsoet D \(September 2009\). "Ischemic stroke and hyperhomocysteinemia: truth or myth?". \*Acta Neurol Belg.\* \*\*109\*\* \(3\): 181–8. \[PMID 19902811\]\(https://pubmed.ncbi.nlm.nih.gov/19902811/\).](#)
  38. [^ Jägerstad, M \(2012\). "Folic acid fortification prevents neural tube defects and may also reduce cancer risks". \*Acta Paediatrica.\* \*\*101\*\* \(10\): 1007–1012. \[doi:10.1111/j.1651-2227.2012.02781.x\]\(https://doi.org/10.1111/j.1651-2227.2012.02781.x\). \[PMID 22783992\]\(https://pubmed.ncbi.nlm.nih.gov/22783992/\).](#)
  39. [^ Weinstein, SJ; Hartman, TJ; Stolzenberg-Solomon, R; Pietinen, P; Barrett, MJ; Taylor, PR; Virtamo, J; Albanes, D \(2003\). "Null association between prostate cancer and serum folate, vitamin B\(6\), vitamin B\(12\), and homocysteine". \*Cancer Epidemiology, Biomarkers & Prevention.\* \*\*12\*\* \(11 Pt 1\): 1271–1272. \[PMID 14652294\]\(https://pubmed.ncbi.nlm.nih.gov/14652294/\). Archived from the original on 22 February 2017.](#)
  40. [^ Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M \(2012\). "Cancer risk with folic acid supplements: a systematic review and meta-analysis". \*BMJ Open.\* \*\*2\*\* \(1\): e000653. \[doi:10.1136/bmjopen-2011-000653\]\(https://doi.org/10.1136/bmjopen-2011-000653\). \[PMC 3278486\]\(https://pubmed.ncbi.nlm.nih.gov/3278486/\). \[PMID 22240654\]\(https://pubmed.ncbi.nlm.nih.gov/22240654/\).](#)
  41. [^ Wang, R; Zheng, Y; Huang, JY; Zhang, AQ; Zhou, YH; Wang, JN \(2014\). "Folate intake, serum folate levels, and prostate cancer risk: a meta-analysis of prospective studies". \*BMC Public Health.\* \*\*14\*\* \(1\): 1326. \[doi:10.1186/1471-2458-14-1326\]\(https://doi.org/10.1186/1471-2458-14-1326\). \[PMC 4320532\]\(https://pubmed.ncbi.nlm.nih.gov/4320532/\). \[PMID 25543518\]\(https://pubmed.ncbi.nlm.nih.gov/25543518/\).](#)
  42. [^ Schwingshackl L, Boeing H, Stelmach-Mardas M, Gottschald M, Dietrich S, Hoffmann G, Chaimani A \(2017\). "Dietary Supplements and Risk of Cause-Specific Death, Cardiovascular Disease, and Cancer: A Systematic Review and Meta-Analysis of Primary Prevention Trials". \*Advances in Nutrition.\* \*\*8\*\* \(1\): 27–39. \[doi:10.3945/an.116.013516\]\(https://doi.org/10.3945/an.116.013516\). \[PMC 5227980\]\(https://pubmed.ncbi.nlm.nih.gov/5227980/\). \[PMID 28096125\]\(https://pubmed.ncbi.nlm.nih.gov/28096125/\). Archived from the original on 8 September 2017.](#)
  43. [^ Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS \(1998\). "Effect of glutamine on methotrexate efficacy and toxicity". \*Ann. Surg.\* \*\*227\*\* \(5\): 772–780. \[doi:10.1097/00000658-199805000-00018\]\(https://doi.org/10.1097/00000658-199805000-00018\). \[PMC 1191365\]\(https://pubmed.ncbi.nlm.nih.gov/1191365/\). \[PMID 9605669\]\(https://pubmed.ncbi.nlm.nih.gov/9605669/\).](#)
  44. [^ Wolff JE, Hauch H, Kuhl J, Egeler RM, Jurgens H \(1998\). "Dexamethasone increases hepatotoxicity of MTX in children with brain tumors". \*Anticancer Research.\* \*\*18\*\* \(4B\): 2895–2899. \[PMID 9713483\]\(https://pubmed.ncbi.nlm.nih.gov/9713483/\).](#)
  45. [^ Kepka L, De Lassence A, Ribrag V, et al. \(1998\). "Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure". \*Leuk. Lymphoma.\* \*\*29\*\* \(1–2\): 205–209. \[doi:10.3109/10428199809058397\]\(https://doi.org/10.3109/10428199809058397\). \[PMID 9638991\]\(https://pubmed.ncbi.nlm.nih.gov/9638991/\).](#)
  46. [^ Branda RF, Nigels E, Lafayette AR, Hacker M \(1998\). "Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats". \*Blood.\* \*\*92\*\* \(7\): 2471–2476. \[PMID 9746787\]\(https://pubmed.ncbi.nlm.nih.gov/9746787/\).](#)
  47. [^ Shiroky JB; Frpc\(c\) \(1997\). "The use of folates concomitantly with low-dose pulse methotrexate". \*Rheum. Dis. Clin. North Am.\* \*\*23\*\* \(4\): 969–980. \[doi:10.1016/S0889-857X\\(05\\)70369-0\]\(https://doi.org/10.1016/S0889-857X\(05\)70369-0\). \[PMID 9361164\]\(https://pubmed.ncbi.nlm.nih.gov/9361164/\).](#)
  48. [^ Keshava C, Keshava N, Whong WZ, Nath J, Ong TM \(1998\). "Inhibition of methotrexate-induced chromosomal damage by folic acid in V79 cells". \*Mutat. Res.\* \*\*397\*\* \(2\): 221–228. \[doi:10.1016/S0027-5107\\(97\\)00216-9\]\(https://doi.org/10.1016/S0027-5107\(97\)00216-9\). \[PMID 9541646\]\(https://pubmed.ncbi.nlm.nih.gov/9541646/\).](#)
  49. [^ Coppen A, Bolander-Gouaille C \(2005\). "Treatment of depression: time to consider folic acid and vitamin B12". \*J. Psychopharmacol. \(Oxford\).\* \*\*19\*\* \(1\): 59–65. \[doi:10.1177/0269881105048899\]\(https://doi.org/10.1177/0269881105048899\). \[PMID 15671130\]\(https://pubmed.ncbi.nlm.nih.gov/15671130/\).](#)
  50. [^ Taylor MJ, Carney SM, Goodwin GM, Geddes JR \(2004\). "Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials". \*J. Psychopharmacol. \(Oxford\).\* \*\*18\*\* \(2\): 251–256. \[doi:10.1177/0269881104042630\]\(https://doi.org/10.1177/0269881104042630\). \[PMID 15260915\]\(https://pubmed.ncbi.nlm.nih.gov/15260915/\).](#)

51. [^ Gilbody S, Lewis S, Lightfoot T \(2007\). "Methylenetetrahydrofolate reductase \(MTHFR\) genetic polymorphisms and psychiatric disorders: a Huge review". \*Am. J. Epidemiol.\* \*\*165\*\*\(1\): 1–13. \[doi:10.1093/aje/kwj347\]\(#\). \[PMID 17074966\]\(#\).](#)
52. [^ Gilbody S, Lightfoot T, Sheldon T \(2007\). "Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity". \*J Epidemiol Community Health.\* \*\*61\*\* \(7\): 631–637. \[doi:10.1136/jech.2006.050385\]\(#\). \[PMC 2465760\]\(#\). \[PMID 17568057\]\(#\).](#)
53. [^ Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H \(2009\). "One-carbon metabolism and schizophrenia: current challenges and future directions". \*Trends Mol Med.\* \*\*15\*\* \(12\): 562–570. \[doi:10.1016/j.molmed.2009.10.001\]\(#\). \[PMID 19896901\]\(#\).](#)
54. [^ Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE \(2009\). "Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study". \*Arch. Intern. Med.\* \*\*169\*\* \(4\): 335–341. \[doi:10.1001/archinternmed.2008.574\]\(#\). \[PMC 2648137\]\(#\). \[PMID 19237716\]\(#\).](#)
55. [^ Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ \(1990\). "Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness". \*Ann. Rheum. Dis.\* \*\*49\*\* \(2\): 93–98. \[doi:10.1136/ard.49.2.93\]\(#\). \[PMC 1003985\]\(#\). \[PMID 2317122\]\(#\).](#)
56. [^ Reynolds E \(2006\). "Vitamin B12, folic acid, and the nervous system". \*Lancet Neurol.\* \*\*5\*\*\(11\): 949–960. \[doi:10.1016/S1474-4422\\(06\\)70598-1\]\(#\). \[PMID 17052662\]\(#\).](#)
57. [^ Allen RH, Stabler SP, Savage DG, Lindenbaum J \(1990\). "Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations". \*Am. J. Hematol.\* \*\*34\*\* \(2\): 90–98. \[doi:10.1002/ajh.2830340204\]\(#\). \[PMID 2339683\]\(#\).](#)
58. [^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> "Folate deficiency: MedlinePlus Medical Encyclopedia". \[www.nlm.nih.gov\]\(#\). \[Archived\]\(#\) from the original on 17 November 2015. Retrieved 16 November 2015.](#)
59. [^ Hamid A, Wani NA, Kaur J \(2009\). "New perspectives on folate transport in relation to alcoholism-induced folate malabsorption—association with epigenome stability and cancer development". \*FEBS J.\* \*\*276\*\* \(8\): 2175–2191. \[doi:10.1111/j.1742-4658.2009.06959.x\]\(#\). \[PMID 19292860\]\(#\).](#)
60. [^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> \[Institute of Medicine\]\(#\) \(1998\). "Folate". \*Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline\*. Washington, DC: The National Academies Press. pp. 196–305. \[ISBN 978-0-309-06554-2\]\(#\). Retrieved 29 August 2017.](#)
61. [^ Lohner, S; Fekete, K; Berti, C; Hermoso, M; Cetin, I; Koletzko, B; Decsi, T \(2012\). "Effect of folate supplementation on folate status and health outcomes in infants, children and adolescents: A systematic review". \*International Journal of Food Sciences and Nutrition.\* \*\*63\*\*\(8\): 1014–1020. \[doi:10.3109/09637486.2012.683779\]\(#\). \[PMID 22574624\]\(#\).](#)
62. [^ Varela-Moreiras G, Murphy MM, Scott JM \(2009\). "Cobalamin, folic acid, and homocysteine". \*Nutrition Reviews.\* \*\*67\*\* Suppl 1: S69–S72. \[doi:10.1111/j.1753-4887.2009.00163.x\]\(#\). \[hdl:2262/34510\]\(#\). \[PMID 19453682\]\(#\).](#)
63. [^ Pasricha S, Shet A, Sachdev HP, Shet AS \(October 2009\). "Risks of routine iron and folic acid supplementation for young children" \(PDF\). \*Indian Pediatr.\* \*\*46\*\* \(10\): 857–66. \[PMID 19887691\]\(#\). \[Archived\]\(#\) \(PDF\) from the original on 12 June 2010.](#)
64. [^ "Overview on Dietary Reference Values for the EU population as derived by the EFSA Panel on Dietetic Products, Nutrition and Allergies" \(PDF\). 2017. \[Archived\]\(#\) \(PDF\) from the original on 28 August 2017.](#)
65. [^ "Nutrition Requirements" \(PDF\). \*British Nutrition Foundation\*. Retrieved 8 July 2018.](#)
66. [^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> Smith AD \(2007\). "Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12". \*Amer J Clinical Nutrition.\* \*\*85\*\* \(1\): 3–5. \[doi:10.1093/ajcn/85.1.3\]\(#\). \[PMID 17209170\]\(#\).](#)
67. [^ "Tolerable Upper Intake Levels For Vitamins And Minerals" \(PDF\). \*European Food Safety Authority\*. 2006.](#)
68. [^ Shibata K, Fukuwatari T, Imai E, Hayakawa T, Watanabe F, Takimoto H, Watanabe T, Umegaki K \(2013\). "Dietary Reference Intakes for Japanese 2010: Water-Soluble Vitamins". \*Journal of Nutritional Science and Vitaminology.\* \*\*2013\*\* \(59\): S67–S82.](#)
69. [^ "Federal Register May 27, 2016 Food Labeling: Revision of the Nutrition and Supplement Facts Labels. FR page 33982" \(PDF\).](#)
70. [^ "Changes to the Nutrition Facts Panel – Compliance Date". \*US Department of Agriculture\*. Retrieved 9 August 2018.](#)

71. [^ "Regulation \(EU\) No 1169/2011 of the European Parliament and of the Council".](#) Official Journal of the European Union. **22** (11): 18–63. 2011.
72. [^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> "Folate content in micrograms per 100 g. All Foods: USDA Food Composition Databases".](#) United States Department of Agriculture, Agricultural Research Service. Release 28. 7 May 2019. Retrieved 27 May 2019.
73. [^ Jump up to:<sup>a</sup> <sup>b</sup> "Why fortify?".](#) Food Fortification Initiative. 2017. Retrieved 30 April 2019.
74. [^ Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> "Map: Count of Nutrients In Fortification Standards".](#) Global Fortification Data Exchange. Retrieved 30 April 2019.
75. [^ "Effects of Cooking on Vitamins \(Table\)".](#) Beyondveg.com. *Archived* from the original on 16 October 2012. Retrieved 30 April 2019.
76. [^ "EC 1.5.1.3".](#) Us.expasy.org. *Archived* from the original on 13 June 2011. Retrieved 9 September 2012.
77. [^ Benkovic SJ, Hammes-Schiffer S \(2003\). "A perspective on enzyme catalysis".](#) Science. **301** (5637): 1196–1202. *Bibcode*:2003Sci...301.1196B. *doi*:10.1126/science.1085515. *PMID* 12947189.
78. [^ Stover P, Schirch V \(1990\). "Serine hydroxymethyltransferase catalyzes the hydrolysis of 5,10-methenyltetrahydrofolate to 5-formyltetrahydrofolate".](#) J. Biol. Chem. **265** (24): 14227–14233. *PMID* 2201683.
79. [^ Jump up to:<sup>a</sup> <sup>b</sup> Hoffbrand AV, Weir DG \(2001\). "The history of folic acid".](#) Br. J. Haematol. **113** (3): 579–589. *doi*:10.1046/j.1365-2141.2001.02822.x. *PMID* 11380441.
80. [^ Jump up to:<sup>a</sup> <sup>b</sup> Bailey SW, Ayling JE \(September 2009\). "The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake".](#) Proceedings of the National Academy of Sciences of the United States of America. **106**(36): 15424–15429. *Bibcode*:2009PNAS..10615424B. *doi*:10.1073/pnas.0902072106. *PMC* 2730961. *PMID* 19706381.
81. [^ Dietrich M, Brown CJ, Block G \(2005\). "The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States".](#) J Am Coll Nutr. **24** (4): 266–274. *doi*:10.1080/07315724.2005.10719474. *PMID* 16093404.
82. [^ "Folic Acid Fortification".](#) Food Standards Australia New Zealand. 2016. Retrieved 25 September 2018.
83. [^ "Work Starts on Wilkinson's Mass Medication Plan" \(Press release\).](#) Association Of Bakers. 8 July 2009. *Archived* from the original on 10 July 2009. Retrieved 13 July 2009.
84. [^ "NZ should push pause on folic fortification" \(Press release\).](#) Green Party. 9 July 2009. *Archived* from the original on 10 July 2009. Retrieved 13 July 2009.
85. [^ NZPA \(8 July 2009\). "Bakers, Govt battle over folic acid".](#) NZ Herald. Retrieved 13 July 2009.
86. [^ Houghton LA \(2014\). "A country left behind: folic acid food fortification policy in New Zealand".](#) N. Z. Med. J. **127** (1399): 6–9. *PMID* 25145300.
87. [^ "Welcome to the Health Canada Web site".](#) Hc-sc.gc.ca. *Archived* from the original on 10 September 2012. Retrieved 9 September 2012.
88. [^ Mason JB, Dickstein A, Jacques PF, et al. \(2007\). "A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis".](#) Cancer Epidemiol. Biomarkers Prev. **16** (7): 1325–1329. *doi*:10.1158/1055-9965.EPI-07-0329. *PMID* 17626997.
89. [^ De Wals P, Tairou F, Van Allen MI, et al. \(2007\). "Reduction in neural-tube defects after folic acid fortification in Canada".](#) N. Engl. J. Med. **357** (2): 135–142. *doi*:10.1056/NEJMoa067103. *PMID* 17625125.
90. [^ FSA \(17 May 2007\). "Board recommends mandatory fortification".](#) *Archived* from the original on 24 June 2007. Retrieved 18 May 2007.
91. [^ "Backing for folic acid in bread".](#) BBC News. 17 May 2007. *Archived* from the original on 18 June 2007. Retrieved 18 May 2007.
92. [^ BBC Experts back folic acid in flour](#) *Archived* 18 August 2007 at the [Wayback Machine](#) 11 May 2007
93. [^ "Why fortify?".](#) Food Fortification Initiative. 2017. *Archived* from the original on 4 April 2017. Retrieved 4 April 2017.
94. [^ Malinow MR, Duell PB, Hess DL, et al. \(1998\). "Reduction of plasma homocyst\(e\)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease".](#) N. Engl. J. Med. **338** (15): 1009–1015. *doi*:10.1056/NEJM199804093381501. *PMID* 9535664.

95. [^](#) [Daly S, Mills JL, Molloy AM, et al. \(1997\). "Minimum effective dose of folic acid for food fortification to prevent neural-tube defects". \*Lancet\*. \*\*350\*\* \(9092\): 1666–1669. \[doi:10.1016/S0140-6736\\(97\\)07247-4\]\(#\). \[PMID 9400511\]\(#\).](#)
96. [^](#) [Crandall BF, Corson VL, Evans MI, Goldberg JD, Knight G, Salafsky IS \(1998\). "American College of Medical Genetics statement on folic acid: fortification and supplementation". \*Am. J. Med. Genet.\* \*\*78\*\* \(4\): 381. \[doi:10.1002/\\(SICI\\)1096-8628\\(19980724\\)78:4<381::AID-AJMG16>3.0.CO;2-E\]\(#\). \[PMID 9714444\]\(#\).](#)
97. [^](#) ["FDA muffed chance to reduce birth defects". \*Boston Globe\*. 6 January 2004. \[Archived\]\(#\) from the original on 13 March 2007.](#)
98. [^](#) [Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF \(2002\). "Folic acid intake from fortification in United States exceeds predictions". \*J. Nutr.\* \*\*132\*\* \(9\): 2792–2798. \[doi:10.1093/jn/132.9.2792\]\(#\). \[PMID 12221247\]\(#\).](#)
99. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup> \[Quinlivan EP, Gregory JF \\(2003\\). "Effect of food fortification on folic acid intake in the United States". \\*Am J Clinical Nutrition\\*. \\*\\*77\\*\\* \\(1\\): 221–225. \\[doi:10.1093/ajcn/77.1.221\\]\\(#\\). \\[PMID 12499345\\]\\(#\\).\]\(#\)](#)
100. [^](#) [Chustecka Z \(2009\). "Folic-acid fortification of flour and increased rates of colon cancer". \*Medscape\*. Retrieved 9 November 2009.](#)
101. [^](#) ["TABLE 1: Nutrient Intakes from Food and Beverages" \(PDF\). \*What We Eat In America, NHANES 2012–2014\* \(2016\). Retrieved 12 October 2018.](#)
102. [^](#) [Centers for Disease Control and Prevention \(CDC\) \(2004\). "Spina bifida and anencephaly before and after folic acid mandate—United States, 1995–1996 and 1999–2000". \*MMWR Morb. Mortal. Wkly. Rep.\* \*\*53\*\* \(17\): 362–365. \[PMID 15129193\]\(#\). \[Archived\]\(#\) from the original on 2 June 2013.](#)
103. [^](#) ["Birth Defects COUNT | Folic Acid | NCBDDD | CDC". \*www.cdc.gov\*. \[Archived\]\(#\) from the original on 13 November 2015. Retrieved 16 November 2015.](#)
104. [^](#) [Jump up to:<sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> \[Lanska, DJ. \\(2009\\). Chapter 30 Historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins. \\*Handb Clin Neurol. Handbook of Clinical Neurology\\*. \\*\\*95\\*\\*. pp. 445–476. \\[doi:10.1016/S0072-9752\\\(08\\\)02130-1\\]\\(#\\). \\[ISBN 978-0-444-52009-8\\]\\(#\\). \\[PMID 19892133\\]\\(#\\).\]\(#\)](#)
105. [^](#) [Wills L \(1978\). "Nutrition Classics. \*British Medical Journal\* 1:1059–64, 1931. Treatment of "pernicious anaemia of pregnancy" and "tropical anaemia" with special reference to yeast extract as a curative agent. By Lucy Wills". \*Nutr. Rev.\* \*\*36\*\* \(5\): 149–151. \[doi:10.1111/j.1753-4887.1978.tb03735.x\]\(#\). \[PMID 355948\]\(#\).](#)
106. [^](#) [Mitchell HK, Snell EE, Williams RJ \(1941\). "The concentration of "folic acid"". \*J Am Chem Soc.\* \*\*63\*\* \(8\): 2284. \[doi:10.1021/ja01853a512\]\(#\).](#)
107. [^](#) [Angier RB, Boothe JH, Hutchings BL, et al. \(1945\). "Synthesis of a Compound Identical with the L. Casei Factor Isolated from Liver". \*Science\*. \*\*102\*\* \(2644\): 227–228. \[Bibcode:1945Sci...102..227A\]\(#\). \[doi:10.1126/science.102.2644.227\]\(#\). \[PMID 17778509\]\(#\).](#)